WO2025147631A1 - Cellules encapsulées pour le traitement de maladies et de troubles respiratoires - Google Patents

Cellules encapsulées pour le traitement de maladies et de troubles respiratoires Download PDF

Info

Publication number
WO2025147631A1
WO2025147631A1 PCT/US2025/010263 US2025010263W WO2025147631A1 WO 2025147631 A1 WO2025147631 A1 WO 2025147631A1 US 2025010263 W US2025010263 W US 2025010263W WO 2025147631 A1 WO2025147631 A1 WO 2025147631A1
Authority
WO
WIPO (PCT)
Prior art keywords
chemokine
motif
ligand
interleukin
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/010263
Other languages
English (en)
Inventor
Omid Veiseh
Samira AGHLARA-FOTOVAT
Samantha FLEURY
Kailyn NUNEZ
Ravi GHANTA
Miguel MENDEZ SOSA
Tyler GUINN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
William Marsh Rice University
Original Assignee
Baylor College of Medicine
William Marsh Rice University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine, William Marsh Rice University filed Critical Baylor College of Medicine
Publication of WO2025147631A1 publication Critical patent/WO2025147631A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Definitions

  • Respiratory diseases and disorders can lead to significant morbidity, with current treatment modalities limited to a small armamentarium of immunosuppressive and antiinflammatory regimens, among other treatments. Respiratory diseases and disorders are among the most ubiquitously encountered illnesses, which can manifest in clinical presentation from very mild to severe. Despite their prevalence, there is a dearth of efficacious treatment modalities to address respiratory dysregulation in severe clinical presentations, such as pneumonia and COVID-19, leading to significant morbidity and fatality. Certain respiratory diseases and disorders can be characterized by a chronic inflammatory response mediated by a dysregulation and hyperactivity in pro-inflammatory markers, e.g., cytokines and chemokines. Current treatments for these diseases and disorders are not ideal, and thus, there exists a need for improvement in methods of treatment.
  • the present disclosure relates to methods of treating respiratory diseases and disorders, such as an autoimmune disease or disorder, a respiratory infection, or an inflammatory disease or disorder in a subject featuring providing a plurality of encapsulated engineered cells.
  • one or more engineered cells in the plurality are capable of producing a therapeutic agent, such as a protein, e.g., an antibody, a hormone, or a cytokine.
  • the methods described herein feature encapsulated engineered cells, wherein at least 0.5%, 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30% or more of the engineered cells in the plurality produce a therapeutic agent, e.g., an antibody, hormone, or cytokine.
  • the capsules comprise a plurality of engineered cells that produce one or more than one therapeutic agent, e.g., more than one protein, e.g., more than one cytokine.
  • the cytokine may be an anti-inflammatory cytokine.
  • the cytokine may be a pro- inflammatory cytokine.
  • the cytokine may comprise IL-10 (e.g., the cytokine is IL- 10).
  • the present disclosure features methods for the treatment of an autoinflammatory disease or disorder, an autoimmune disease or disorder, a respiratory infection, or an inflammatory disease or disorder in a subject through administration of a capsule that is degradable.
  • the capsule may comprise a polymer.
  • the polymer may be a naturally occurring polymer.
  • the polymer may be a synthetic polymer.
  • the polymer may be a polysaccharide (e.g., an alginate).
  • the present disclosure features methods for the treatment of an autoinflammatory disease or disorder, an autoimmune disease, a respiratory infection, or an inflammatory disease or disorder featuring an encapsulated engineered cell.
  • the engineered cell may be an epithelial cell.
  • the engineered cell may be selected from a Chinese hamster ovary (CHO) cell, retinal pigment epithelial (ARPE-19) cell, human mammary epithelial (MCF-lOa and MCF-7) cell, human embryonic kidney (HEK) cell, mesenchymal stem cell (MSC), human umbilical vein endothelial cell (HUVEC), NIH/3T3 cell, BJ fibroblast, and human renal mix epithelial cell (HREC).
  • CHO Chinese hamster ovary
  • ARPE-19 retinal pigment epithelial
  • MCF-lOa and MCF-7 human mammary epithelial
  • HEK human embryonic kidney
  • MSC mesenchymal stem cell
  • HAVEC human umbilical
  • the engineered cell may be engineered for regulatable expression of a cytokine.
  • the engineered cell may be engineered for regulatable expression of an antibody, e g., anti-TNFa, anti-fFNy, and the like.
  • the present disclosure features methods wherein the therapeutic agent is selected from interleukin- 1 (IL-1), interleukin- 1 alpha (IL- la), interleukin- 1 beta (IL- 1 ), interleukin-1 receptor antagonist protein (IL-IRA), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin- 10 (IL-10), interleukin- 11 (IL-11) , interleukin- 12 (IL-12), interleukin- 12 alpha (IL-12a), interleukin- 12 beta (IL-12P), interleukin- 13 (IL-13), interleukin- 14 (IL-14), interleukin- 15 (IL-15), interleukin- 16 (IL-16), interleukin- 17 (IL-17), interleukin-20 (IL-20), interleukin-22 (IL-22), interleukin
  • the therapeutic agent is an anti-inflammatory antibody, e.g., an antibody that binds to a cytokine.
  • the present disclosure features methods wherein the therapeutic agent is selected from IL-IRA, IL-4, IL-10, IL-11, IL-13, and IL-35, and a combination thereof.
  • the therapeutic agent comprises IL-lRa.
  • the present disclosure features methods wherein the therapeutic agent is an anti-cytokine antibody or an anti-chemokine antibody, e.g., anti-IL-1, anti-IL-la, anti-IL-ip, anti- IL-1RA, anti-IL-2, anti-IL-4, anti-IL-5, anti-IL-6, anti-IL-7, anti-IL-8, anti-IL-9, anti-IL-10, anti- IL-11, anti-IL-12, anti-IL-12a, anti-IL-12p, anti-IL-13, anti-IL-14, anti-IL-15, anti-IL-16, anti -IL- 17, anti-IL-20, anti-IL-22, anti-IFN-a, anti-IFN-P, anti-IFN-y, anti-TNF-oi, anti-TNF-P, anti-TGF- P, anti-CCLl, anti-CCL2, anti-CCL3, anti-CCL4, anti-CCL5, anti-CCL6, anti-CCL7, anti-CCL8, anti-CCL9, anti-CC
  • the methods as described herein may feature treating a respiratory disease, disorder, or condition.
  • the respiratory disease, disorder, or condition is selected from anti -glomerular basement membrane disease, acute interstitial pneumonitis, asthma, bronchopulmonary dysplasia, bronchiectasis, chemical pneumonitis, chronic bronchitis, chronic obstructive pulmonary disease (COPD), conditions with a pleural effusion, cystic fibrosis, hypersensitivity pneumonitis (e.g., due to an environmental allergen, e.g., pollen, mold, dust, dander, and the like), (eosinophilic) granulomatosis with polyangiitis, Langerhans cell histiocytosis, lymphangioleiomyomatosis, infant respiratory distress syndrome (IRDS), pneumoconiosis (e.g., asbestosis), primary ciliary dyskinesia, pulmonary alveolar proteinosis (e.g., of autoimmune e
  • the respiratory infection is be caused by a pathogen.
  • the pathogen is a bacterium, a fungus, a virus, a protozoan, a nematode, or a flatworm.
  • the virus may be a coronavirus.
  • the virus may be SARS-CoV2.
  • the present disclosure features methods for treating a respiratory infection selected from acute bronchitis, acute chest syndrome, acute respiratory distress syndrome (ARDS) aspergillosis, bronchiectasis, bronchiolitis, bronchiolitis obliterans, chronic bronchitis, chronic coughing, coccidioidomycosis, common cold, COVID- 19, cryptogenic organizing pneumonia, emphysema, hantavirus pulmonary syndrome, histoplasmosis, human metapneumovirus, influenza, interstitial lung disease (ILD), legionnaire’s disease, mycobacterium avium complex disease, middle eastern respiratory syndrome (MERS), nontuberculous mycobacteria lung disease, pertussis, pneumonia, pneumothorax, respiratory syncytial virus (RSV), severe acute respiratory syndrome (SARS), and tuberculosis, and a combination thereof.
  • ARDS acute respiratory distress syndrome
  • the inflammatory disease or disorder may be a local inflammatory disease or disorder or a systemic inflammatory disease or disorder.
  • the inflammatory disease is a local inflammatory disease or disorder.
  • the inflammatory disease is a systemic inflammatory disease or disorder.
  • the inflammatory disease or disorder is selected from endometriosis, arthritis, psoriasis, alopecia, areata, eczema, familial Mediterranean fever, adenomyosis and uterine fibroids, Addison’s disease, autoimmune hepatitis, celiac disease, Crohn’s disease, type I diabetes, Grave’s disease, Hashimoto’s thyroiditis, pernicious anemia, multiple sclerosis, primary biliary cholangitis (biliary cirrhosis), sclerosing cholangitis, ulcerative colitis, myasthenia gravis, and Gillian Barre syndrome, and a combination thereof.
  • the inflammatory disease or disorder is endometriosis.
  • the methods as described herein feature administering capsules via local delivery or delivery via inhalation.
  • the administering may feature disposing, e.g., implanting, e.g., surgically implanting, capsules in a cellular compartment of the subject.
  • the cellular compartment may be an organ, a cavity, or a serous membrane.
  • the cavity is selected from intraperitoneal cavity (e.g., adjacent to the peritoneum), abdomino-pelvic cavity, cranial cavity, dorsal cavity, ventral cavity, and thoracic cavity.
  • the cavity is the intraperitoneal cavity.
  • the local delivery may comprise delivery via instillation, e.g., with a bronchoscope or via bronchoalveolar lavage (BAL).
  • the delivery via inhalation may also comprise delivery via an inhalation device (e.g., inhaler).
  • the methods as described herein feature administering capsules via implantation, e.g., surgical implantation into a cavity, e.g., the thoracic cavity.
  • the methods described herein feature a subject, wherein the subject is a mammal (e.g., a human).
  • the capsule may be formulated as a pharmaceutical composition, optionally comprising a pH modifier, a tonicity agent, a viscosity modifier, a carrier or diluent (e.g., a pharmaceutically acceptable carrier or diluent), a preservative, a surfactant, or a polymer, or a combination thereof.
  • a pharmaceutical composition optionally comprising a pH modifier, a tonicity agent, a viscosity modifier, a carrier or diluent (e.g., a pharmaceutically acceptable carrier or diluent), a preservative, a surfactant, or a polymer, or a combination thereof.
  • the present disclosure also features methods of treating a respiratory infection, disease, disorder or condition, or an inflammatory disease or disorder in a subject, wherein the method comprises providing a capsule comprising a plurality of encapsulated engineered retinal pigmented epithelial (RPE) cells expressing a cytokine to a subject and administering the capsule to the subject via local delivery (e.g., delivery about 1 mm, 5 nm, 10 mm, 25 mm, 50 mm, 100 mm, or further from the lung or pleural cavity).
  • RPE retinal pigmented epithelial
  • FIG. 1A-1B are schematic illustrations of an engineered cell and various cellular compartments which may be targeted by the composition by external regulation, e.g., by a small molecule inducer or via inflammatory induction.
  • FIG. 1A is a schematic illustration of an engineered cell wherein perception of an external signal initiates a cellular response.
  • FIG. IB is a schematic of engineered cells illustrating that the stimulus may be a small molecule inducer or via an inflammatory marker.
  • FIG. 2 is a schematic illustrating an alternative delivery mode comprising instillation of capsules into the airway and delivery of anti-inflammatory proteins to the alveolar tissue in the lungs, enabling superior localization of the therapeutic agent to targeted tissue.
  • FIGS. 3A-3D demonstrate that capsules of various diameters (e.g., 150pm-1700pm) can be reproducibly generated for delivery of therapeutic agents to a rat lung via intratracheal instillation.
  • FIG. 3A shows representative brightfield images of alginate hydrogels with diameter of 300 pm (top) and cell-laden 300 pm hydrogels (bottom).
  • FIG. 3B shows that capsules having diameters of 150, 300, 600, 800, 1200, and 1700 pm may be synthesized via the methods of making described herein.
  • FIG. 3C is a series of micrographs of capsules measuring 300, 600, 800 and 900 pm.
  • FIG. 3D is a series of micrographs of capsules measuring 300, 500, 800, and 1000 pm.
  • FIGS. 4A-4C demonstrate that the synthesis of capsules is size-controlled with the target size closely aligning with the actually measured capsule diameter.
  • FIG. 4A is a bar graph showing the reproducible, size-controlled synthesis of capsules of various target sizes and actual diameters of -150, 300, 600, 800, 1200 and 1700 pm.
  • FIG. 4B is a bar graph showing the reproducible, size-controlled synthesis of capsules of various target sizes and actual diameters of -300, 600, 800, and 900 pm.
  • FIG. 4C is a bar graph showing the reproducible, size-controlled synthesis of capsules of various target sizes and actual diameters of -300, 600, 800, and 1200 pm.
  • FIGS. 5A-5D demonstrate that cell viability of the encapsulated engineered cells and the cytokine concentration are substantially independent of capsule diameter.
  • FIG. 5A is a bar graph illustrating that the cell viability of the encapsulated engineered cells in capsules of 150, 300, 800 and 1200 pm are all greater than 80% and are not statistically different.
  • FIG. 5B is a bar graph showing that the cell viability of 300 pm-diameter capsules is greater than 90% (left), and In vivo bioluminescent imaging confirming the presence and distribution of the capsules within the lung tissue (right).
  • FIG. 5C is a bar graph showing that the cell dose is maintained at approximately 2*10 6 cells in capsules of 150, 300, 800 and 1200pm.
  • FIG. 6 is a graph of cytokine production (namely, IL-13, FGF21 and IL-IRa) over time in encapsulated engineered ARPE-19 cells as measured by protein-specific ELIS As. Cytokine productions appears to plateau in approximately 5-10 hours.
  • FIGS. 7A-7B show delivery and retrieval of the capsules comprising the encapsulated cell therapies intratracheally instilled in the lungs.
  • FIG. 7A is a series of images of 100, 200, and 300 pl volumes of capsules delivered by intratracheal instillation to rat lungs and recovered by bronchoalveolar lavage (BAL).
  • FIG. 7B is an image of a fixed and stained rat lung section showing 100, 200, and 300 pl samples of the capsules localized to the targeted alveolar tissue.
  • FIGS. 8A-8B demonstrate that instillation of capsules to the lungs results in local delivery of therapeutic cytokines.
  • FIG. 8A is a bar graph showing that capsules administered via intubation result in a 10,000-fold increase in the local versus systemic concentrations of IL-IRa, i.e., in the fraction recovered by bronchoalveolar lavage (BAL) compared with the fraction recovered from the pleural cavity and the plasma IL-lRa.
  • FIG. 8B is a bar graph demonstrating that in a lipopolysaccharide (LPS)-induced lung injury model of inflammation, there is significantly less IL- 17 in the bronchoalveolar lavage fluid after 24 h with locally delivered capsules secreting IL-lRa.
  • LPS lipopolysaccharide
  • FIGS. 9A-9C show a reduction in neutrophil infiltration at 24-h post-treatment with capsules comprising engineered cells. Instillation of 200-pm, IL-lRa-producing capsules results in significantly less immune filtration at 24 hours after lipopolysaccharide (LPS)-induced lung injury treatment compared to untreated control rats administered vehicle.
  • FIG 9A is an image of a histological section of a rat lung after lipopolysaccharide (LPS)-induced lung injury treatment only.
  • FIG 9B is an image of a histological section of a rat after lung lipopolysaccharide (LPS)- induced lung injury treatment and IL-lRa capsule instillation.
  • FIG 9C is an image of a histological section of a healthy rat lung as a positive control.
  • FIG. 10 Illustrates the distribution of fluorescent capsules loaded with FITC dextran are distributed in instilled rat lungs as imaged using a Leica microscope in the GFP channel. Bright spots indicate the presence of capsules.
  • FIG. 11 is a schematic illustration of transposing therapeutic sequences comprising IL- 10, IL-lRa, IL-13, IL-4, and FG-21 with a PiggyBac transposon employing a cut-and-paste method into genomic DNA of an engineered cell line for expression of a therapeutic agent.
  • FIG. 12 is a graph showing FGF-21 concentration (ng/mL) over time in a therapeutic cell, wherein the FGF-21 gene was pasted into the genomic DNA using a PiggyBac mobile element transposition.
  • FIGS. 13A-13E demonstrate the load and distribution of capsules for instillation in rodent alveolar tissue.
  • FIG. 13A is a representative micrograph of the 300 pm -diameter cellladen capsules loaded with FITC dextran.
  • FIG. 13B is a representative IVIS (In Vivo Imaging System) image of rat lungs after instillation of 300 pm capsules comprising GFP-expressing cells which show their uniformity in rat alveolae.
  • FIGS. 13C-D are representative ex vivo fluorescent images of lungs of instillation with dextran capsules which demonstrate their homogeneous distribution in rat alveolar tissue.
  • FIG. 13A is a representative micrograph of the 300 pm -diameter cellladen capsules loaded with FITC dextran.
  • FIG. 13B is a representative IVIS (In Vivo Imaging System) image of rat lungs after instillation of 300 pm capsules comprising GFP-expressing cells which show their uniformity in rat alveolae.
  • FIG. 13E is a micrograph of 300 pm-diameter capsules comprising cells capable of expressing the firefly luciferase protein, indicating that the cell-laden capsules are all apportioned a similar amount of cells, e.g., about 10,000 cells.
  • FIG. 14A-14C demonstrate the distribution and longevity of capsules instilled in rat lungs.
  • FIG. 14A is a graph depicting the average radiance of rats instilled with either 300 pm capsules comprising a plurality of firefly-luciferase cells or free cells over a 1 week period.
  • FIG. 14B is a series of representative images of rats that were instilled 300 pm-diameter capsules comprising a plurality of firefly-luciferase expressing cells.
  • FIG. 14C is a graph demonstrating in vivo bioluminescent total flux analysis demonstrating capsule retention for up to three days versus one day in unencapsulated cells (left), ex vivo fluorescent images of lungs after instillation with fluorescent dextran-loaded capsules (middle panel), and in vivo bioluminescent imaging of ex vivo lung one day after capsule instillation (top right panel) and unencapsulated cells (lower right panel) instillation.
  • FIG. 15B is a bar graph of IL-IRa concentration (ng/mL) in BAL and plasma 24 h after instillation with capsules containing engineered ARPE-19 cells capable of IL-IRa expression.
  • FIG. 15C is a bar graph of FGF21 concentration (ng/mL) in BAL and plasma 24 h after instillation with capsules containing engineered ARPE-19 cells capable of FGF21 expression.
  • FIG. 15D is a bar graph of IL- 13 concentration (ng/mL) in BAL and plasma 24 h after instillation with capsules containing engineered ARPE-19 cells capable of IL-13 expression.
  • FIGS. 16A-16H demonstrate dose escalation and pharmacokinetics of instilled capsules delivered intratracheally to rat lungs.
  • FIG. 16A is a bar graph showing IL-10 protein levels in bronchoalveolar lavage (BAL) and plasma from rats instilled 300 pm-diameter capsules at increasing volumes, i.e., 0, 50, 100, and 150 pl.
  • FIG. 16B is a bar graph illustrating the relationship between increasing cell density per capsule (cell concentration per mL alginate) and rat IL- 10 production as measured in bronchoalveolar lavage (BAL) and plasma.
  • FIG. 16A is a bar graph showing IL-10 protein levels in bronchoalveolar lavage (BAL) and plasma from rats instilled 300 pm-diameter capsules at increasing volumes, i.e., 0, 50, 100, and 150 pl.
  • FIG. 16B is a bar graph illustrating the relationship between increasing cell density per capsule (cell concentration per mL alg
  • FIG. 16C is a bar graph of BAL and plasma concentrations of IL-10 24 hours post-instillation with 100 pL of RPE-IL-10 capsules and upon repeat dose at 30 days. Results show no significant difference in local concentrations between day 1 and day 31, indicating no anti-drug antibody development.
  • FIG. 16D is a graph quantifying rat IL-10 levels in bronchoalveolar lavage (BAL) and plasma over the duration of 14 days post-instillation with rat IL-10-producing capsules.
  • FIG. 16E are graphs of in vitro concentrations of IL-IRa, FGF-21, IL-13, and IL-4 24 hours after administration of 100 pl of 300 pm capsules.
  • FIG. 16F is a bar graph showing the IL-10 levels in the post caval, middle, superior, inferior, and left lobes of lungs of rats 24 hours after instillation with IL- 10 producing capsules.
  • FIG. 16G is a bar graph of Rat IL-10 concentration in bronchoalveolar lavage (BAL) and plasma at Day 100, representing a return to baseline levels.
  • FIG. 16H is a series of histological sections of rat lung (alveolar) tissue corresponding to the kinetic timepoints (Day 1, Day 2, Day 3, Day 4, Day 7, and Day 14).
  • FIGS. 17A-17C are histological sections of fixed and stained rat alveolar tissue after instillation with capsules expressing anti-inflammatory mediators.
  • FIG. 17A shows a histological section of rat alveolar tissue one day after instillation of the capsules.
  • FIG. 17B shows a histological section of rat alveolar tissue seven days after instillation of the capsules.
  • FIG. 17C shows a histological section of rat alveolar tissue 14 days after instillation of the capsules.
  • FIGS. 18A-18G illustrate capsule administration in porcine lungs via bronchoscopy.
  • FIG. 18A is a representative image of blue-dyed capsules instilled into porcine lungs via bronchoscope.
  • FIG. 18B shows IL-10 and IL-IRa concentrations in BAL and plasma on Day 0, Day 2 and Day 28.
  • FIG. 18C is a bar graph of human IL-IRa (hIL-IRa) levels in bronchoalveolar lavage (BAL) and plasma prior to and two days after instillation of hlL-lRa- secreting capsules.
  • hIL-IRa human IL-IRa
  • FIG. 18D is a bar graph of human IL-10 (hIL-10) levels in bronchoalveolar lavage (BAL) and plasma prior to and two days after instillation of hIL-10-secreting capsules.
  • FIG. 18E presents the general health of pigs prior to, two days after, and twenty-eight days after instillation of IL-10 and IL-IRa producing capsules as characterized by triglycerides, total cholesterol and glucose.
  • FIG. 18F shows any changes in liver function of pigs prior to, two days after, and twenty-eight days after instillation of hIL-IRa- and hIL-10 producing capsules as characterized by albumin concentration.
  • FIGS. 19A-19G describe the establishment of an LPS model of ARDS.
  • FIG. 19A summaries the study design: on Day 0, animals receive 200 mg/k LPS or volume-matched saline.
  • Levels of various inflammatory markers, e.g., TNF-a, IL-la, MCP1, MIP2, in addition to total cell count from lung homogenate were measured in bronchoalveolar lavage (BAL) fluid on Day 2 after instillation.
  • BAL bronchoalveolar lavage
  • 19B is a bar graph showing that BAL levels of TNF-a on Day 2 post administration of 20 mg/kg LPS are between about 100 and 1000 pg/mL compared to about 1 to about 10 pg/mL for the saline group.
  • FIG. 19C is a bar graph showing that BAL levels of IL-la on Day 2 post-administration of 20 mg/kg LPS are about 1000 pg/mL compared to about 10 pg/mL for the saline group.
  • FIG 19D is a bar graph showing that BAL levels of MCP1 on Day 2 post-administration of 20 mg/kg LPS are about 10 5 pg/mL compared to about 10 pg/mL for the saline group.
  • 19E is a bar graph showing that BAL levels of MIP2 on Day 2 postadministration of 20 mg/kg LPS is between about 10 3 and about 10 4 pg/mL compared to between about 10 to about 100 pg/mL for the saline group.
  • FIG. 19F is a bar graph showing that BAL levels of total cell count derived lung homogenate are about 4* 10 7 cells compared to about 1 * 10 7 to about 2*10 7 cells for the saline group.
  • FIG. 19G shows representative images from a homogenized post caval left lung lobe.
  • FIG. 20 is a series of images showing the localization of capsules fabricated with a fluorescent dye, which is excitable at a wavelength of 680 nm, instilled in rat lungs.
  • FIG. 21 shows, in the image on the left, the distribution of fluorescently labelled FITC dextran capsules instilled in the lungs of rats.
  • To the right is an image of LIVE/DEAD staining of cells encapsulated within 300 pm capsules indicating that the cells are alive (live channel has signal and dead channel has no signal).
  • FIGS. 22A-22B demonstrate the response of engineered ARPE-19 cells to pro- inflammatory cytokines.
  • FIG. 22A shows the plasmid used to engineer the ARPE-19 cells to upregulate production of a transgene in response to pro-inflammatory cytokines.
  • FIG. 22B is a graph of the relative luminescence of transgene expression in engineered ARPE-19 cells with exposure to the cytokines IFN-y (10 ng/mL), IL-ip (15 ng/mL), and TNF-a (15 ng/mL), and no exposure to cytokines (Control).
  • RLU relative luminescence units.
  • FIG. 23A-23C show results of IL-10 and IL-IRa combination therapy in an LPS model of ARDS.
  • FIG. 23A are graphs showing concentrations of rat IL-IRa and Rat IL- 10 in pleural fluid and plasma over 28 days after intratracheal instillation with LPS and implantation of ⁇ 15 .g/day IL-IRa and ⁇ 3 pg/day IL-10 in the pleural cavity.
  • FIG. 23B are microscopy images of explanted capsules on Day 1, 3, 7, and 28 demonstrating minimal fibrotic overgrowth.
  • FIG. 23C is a graph showing lung histology score for the LPS only and LPS + IL-10 + IL-Ra capsules.
  • FIG. 24A-24B show the distribution and kinetics of capsules instilled into the lungs of mice.
  • FIG. 24A is a series of IVIS images showing the distribution and kinetics of localization of luminescent RPE -Flue capsules in the lungs of mice over 11 days.
  • FIG. 24B is a graph quantifying the total flux of RPE -Flue capsules in the lungs of mice over 11 days.
  • FIG. 25 is a series of fluorescence microscopy and fluorescent IVIS images of rat lungs instilled with 100 pl of 300pm green fluorescent protein (GFP) capsules.
  • GFP green fluorescent protein
  • FIGS. 26A-26C show results of an LPS model of ARDS.
  • FIG. 26A shows images of histological sections of lungs treated with LPS with our without IL- 10 producing capsules 24 hours after treatment.
  • FIG. 26B show graphs showing total cell counts collected 24 hours after LPS instillation and treatment with saline, blank capsules and IL- 10 producing capsules, with healthy rats serving as control (left), and IL la BAL concentrations 24 hours after LPS and capsule treatment (right).
  • FIG. 26C show graphs of ILlb and MCP-1 BAL concentrations 24 hours after LPS and capsule treatment.
  • FIGS. 27A-27B demonstrate the therapeutic efficacy of IL-10 and IL-IRA combination therapy in an ARDS model.
  • FIG. 27A shows total cell counts collected 12 and 24 hours after LPS instillation (left), IL- la (middle) and TNFa (right) BAL concentrations 12 and 24 days after LPS treatment and administration of IL-10/IL-la producing capsules.
  • FIG. 27B show MCP1 (left), IL-lb concentrations 12 and 24 days after LPS treatment and administration of IL-10/IL- la producing capsules and perivascular lymphoid cuffing on day 28 for LPS only and LPS/ILlRa+IL-10 producing capsule group.
  • FIGS. 28A-28E demonstrate the therapeutic efficacy of capsules in an LPS model of ARDS.
  • FIG. 28A shows total cell counts collected 24 hours after LPS instillation and treatment with saline, blank capsules and IL- 10 producing capsules, with healthy rats serving as control (left), and ILla (middle) and TNFa (right) BAL concentrations 24 hours after LPS and capsule treatment.
  • FIG. 28B are graphs of ILlb and MCP-1 BAL concentrations 24 hours after LPS and capsule treatment.
  • FIG. 28C are graphs showing histological scores of inflammation over time as a factor of neutrophil density, distribution, and immune consolidations (left) and of regulatory response following treatment as a factor of macrophage, fibroblast, and chronic inflammatory cells.
  • FIG. 28D is graph quantifying perivascular lymphoid cuffing over time, which is representative of unresolved inflammation.
  • FIG. 28E is a representative histological scan of the right lung 1, 7, 14, and 21 days after LPS with or without capsule treatment. Inset is a 20x magnification of the same image showing the immune phenotypes quantified in the histological scoring (i.e. neutrophils, regulatory cells, and perivascular cuffing).
  • FIGS. 29A-29C are bar graphs illustrating that ARPE-19 cells can be engineered to constitutively produce different therapeutic agents according to the piggyback transposase system.
  • FIG. 29A is a bar graph showing constitutive Anti-IL8 production from ARPE-19 cells.
  • FIG. 29B is a bar graph showing constitutive IL-10 production from ARPE-19 cells.
  • FIG. 29C is a bar graph showing constitutive IL-IRA production from ARPE-19 cells.
  • FIG. 30 is a bar graph showing Constitutive Anti-IL6 production from ARPE-19 cells.
  • FIGS. 31A-31C demonstrate that ARPE-19 cells can be engineered to produce therapeutic agents in response to inflammation.
  • FIG. 31A is a bar graph showing anti-IL-8 production in response to pro-inflammatory cytokines TNF-a and IL- 10 with ARPE-19 cells engineered with plasmids encoding ant-IL-8 under the control of a NF-KB-responsive promoter.
  • FIG. 31B is a bar graph showing IL-10 production in response to pro-inflammatory cytokines TNF-a and IL- 10 with ARPE-19 cells engineered with plasmids encoding IL-10 under the control of a NF-KB-responsive promoter.
  • FIG. 31A is a bar graph showing anti-IL-8 production in response to pro-inflammatory cytokines TNF-a and IL- 10 with ARPE-19 cells engineered with plasmids encoding IL-10 under the control of a NF-KB-responsive promoter.
  • 31C is a bar graph showing IL-IRa production in response to pro-inflammatory cytokines TNF-a and IL-ip with ARPE-19 cells engineered with plasmids encoding IL-IRA under the control of a NF-KB-responsive promoter.
  • FIG. 32 is a bar graph showing luciferase production in response to pro inflammatory cytokines from ARPE-19 cells engineered with NFkB-luciferase.
  • FIG. 33 is a bar graph showing luciferase production from ARPE-19 cells engineered with NFkB-luciferase in response to different forms and concentrations of IL1 (mlLla is mouse ILla; hILla is human ILla).
  • FIGS. 34A-34B demonstrate that cytokine production from engineered ARPE-19 cells is dose-responsive.
  • FIG. 34A is a graph showing that engineered ARPE-19 cells produce IL-IRA in a dose-dependent manner when treated with IL- 10 and TNF-a.
  • the ARPE-19 cells were engineered to produce IL-IRA by stable transfection with a plasmid containing a NFKB- responsive promoter.
  • FIG. 34B is graph illustrating IL-10 production from ARPE-19 cells engineered with NFkB-mlLlO. Response to 15mg/mL or 15pg/mL of IL lb over time.
  • FIGS. 34A is a graph showing that engineered ARPE-19 cells produce IL-IRA in a dose-dependent manner when treated with IL- 10 and TNF-a.
  • the ARPE-19 cells were engineered to produce IL-IRA by stable transfection with a plasmid containing a NFKB- responsive promoter.
  • FIG. 35A-C illustrate the engineering of ARPE-19 cells expressing anti-inflammatory cytokines, their subsequent encapsulation in hydrogel capsules, and finally local delivery to affected tissue to modulate the immune response.
  • FIG. 35A is a schematic illustrating the piggyback transposase system for engineering cells capable of expressing anti-inflammatory cytokines.
  • FIG. 35B is a schematic illustrating the encapsulation of engineered cells in hydrogel to isolate the cells from an immune response.
  • FIG. 35C is a schematic of the implantation of capsules in a rodent model to locally modulate inflammation at the site of endometrial lesions.
  • FIG. 36A-36D demonstrate that ARPE-19 cells maintain viability and productivity after encapsulated in alginate capsules.
  • FIG. 36A is a brightfield microscopy image of capsules encapsulated with ARPE-19 cells capable of expressing IL-10 under control of a NF-KB- responsive promoter.
  • FIG. 36B is a microscopy image of Calcein AM-stained capsules encapsulated with ARPE-19 cells capable of expressing IL-10 under control of a NF-KB- responsive promoter. The color green indicates viability.
  • FIG. 36C is a microscopy image of ethidium homodimer-stained capsules encapsulated with ARPE-19 cells capable of expressing IL- 10 under control of a NF-KB-responsive promoter.
  • FIG. 36D is a bar graph showing IL- 10 production responsive to the pro-inflammatory markers IL- 10 and TNF-a.
  • the capsules contain ARPE-19 cells capable of producing IL- 10 under the control of a NF-KB-responsive promoter.
  • the subject may include a human (i.e., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult, or senior adult)) and/or other non-human animals, for example, mammals (e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and/or dogs) and birds (e.g., commercially relevant birds such as chickens, ducks, geese, and/or turkeys).
  • the animal is a mammal.
  • the animal may be a male or female and at any stage of development.
  • a non-human animal may be a transgenic animal.
  • treatment refers to reversing, alleviating, delaying the onset of, or inhibiting of one or more of a symptom, manifestation, or underlying cause of, e.g., a disease, disorder or condition for which the composition is administered.
  • the compounds disclosed herein may also comprise one or more isotopic substitutions.
  • H may be in any isotopic form, including 1 H, 2 H (D or deuterium), and 3 H (T or tritium);
  • C may be in any isotopic form, including 12 C, 13 C, and 14 C;
  • O may be in any isotopic form, including 16 O and 18 O; and the like.
  • Alkyl refers to a hydrocarbon group containing one or more carbon atoms, where multiple carbon atoms if present are joined by single bonds.
  • the alkyl hydrocarbon group may be straight-chain or contain one or more branches or cyclic groups having from 1 to 24 carbon atoms (“C1-C24 alkyl”).
  • an alkyl group has 1 to 12 carbon atoms (“C1-C12 alkyl”), 1 to 10 carbon atoms (“C1-C12 alkyl”), 1 to 8 carbon atoms (“Ci-Cs alkyl”), 1 to 6 carbon atoms (“Ci-Ce alkyl”), 1 to 5 carbon atoms (“C1-C5 alkyl”), 1 to 4 carbon atoms (“Ci-C4alkyl”), 1 to 3 carbon atoms (“C1-C3 alkyl”), 1 to 2 carbon atoms (“C1-C2 alkyl”), or 1 carbon atom (“Ci alkyl”).
  • an alkyl group has 2 to 6 carbon atoms (“C2-C6 alkyl”).
  • Ci-Ce alkyl groups include methyl (C 1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (Cs), 3-pentanyl (C5), amyl (C5), neopentyl (Cs), 3-methyl-2-butanyl (Cs), tertiary amyl (Cs), and n-hexyl (Ce).
  • alkyl groups include n-heptyl (C7), n-octyl (Cs) and the like.
  • Each instance of an alkyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkyl”) or substituted (a “substituted alkyl”) with one or more substituents; e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
  • Haloalkyl refers to an alkyl, wherein one or more hydrogen atoms of the hydrocarbon group are replaced with a halogen, i.e., fluorine, chlorine, bromine, and iodine.
  • fluoroalkyl refers to an alkyl, wherein one or more hydrogen atoms of the hydrocarbon group are replaced with a fluorine.
  • Chloroalkyl refers to an alkyl, wherein one or more hydrogen atoms of the hydrocarbon group are replaced with a chlorine.
  • Haloalkyl refers to an alkyl, wherein one or more hydrogen atoms of the hydrocarbon group are replaced with a bromine.
  • “lodoalkyl” refers to an alkyl, wherein one or more hydrogen atoms of the hydrocarbon group are replaced with a iodine.
  • halo encompasses fluoro, chloro, bromo, and iodo.
  • alkenyl refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 24 carbon atoms, one or more carbon-carbon double bonds, and no triple bonds (“C2-C24 alkenyl”).
  • an alkenyl group has 2 to 12 carbon atoms (“C2-C12 alkenyl”), 2 to 10 carbon atoms (“C2-C10 alkenyl”), 2 to 8 carbon atoms (“C2-C8 alkenyl”), 2 to 6 carbon atoms (“C2-C6 alkenyl”), 2 to 5 carbon atoms (“C2-C5 alkenyl”), 2 to 4 carbon atoms (“C2-C4 alkenyl”), 2 to 3 carbon atoms (“C2-C3 alkenyl”), or 2 carbon atoms (“C2 alkenyl”).
  • the one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl).
  • Examples of C2-C4 alkenyl groups include ethenyl (C2), 1- propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like.
  • Examples of C2-C6 alkenyl groups include the aforementioned C2-4 alkenyl groups as well as pentenyl (Cs), pentadienyl (Cs), hexenyl (Ce), and the like.
  • Each instance of an alkenyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
  • alkynyl refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 24 carbon atoms, one or more carbon-carbon triple bonds (“C2-C24 alkenyl”).
  • an alkynyl group has 2 to 12 carbon atoms (“C2-C10 alkynyl”), 2 to 10 carbon atoms (“C2-C10 alkynyl”), 2 to 8 carbon atoms (“C2-C8 alkynyl”), 2 to 6 carbon atoms (“C2-C6 alkynyl”), 2 to 5 carbon atoms (“C2-C5 alkynyl”), 2 to 4 carbon atoms (“C2-C4 alkynyl”), 2 to 3 carbon atoms (“C2-C3 alkynyl”), or 2 carbon atoms (“C2 alkynyl”).
  • the one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl).
  • Examples of C2-C4 alkynyl groups include ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like.
  • Each instance of an alkynyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkynyl”) or substituted (a “substituted alkynyl”) with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
  • heteroalkyl refers to a non-cyclic stable straight or branched chain, or combinations thereof, including at least one carbon atom and at least one heteroatom selected from the group consisting of O, N, P, Si, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
  • the heteroatom(s) O, N, P, S, and Si may be placed at any position of the heteroalkyl group.
  • heteroalkyl Up to two or three heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3.
  • heteroalkyl is recited, followed by recitations of specific heteroalkyl groups, such as -CH2O, -NR C R D , or the like, it will be understood that the terms heteroalkyl and -CH2O or -NR C R D are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term “heteroalkyl” should not be interpreted herein as excluding specific heteroalkyl groups, such as -CH2O, -NR C R D , or the like.
  • Each instance of a heteroalkyl group may be independently optionally substituted, z.e., unsubstituted (an “unsubstituted heteroalkyl”) or substituted (a “substituted heteroalkyl”) with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
  • cycloalkyl refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms (“C3-C10 cycloalkyl”) and zero heteroatoms in the non-aromatic ring system.
  • a cycloalkyl group has 3 to 8 ring carbon atoms (“Cs-Cscycloalkyl”), 3 to 6 ring carbon atoms (“C3-C6 cycloalkyl”), or 5 to 10 ring carbon atoms (“C5-C10 cycloalkyl”).
  • a cycloalkyl group may be described as, e.g., a C4-C?-membered cycloalkyl, wherein the term “membered” refers to the non-hydrogen ring atoms within the moiety.
  • Exemplary C3-C6 cycloalkyl groups include, without limitation, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (Ce), cyclohexenyl (Ce), cyclohexadienyl (Ce), and the like.
  • Exemplary C3-C8 cycloalkyl groups include, without limitation, the aforementioned C3-C6 cycloalkyl groups as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (Cs), cyclooctenyl (Cs), cubanyl (Cs), bicyclo[l.l.l]pentanyl (Cs), bicyclo[2.2.2]octanyl (Cs), bicyclo[2.1.1]hexanyl (Ce), bicyclo[3.1.1]heptanyl (C7), and the like.
  • Exemplary C3-C10 cycloalkyl groups include, without limitation, the aforementioned C3-C8 cycloalkyl groups as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro-1 7-indenyl (C9), decahydronaphthalenyl (C10), spiro [4.5] decanyl (C10), and the like.
  • the cycloalkyl group is either monocyclic (“monocyclic cycloalkyl”) or contain a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic cycloalkyl”) and can be saturated or can be partially unsaturated.
  • “Cycloalkyl” also includes ring systems wherein the cycloalkyl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is on the cycloalkyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the cycloalkyl ring system.
  • Each instance of a cycloalkyl group may be independently optionally substituted, z.e., unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents.
  • Heterocyclyl refers to a radical of a 3- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“3-10 membered heterocyclyl”).
  • the point of attachment can be a carbon or nitrogen atom, as valency permits.
  • a heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”), and can be saturated or can be partially unsaturated.
  • Heterocyclyl bicyclic ring systems can include one or more heteroatoms in one or both rings.
  • Heterocyclyl also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more cycloalkyl groups wherein the point of attachment is either on the cycloalkyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system.
  • a heterocyclyl group may be described as, e.g., a 3-7-membered heterocyclyl, wherein the term “membered” refers to the nonhydrogen ring atoms, i.e., carbon, nitrogen, oxygen, sulfur, boron, phosphorus, and silicon, within the moiety.
  • Each instance of heterocyclyl may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a “substituted heterocyclyl”) with one or more substituents.
  • the heterocyclyl group is unsubstituted 3-10 membered heterocyclyl.
  • the heterocyclyl group is substituted 3- 10 membered heterocyclyl.
  • hydroxy refers to the radical -OH.
  • Alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, and heterocyclyl groups, as defined herein, are optionally substituted (e.g., “substituted” or “unsubstituted” alkyl, “substituted” or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl, “substituted” or “unsubstituted” heteroalkyl, “substituted” or “unsubstituted” cycloalkyl, “substituted” or “unsubstituted” heterocyclyl, “substituted” or “unsubstituted” aryl or “substituted” or “unsubstituted” heteroaryl group).
  • substituted means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction.
  • a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position.
  • substituted is contemplated to include substitution with all permissible substituents of organic compounds, such as any of the substituents described herein that result in the formation of a stable compound.
  • the present disclosure contemplates any and all such combinations to arrive at a stable compound.
  • heteroatoms such as nitrogen may have hydrogen substituents and/or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety.
  • Inflammatory hyperactivity and/or dysregulation may stem from congenital defects in inflammatory mediators such as Interleukin- 1 [3, NF-KB, Interferon 1 (IFN-1), Interleukin-1 Receptor (IL-IRa), Interleukin- 10 Receptor (IL-10R), Interleukin-36 Receptor (IL-36Ra), inter alia.
  • IFN-1 Interleukin-1
  • IL-IRa Interleukin-1 Receptor
  • IL-10R Interleukin- 10 Receptor
  • IL-36Ra Interleukin-36 Receptor
  • Autoimmune diseases arise as a result of a failure of the adaptive immune system, which eliminates potential threats by the generation of antibodies capable of identifying antigens associated with a pathogen.
  • Dysregulation of the adaptive immune system may have deleterious consequences in the immune response of a patient, having potentially cascading effects on the innate immune system as well, resulting in an aberrant inflammatory state in response to an autoantigen the patient’s immune system has mistakenly identified as a threat.
  • Respiratory diseases or conditions which arise from a proinflammatory stimulus, autoinflammatory, or autoimmune condition are myriad and include: anti-glomerular basement membrane disease, acute interstitial pneumonitis, asthma, bronchopulmonary dysplasia, bronchiectasis, chemical pneumonitis, chronic bronchitis, chronic obstructive pulmonary disease (COPD), conditions with a pleural effusion, cystic fibrosis, hypersensitivity pneumonitis (e.g., due to an environmental allergen, e.g., pollen, mold, dust, dander, and the like), (eosinophilic) granulomatosis with polyangiitis, Langerhans cell histiocytosis, lymphangioleiomyomatosis, infant respiratory distress syndrome (IRDS), pneumoconiosis (e g., asbestosis), primary ciliary dyskinesia, pulmonary alveolar proteinosis (e.g., of autoimmune etiology), pleural
  • Potential treatment modalities for autoinflammatory, or autoimmune conditions may be addressable with the inventive composition as described herein via modulation of the inflammatory response via release of a therapeutic agent from the inventive composition as described herein.
  • Respiratory infection are among the most ubiquitously encountered illnesses, which can manifest in clinical presentation from very mild to severe. Respiratory infections are broadly categorized by the location of infection, i.e., as an upper respiratory infection, e.g., a common cold; or as a lower respiratory infection, e.g., pneumonia, e.g., acute respiratory distress syndrome (ARDS) caused by, e.g., the SARS-CoV-2 coronavirus (COVID-19).
  • ARDS acute respiratory distress syndrome
  • Non-limiting examples of respiratory infections include: acute bronchitis, acute chest syndrome, acute respiratory distress syndrome (ARDS) aspergillosis, bronchiectasis, bronchiolitis, bronchiolitis obliterans, chronic bronchitis, chronic coughing, coccidioidomycosis, common cold, COVID-19, cryptogenic organizing pneumonia, emphysema, hantavirus pulmonary syndrome, histoplasmosis, human metapneumovirus, influenza, interstitial lung disease (ILD), legionnaire’s disease, mycobacterium avium complex disease, middle eastern respiratory syndrome (MERS), nontuberculous mycobacteria lung disease, pertussis, pneumonia, pneumothorax, respiratory syncytial virus (RSV), severe acute respiratory syndrome (SARS), and tuberculosis.
  • ARDS acute respiratory distress syndrome
  • ARDS acute respiratory distress syndrome
  • bronchiectasis bronchiolitis
  • respiratory infections may be characterized by inflammatory dysregulation, e.g., the inflammatory hyperactivity referred to as a “cytokine storm” in the evolution of severe COVID-19 pneumonia and ARDS.
  • a cytokine storm the inflammatory hyperactivity referred to as a “cytokine storm” in the evolution of severe COVID-19 pneumonia and ARDS.
  • the class of respiratory infections are promising targets for the inventive capsules capable of releasing a therapeutic agent, e.g., a protein such as a cytokine, as described herein.
  • a capsule described herein comprises a material that reduces or inhibits a reaction (e.g., such as an immunomodulatory reaction) with an engineered cell disposed within.
  • a capsule may comprise a material that shields the engineered cell from exposure to the surrounding milieu, such as host tissue, host cells, or host cell products.
  • a capsule minimizes the effect of a host response (e.g., an immune response) directed at an engineered cell disposed within, e.g., as compared with a similar cell that is not disposed within an capsule.
  • the capsule make take any shape.
  • the surface may be flat surface or a curved surface, and can take a variety of more complex forms such a sphere, a tube (e.g., inside or outside of the tube), a bead, a rod, a wire, or even more complex 3-D structures such as medical devices.
  • the capsule may comprise a permeable, semi-permeable, or impermeable material to, for example, control the flow of solution in and out of the capsule and/or adopt the shape or size of its surroundings.
  • the material may be permeable or semi-permeable to allow free passage of small molecules, such as nutrients and waste products, in and out of the construct.
  • the material may be permeable or semi-permeable to allow the transport of an cytokine, out of the capsule.
  • Exemplary materials include polymers, metals, ceramics, and combinations thereof.
  • the capsule comprises a polymer (e.g., a naturally occurring polymer or a synthetic polymer).
  • a polymer may comprise polystyrene, polyester, polycarbonate, polyethylene, polypropylene, polyfluorocarbon, nylon, polyacetylene, polyvinyl chloride (PVC), polyolefin, polyurethane, polyacrylate, polymethacrylate, polyacrylamide, polymethacrylamide, polymethyl methacrylate, poly(2-hydroxyethyl methacrylate), polysiloxane, polydimethylsiloxane (PDMS), polyhydroxyalkanoate, PEEK®, polytetrafluoroethylene, polyethylene glycol, polysulfone, polyacrylonitrile, collagen, cellulose, cellulosic polymers, polysaccharides, polyglycolic acid, poly(L -lactic acid) (PLLA), poly(lactic glycolic acid) (PLGA), polydioxanone (PDA), poly(
  • the capsule comprises a polysaccharide (e.g., alginate, cellulose, hyaluronic acid, or chitosan). In an embodiment, the capsule comprises hyaluronic acid. In an embodiment, the capsule comprises alginate.
  • a polysaccharide e.g., alginate, cellulose, hyaluronic acid, or chitosan.
  • the capsule comprises hyaluronic acid.
  • the capsule comprises alginate.
  • the average molecular weight of the polymer is from about 2 kDa to about 500 kDa (e.g., from about 2.5 kDa to about 175 kDa, from about 5 kDa about 150 kDa, from about 10 kDa to about 125 kDa, from about 12.5 kDa to about 100 kDa, from about 15 kDa to about 90 kDa, from about 17.5 kDa to about 80 kDa, from about 20 kDa to about 70 kDa, from about 22.5 kDa to about 60 kDa, or from about 25 kDa to about 50 kDa).
  • kDa to about 500 kDa e.g., from about 2.5 kDa to about 175 kDa, from about 5 kDa about 150 kDa, from about 10 kDa to about 125 kDa, from about 12.5 kDa to about 100 kDa, from about
  • the capsule may comprise at least 0.5%, 1%, 2%, 3%, 4%, 5%, 7.5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or more of a polymer, e.g., a polymer described herein.
  • the capsule comprises a polysaccharide, e.g., hyaluronic acid or an alginate.
  • Alginate is a naturally occurring polymer comprising -(l-4)-linked mannuronic acid and guluronic acid residues, and as a result of its high density of negatively charged carboxylates, may be cross-linked with certain cations to form a larger structure, such as a hydrogel.
  • Alginate polymers described herein may have an average molecular weight from about 2 kDa to about 500 kDa (e.g., from about 2.5 kDa to about 175 kDa, from about 5 kDa about 150 kDa, from about 10 kDa to about 125 kDa, from about 12.5 kDa to about 100 kDa, from about 15 kDa to about 90 kDa, from about 17.5 kDa to about 80 kDa, from about 20 kDa to about 70 kDa, from about 22.5 kDa to about 60 kDa, or from about 25 kDa to about 50 kDa).
  • kDa to about 500 kDa e.g., from about 2.5 kDa to about 175 kDa, from about 5 kDa about 150 kDa, from about 10 kDa to about 125 kDa, from about 12.5 kDa to about 100 k
  • the capsule comprises at least 0.5%, 1%, 2%, 3%, 4%, 5%, 7.5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or more of an alginate polymer.
  • the alginate is an ultrapure alginate (e.g., SLG20 alginate).
  • the capsule comprises a metal or a metallic alloy.
  • metals or metallic alloys include titanium (e.g., nitinol, nickel titanium alloys, thermo-memory alloy materials), platinum, platinum group alloys, stainless steel, tantalum, palladium, zirconium, niobium, molybdenum, nickel-chrome, cobalt, tantalum, chromium molybdenum alloys, nickeltitanium alloys, and cobalt chromium alloys.
  • the capsule comprises stainless steel grade.
  • the capsule may comprise at least 0.5%, 1%, 2%, 3%, 4%, 5%, 7.5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or more of a metal or metallic alloy, e.g., a metal or metallic alloy described herein.
  • a metal or metallic alloy e.g., a metal or metallic alloy described herein.
  • the capsule comprises a ceramic.
  • Exemplary ceramics include carbide, nitride, silica, or oxide materials (e.g., titanium oxides, hafnium oxides, iridium oxides, chromium oxides, aluminum oxides, and zirconium oxides).
  • the capsule may comprise at least 0.5%, 1%, 2%, 3%, 4%, 5%, 7.5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or more of a ceramic, e.g, a ceramic described herein.
  • the capsule may comprise glass.
  • the capsule may comprise at least 0.5%, 1%, 2%, 3%, 4%, 5%, 7.5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or more glass.
  • a material within the capsule may be further modified, for example, with a chemical modification.
  • a material may be coated or derivatized with a chemical modification that provides a specific feature, such as an immunomodulatory or antifibrotic feature.
  • exemplary chemical modifications include small molecules, peptides, proteins, nucleic acids, lipids, or oligosaccharides.
  • the capsule may comprise at least 0.5%, 1%, 2%, 3%, 4%, 5%, 7.5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or more of a material that is chemically modified, e.g., with a chemical modification described herein.
  • the material is chemically modified with a specific density of modifications.
  • the specific density of chemical modifications may be described as the average number of attached chemical modifications per given area.
  • the density of a chemical modification on a material in, on, or within an capsule described herein may be 0.01, 0.1, 0.5, 1, 5, 10, 15, 20, 50, 75, 100, 200, 400, 500, 750, 1,000, 2,500, or 5,000 chemical modifications per square pm or square mm.
  • the chemical modification of a material may include a linker or other attachment moiety.
  • linkers may include a cross-linker, an amine-containing linker, an ester- containing linker, a photolabile linker, a peptide-containing linker, a disulfide-containing linker, an amide-containing linker, a phosphoryl -containing linker, or a combination thereof.
  • a linker may be labile (e.g., hydrolysable).
  • Exemplary linkers or other attachment moi eties is summarized in Bioconjugate Techniques (3 rd ed, Greg T. Hermanson, Waltham, MA: Elsevier, Inc, 2013), which is incorporated herein by reference in its entirety.
  • capsules comprising a polymer and a plurality of cells have been engineered to deliver a therapeutic agent, e.g., a protein, e.g., a cytokine.
  • a therapeutic agent e.g., a protein, e.g., a cytokine.
  • the polymer forms a hydrogel, or is capable of forming a hydrogel.
  • the polymer forms a hydrogel, or is capable of forming a hydrogel, that encapsulates a plurality of engineered cells.
  • a hydrogel is a crosslinked structure of polymers comprising a substantial amount of water, with a myriad of applications in drug delivery, biomedical devices, sensors, tissue engineering, and semiconductors due to its unique combination of physical and mechanical properties as varied as biodegradability, biocompatibility, stimuli-responsiveness (e.g., thermo- or pH responsiveness), non-Newtonian behavior, viscoelasticity, and its ability to self-heal.
  • Hydrogels may comprise a natural polymer or a synthetic polymer.
  • the hydrogel comprises a natural polymer, wherein the natural polymer is a polypeptide.
  • Exemplary polymers and copolymers capable of forming a hydrogel include, without limitation, alginate, alginate-polyethylene glycol (alginate-PEG), alginate-polyacrylamide (alginate-PAAm), a- cyclodextrin, a-cyclodextrin-polyethylene glycol (a-cyclodextrin-PEG), chitosan, collagen, fibrin, heparin, hyaluronic acid (HA), polyethylene glycol (PEG), polyacrylic acid (PAA), polyacrylamide (PAAm), polyacrylamide-ferrocene (PAAm-Fc), poly(L-lysine)/polyacrylic acid (PLL/PAA), poly(N-isopropylacylamide) (PNIPAAM), poly((N-isopropylacrylamide)-co- (sodium acrylic acid)) (P(NIPAAM-co-AAcNa)), polyvinyl alcohol-polyacrylamide (PVA-
  • the capsule may comprise a polymer which is degradable, e.g., biodegradable.
  • the polymer is degradable or capable of being degraded.
  • the polymer is biodegradable or capable of being biodegraded.
  • the polymer is degradable, or capable of being degraded, and hydrogel-forming, or capable of forming a hydrogel.
  • the polymer is biodegradable, or capable of being biodegraded, and hydrogel -forming, or capable of forming a hydrogel.
  • the biodegradable polymer is a naturally derived polymer.
  • the biodegradable polymer is a synthetic polymer.
  • the biodegradable polymer may be a natural polymer.
  • Exemplary natural biodegradable polymers include alginic acid and pharmaceutically acceptable salts thereof (e.g., barium alginate calcium alginate, sodium alginate, potassium alginate and the like), cellulose, cellulose ethers (e.g., cellulose hydrocolloids), chitosan, chondroitin sulphate, starch, collagen, hyaluronic acid (HA), polyphosphosphate, and poly (hydroxybutyrate) (PHB).
  • the biodegradable polymer may be a synthetic polymer.
  • Exemplary synthetic biodegradable polymers include polycaprolactone (PCL), poly(hydroxybutyrate-co- hydroxyvalerate), poly(y-glutamic acid), polyglycolic acid (PGA), polylactic acid (PLA), poly(L-lactic acid) (PLLA), and poly(lactic-co-glycolic acid) (PLGA).
  • the biodegradable polymer may be a poly(amino acid).
  • exemplary biodegradable amino acids include polylysine, e.g., poly(D/L-lysine), poly(L-lysine), and poly(D-lysine).
  • the biodegradable polymer may comprise a polyethylene glycol copolymer.
  • Exemplary biodegradable polyethylene glycol copolymers include poly(ethylene glycol)-/>-hyaluronic acid (PEG-HA), poly(ethylene glycol)-/>-polycaprolactone (PEG-PCL), poly(ethylene glycol)- ⁇ - poly(glutamic acid) (PEG-PGA), poly(ethylene glycol)-A-polylactic acid (PEG-PLA), poly(ethylene glycol)-Z>-poly(glycolic-co-lactic acid) (PEG-PLGA), poly(ethylene glycol)-/>- poly(L-lactic acid) (PEG-PLLA), and polyethylene glycol -A-poly (ethyleneimine) (PEG-PEI).
  • the biodegradable polymer may be a polyanhydride.
  • exemplary biodegradable polyanhydrides include poly(adipic anhydride), poly(azelaic anhydride), poly (dodecanedi oc anhydride), poly(dodecane carboxylic acid), poly(fumaric anhydride), poly(fumaric anhydride- sebacic anhydride), poly(furmaric anhydride dodecanedioc anhydride) poly(fumaric anhydride adipic anhydride), poly(hexadecenoic anhydride), poly(isophthalic anhydride), poly(pimelic anhydride), poly(sebacic anhydride), poly(sebacic acid-co-l,3-bis(p-carboxyphenoxy)propane (P(CPP-SA)), poly(suberic anhydride), and poly(terephthalic anhydride) or a copolymer thereof.
  • the biodegradable polymer may be a poly(diol citrate), e.g., a poly(diol citrate) elastomer as disclosed in U.S. Patent No. 8,911,720, which is herein incorporated by reference in its entirety.
  • the biodegradable polymer may be a polyphosphazene or a derivative thereof, e.g., a polyphosphazene disclosed in U.S. Patent Nos. 11,584,828; 5,562,909; 5,562,099; and 5,500,161, which are herein incorporated by reference in their entirety.
  • the biodegradable polymer may be a polyurethane, e.g., a biodegradable polyurethane or derivative thereof as described in U.S. Patent No. 9,540,478, which is herein incorporated by reference in its entirety.
  • the biodegradable polymer may be a polycarbonate, e.g., a biodegradable polycarbonate, copolymer, or derivative thereof, as disclosed in U.S. Patent No. 9,901,649, which is herein incorporated by reference in its entirety.
  • the biodegradable polymer may be a polyorthoester, e.g., a biodegradable polyorthoester or derivative thereof, as disclosed in U.S. Patent No. 11,413,350, which is herein incorporated by reference in its entirety.
  • the biodegradable polymer comprises any of the biodegradable polymers disclosed in Doppalapudi S. etal. Polym. Adv. Technol. 2014, 25, 5, 427-435.
  • the capsule diameter is between about 5 pm to about 3000 pm, about 6 pm to about 3000 pm, about 7 pm to about 3000 pm, about 8 pm to about 3000 pm, about 9 pm to about 3000 pm, about 10 pm to about 3000 pm, about 20 pm to about 3000 pm, about 30 pm to about 3000 pm, about 40 pm to about 3000 pm, about 50 pm to about 3000 pm, about 100 pm to about 3000 pm, about 200 pm to about 3000 pm, about 300 pm to about 3000 pm, about 400 pm to about 3000 pm, about 500 pm to about 3000 pm, about 1000 pm to about 3000 pm, or about 2000 pm to about 3000 pm.
  • the therapeutic agent e.g., a protein, e.g., a cytokine, a chemokine, or secondary polypeptide therapeutic.
  • the capsule diameter is between about 5 pm to about 3000 pm, about 6 pm to about 3000 pm, about 7 pm to about 3000 pm, about 8 pm to about 3000 pm, about 9 pm to about 3000 pm, about
  • the capsule diameter is between about 6 pm to about 3000 pm. In some embodiments, the capsule diameter is between about 7 pm to about 3000 pm. In some embodiments, the capsule diameter is between about 8 pm to about 3000 pm. In some embodiments, the capsule diameter is between about 9 pm to about 3000 pm. In some embodiments, the capsule diameter is between about 10 pm to about 3000 pm. In some embodiments, the capsule diameter is between about 20 pm to about 3000 pm. In some embodiments, the capsule diameter is between about 30 pm to about 3000 pm. In some embodiments, the capsule diameter is between about 40 pm to about 3000 pm. In some embodiments, the capsule diameter is between about 50 pm to about 3000 pm. In some embodiments, the capsule diameter is between about 100 pm to about 3000 pm.
  • the capsule diameter is between about 200 pm to about 3000 pm. In some embodiments, the capsule diameter is between about 300 pm to about 3000 pm. In some embodiments, the capsule diameter is between about 400 pm to about 3000 pm. In some embodiments, the capsule diameter is between about 500 pm to about 3000 pm. In some embodiments, the capsule diameter is between about 1000 pm to about 3000 pm. In some embodiments, the capsule diameter is between about 2000 pm to about 3000 pm.
  • the capsule diameter is about 150 pm, about 300 pm, about 600 pm, about 800 pm, about 1200 pm, or about 1700 pm. In some embodiments, the capsule diameter is about 150 pm. In some embodiments, the capsule diameter is about 300 pm. In some embodiments, the capsule diameter is about 600 pm. In some embodiments, the capsule diameter is about 800 pm. In some embodiments, the capsule diameter is about 1200 pm. In some embodiments, the capsule diameter is about 1700 pm.
  • the capsule diameter is greater than about 100 pm. In some embodiments, the capsule diameter is greater than about 150 pm, about 200 pm, about 300 pm, about 400 pm, about 500 pm, about 600 pm, about 700 pm, about 800 pm, about 900 pm, about 1000 pm, about 1100 pm, about 1200 pm, about 1300 pm, about 1400 pm, about 1500 pm, about 1600 pm, about 1700 pm, about 1800 pm, about 1900 pm, or about 2000 pm. In some embodiments, the capsule diameter is greater than about 150 pm. In some embodiments, the capsule diameter is greater than about 200 pm. In some embodiments, the capsule diameter is greater than about 300 pm. In some embodiments, the capsule diameter is greater than about 400 pm. In some embodiments, the capsule diameter is greater than about 500 pm.
  • the capsule diameter is greater than about 600 pm. In some embodiments, the capsule diameter is greater than about 700 pm. In some embodiments, the capsule diameter is greater than about 800 pm. In some embodiments, the capsule diameter is greater than about 900 pm. In some embodiments, the capsule diameter is greater than about 1000 pm. In some embodiments, the capsule diameter is greater than about 1100 pm. In some embodiments, the capsule diameter is greater than about 1200 pm. In some embodiments, the capsule diameter is greater than about 1300 pm. In some embodiments, the capsule diameter is greater than about 1400 pm. In some embodiments, the capsule diameter is greater than about 1500 pm. In some embodiments, the capsule diameter is greater than about 1600 pm. In some embodiments, the capsule diameter is greater than about 1700 pm. In some embodiments, the capsule diameter is greater than about 1800 pm. In some embodiments, the capsule diameter is greater than about 1900 pm. In some embodiments, the capsule diameter is greater than about 2000 pm.
  • the capsule diameter is between about 100 pm and 2000 pm. In some embodiments, the capsule diameter is between about 100 pm and about 1900 pm, about 100 pm and about 1800 pm, about 100 pm and about 1700 pm, about 100 pm and about 1600 pm, about 100 pm and about 1500 pm, about 100 pm and about 1400 pm, about 100 pm and about 1300 pm, about 100 pm and about 1200 pm, about 100 pm and about 1100 pm, about 100 pm and about 1000 pm, about 100 pm and about 900 pm, about 100 pm and about 800 pm, about 100 pm and about 700 pm, about 100 pm and about 600 pm, about 100 pm and about 500 pm, about 100 pm and about 400 pm, about 100 pm and about 300 pm, or about 100 pm and about 200 pm.
  • the capsule diameter is between about 100 pm and about 1900 pm. In some embodiments, the capsule diameter is between about 100 pm and about 1800 pm. In some embodiments, the capsule diameter is between about 100 pm and about 1700 pm. In some embodiments, the capsule diameter is between about 100 pm and about 1600 pm. In some embodiments, the capsule diameter is between about 100 pm and about 1500 pm. In some embodiments, the capsule diameter is between about 100 pm and about 1400 pm. In some embodiments, the capsule diameter is between about 100 pm and about 1300 pm. In some embodiments, the capsule diameter is between about 100 pm and about 1200 pm. In some embodiments, the capsule diameter is between about 100 pm and about 1100 pm. In some embodiments, the capsule diameter is between about 100 pm and about 1000 pm.
  • the capsule diameter is between about 100 pm and about 900 pm. In some embodiments, the capsule diameter is between about 100 pm and about 800 pm. In some embodiments, the capsule diameter is between about 100 pm and about 700 pm. In some embodiments, the capsule diameter is between about 100 pm and about 600 pm. In some embodiments, the capsule diameter is between about 100 pm and about 500 pm. In some embodiments, the capsule diameter is between about 100 pm and about 400 pm. In some embodiments, the capsule diameter is between about 100 pm and about 300 pm. In some embodiments, the capsule diameter is between about 100 pm and about 200 pm.
  • the capsule diameter is about 150 pm.
  • the capsule diameter is between about 200 pm and 2000 pm. In some embodiments, the capsule diameter is between about 200 pm and about 1900 pm, about 200 pm and about 1800 pm, about 200 pm and about 1700 pm, about 200 pm and about 1600 pm, about 200 pm and about 1500 pm, about 200 pm and about 1400 pm, about 200 pm and about 1300 pm, about 200 pm and about 1200 pm, about 200 pm and about 1100 pm, about 200 pm and about 1000 pm, about 200 pm and about 900 pm, about 200 pm and about 800 pm, about 200 pm and about 700 pm, about 200 pm and about 600 pm, about 200 pm and about 500 pm, about 200 pm and about 400 pm, or about 200 pm and about 300 pm. In some embodiments, the capsule diameter is between about 200 pm and about 1900 pm.
  • the capsule diameter is between about 200 pm and about 1800 pm. In some embodiments, the capsule diameter is between about 200 pm and about 1700 pm. In some embodiments, the capsule diameter is between about 200 pm and about 1600 pm. In some embodiments, the capsule diameter is between about 200 pm and about 1500 pm. In some embodiments, the capsule diameter is between about 200 pm and about 1400 pm. In some embodiments, the capsule diameter is between about 200 pm and about 1300 pm. In some embodiments, the capsule diameter is between about 200 pm and about 1200 pm. In some embodiments, the capsule diameter is between about 200 pm and about 1100 pm. In some embodiments, the capsule diameter is between about 200 pm and about 1000 pm. In some embodiments, the capsule diameter is between about 200 pm and about 900 pm.
  • the capsule diameter is between about 200 pm and about 800 pm. In some embodiments, the capsule diameter is between about 200 pm and about 700 pm. In some embodiments, the capsule diameter is between about 200 pm and about 600 pm. In some embodiments, the capsule diameter is between about 200 pm and about 500 pm. In some embodiments, the capsule diameter is between about 200 pm and about 400 pm. In some embodiments, the capsule diameter is between about 200 pm and about 300 pm.
  • the capsule diameter is about 300 pm.
  • the capsule diameter is between about 500 pm and 2000 pm. In some embodiments, the capsule diameter is between about 500 pm and about 1900 pm, about 500 pm and about 1800 pm, about 500 pm and about 1700 pm, about 500 pm and about 1600 pm, about 500 pm and about 1500 pm, about 500 pm and about 1400 pm, about 500 pm and about 1300 pm, about 500 pm and about 1200 pm, about 500 pm and about 1100 pm, about 500 pm and about 1000 pm, about 500 pm and about 900 pm, about 500 pm and about 800 pm, about 500 pm and about 700 pm, or about 500 pm and about 600 pm. In some embodiments, the capsule diameter is between about 500 pm and about 1900 pm. In some embodiments, the capsule diameter is between about 500 pm and about 1800 pm.
  • the capsule diameter is between about 500 pm and about 1700 pm. In some embodiments, the capsule diameter is between about 500 pm and about 1600 pm. In some embodiments, the capsule diameter is between about 500 pm and about 1500 pm. In some embodiments, the capsule diameter is between about 500 pm and about 1400 pm. In some embodiments, the capsule diameter is between about 500 pm and about 1300 pm. In some embodiments, the capsule diameter is between about 500 pm and about 1200 pm. In some embodiments, the capsule diameter is between about 500 pm and about 1100 pm. In some embodiments, the capsule diameter is between about 500 pm and about 1000 pm. In some embodiments, the capsule diameter is between about 500 pm and about 900 pm. In some embodiments, the capsule diameter is between about 500 pm and about 800 pm. In some embodiments, the capsule diameter is between about 500 pm and about 700 pm. In some embodiments, the capsule diameter is between about 500 pm and about 600 pm.
  • the capsule diameter is about 600 pm.
  • the capsule diameter is between about 700 pm and 2000 pm. In some embodiments, the capsule diameter is between about 700 pm and about 1900 pm, about 700 pm and about 1800 pm, about 700 pm and about 1700 pm, about 700 pm and about 1600 pm, about 700 pm and about 1500 pm, about 700 pm and about 1400 pm, about 700 pm and about 1300 pm, about 700 pm and about 1200 pm, about 700 pm and about 1100 pm, about 700 pm and about 1000 pm, about 700 pm and about 900 pm, or about 700 pm and about 800 pm. In some embodiments, the capsule diameter is between about 700 pm and about 1900 pm. In some embodiments, the capsule diameter is between about 700 pm and about 1800 pm. In some embodiments, the capsule diameter is between about 700 pm and about 1700 pm.
  • the capsule diameter is between about 700 pm and about 1600 pm. In some embodiments, the capsule diameter is between about 700 pm and about 1500 pm. In some embodiments, the capsule diameter is between about 700 pm and about 1400 pm. In some embodiments, the capsule diameter is between about 700 pm and about 1300 pm. In some embodiments, the capsule diameter is between about 700 pm and about 1200 pm. In some embodiments, the capsule diameter is between about 700 pm and about 1100 pm. In some embodiments, the capsule diameter is between about 700 pm and about 1000 pm. In some embodiments, the capsule diameter is between about 700 pm and about 900 pm. In some embodiments, the capsule diameter is between about 700 pm and about 800 pm.
  • the capsule diameter is about 800 pm. In some embodiments, the capsule diameter is between about 1100 pm and 2000 pm. In some embodiments, the capsule diameter is between about 1100 pm and about 1900 pm, about 1100 pm and about 1800 pm, about 1100 pm and about 1700 pm, about 1100 pm and about 1600 pm, about 1100 pm and about 1500 pm, about 1100 pm and about 1400 pm, about 1100 pm and about 1300 pm, or about 1100 pm and about 1200 pm. In some embodiments, the capsule diameter is between about 1100 pm and about 1900 pm. In some embodiments, the capsule diameter is between about 1100 pm and about 1800 pm. In some embodiments, the capsule diameter is between about 1100 pm and about 1700 pm.
  • the capsule diameter is between about 1100 pm and about 1600 pm. In some embodiments, the capsule diameter is between about 1100 pm and about 1500 pm. In some embodiments, the capsule diameter is between about 1100 pm and about 1400 pm. In some embodiments, the capsule diameter is between about 1100 pm and about 1300 pm. In some embodiments, the capsule diameter is between about 1100 pm and about 1200 pm.
  • the capsule diameter is about 1200 pm.
  • the capsule diameter is between about 1600 pm and 2000 pm. In some embodiments, the capsule diameter is between about 1600 pm and about 1900 pm, about 1600 pm and about 1800 pm, or about 1600 pm and about 1700 pm. In some embodiments, the capsule diameter is between about 1600 pm and about 1900 pm. In some embodiments, the capsule diameter is between about 1600 pm and about 1800 pm. In some embodiments, the capsule diameter is between about 1600 pm and about 1700 pm.
  • the capsule diameter is about 1700 pm.
  • the capsule diameter is less than about 2000 pm. In some embodiments, the capsule diameter is less than about 1900 pm, about 1800 pm, about 1700 pm, about 1600 pm, about 1500 pm, about 1400 pm, about 1300 pm, about 1200 pm, about 1100 pm, about 1000 pm, about 900 pm, about 800 pm, about 700 pm, about 600 pm, about 500 pm, about 400 pm, about 300 pm, about 200 pm, or about 100 pm. In some embodiments, the capsule diameter is less than about 1900 pm. In some embodiments, the capsule diameter is less than about 1800 pm. In some embodiments, the capsule diameter is less than about 1700 pm. In some embodiments, the capsule diameter is less than about 1600 pm. In some embodiments, the capsule diameter is less than about 1500 pm.
  • the capsule diameter is less than about 1400 pm. In some embodiments, the capsule diameter is less than about 1300 pm. In some embodiments, the capsule diameter is less than about 1200 pm. In some embodiments, the capsule diameter is less than about 1100 pm. In some embodiments, the capsule diameter is less than about 1000 pm. In some embodiments, the capsule diameter is less than about 900 pm. In some embodiments, the capsule diameter is less than about 800 pm. In some embodiments, the capsule diameter is less than about 700 pm. In some embodiments, the capsule diameter is less than about 600 pm. In some embodiments, the capsule diameter is less than about 500 pm. In some embodiments, the capsule diameter is less than about 400 pm. In some embodiments, the capsule diameter is less than about 300 pm. In some embodiments, the capsule diameter is less than about 200 pm. In some embodiments, the capsule diameter is less than about 100 pm.
  • the capsules comprise a plurality of cells that are engineered to deliver a therapeutic agent, e.g., a protein, e.g., a cytokine.
  • a therapeutic agent e.g., a protein, e.g., a cytokine.
  • cells are capable of expressing the therapeutic agent constitutively and/or inducibly (e.g., responsive to a stimulus, e.g., responsive to secretion of a marker, e.g., a pro-inflammatory or anti-inflammatory marker) after transfection with a nucleic acid vector encoding for the therapeutic agent, e.g., transfection with a DNA plasmid using LipofectamineTM 3000 (commercially available from ThermoFisher Scientific).
  • the engineered cells for encapsulation may be derived from an immortalized cell line.
  • the engineered cells for encapsulation may be derived and cultured ex vivo from a living organism, e g., a human.
  • the engineered cells may be derived from any histology of a living organism, e g., derived from the connective tissue, the epithelium, the muscle tissue and the central or peripheral nervous system.
  • the engineered cells for encapsulation may be an undifferentiated cell.
  • the engineered cells for encapsulation may comprise an undifferentiated cell that is a unipotent cell or a pluripotent cell, e.g., a stem a cell.
  • Exemplary cell lines include Chinese hamster ovary (CHO), retinal pigment epithelial (ARPE-19), human mammary epithelial (MCF- 10a and MCF-7), Human embryonic kidney (HEK), mesenchymal stem cells (MSC), Human umbilical vein endothelial cells (HUVEC), NIH/3T3 cells, BJ fibroblasts, Human renal mix epithelial cells (HREC) and Human Pluripotent Stem Cells (HPSCs).
  • the cell line is ARPE-19.
  • cytokines and chemokines include interleukin- 1 (IL-1), interleukin-1 alpha (IL- la), interleukin- 1 beta (IL- Ip), interleukin- 1 receptor antagonist protein (IL-IRA), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin- 10 (IL-10), interleukin- 11 (IL-11) , interleukin- 12 (IL-12), interleukin- 12 alpha (IL- 12a), interleukin-12 beta (IL-120), interleukin- 13 (IL-13), interleukin- 14 (IL-14), interleukin-
  • IL-1 interleukin-1 alpha
  • IL- 1 beta IL- Ip
  • IL-IRA interleukin- 1 receptor antagonist protein
  • IL-2 interleukin-2
  • the therapeutic agent may be an anti-cytokine antibody or an anti-chemokine antibody, anti-IL-1, anti-IL-la, anti-IL-ip, anti-IL-IRA, anti-IL-2, anti-IL-4, anti-IL-5, anti-IL-6, anti-IL- 7, anti-IL-8, anti-IL-9, anti-IL-10, anti-IL-11, anti-IL-12, anti-IL-12a, anti-IL-12 , anti-IL-13, anti-IL-14, anti-IL-15, anti-IL-16, anti-IL-17, anti-IL-20, anti-IL-22, anti-IFN-a, anti-IFN-P, anti- IFN-y, anti-TNF-a, anti-TNF-p, anti-TGF-p, anti-CCLl, anti-CCL2, anti-CCL3, anti-CCL4, anti- CCL5, anti-CCL6, anti-CCL7, anti-CCL8, anti-CCL9, anti-CCLIO, anti-CCLl 1, anti-CCLl 2, anti-CCL
  • the cells may be engineered to produce a cytokine and a secondary polypeptide therapeutic.
  • the secondary polypeptide therapeutic is an antibody, e.g., a monoclonal antibody, a polyclonal antibody, an immunoglobulin, or a functional antibody fragment capable of binding to an epitope of an antigen.
  • the secondary polypeptide therapeutic features an antibody selected from anti-interleukin 6 (anti-IL-6) and antiinterleukin 8 (anti-IL-8).
  • the secondary polypeptide therapeutic features a receptor agonist or antagonist, e.g., interleukin-1 receptor antagonist protein (IL-1RN).
  • the secondary polypeptide therapeutic features an enzyme, e.g., aromatase.
  • the cells may be engineered to produce a cytokine and a secondary polypeptide therapeutic.
  • the secondary polypeptide therapeutic is an antibody, e.g., a monoclonal antibody, a polyclonal antibody, an immunoglobulin, or a functional antibody fragment capable of binding to an epitope of antigen.
  • the secondary polypeptide therapeutic features an antibody selected from anti-interleukin 6 (anti-IL-6) and antiinterleukin 8 (anti-IL-8).
  • the secondary polypeptide therapeutic features a receptor agonist or antagonist, e.g., interleukin-1 receptor antagonist protein (IL-1RN).
  • the secondary polypeptide therapeutic features an enzyme, e.g., aromatase.
  • the cells may be engineered to produce an antibody, e.g., an a monoclonal antibody, a polyclonal antibody, an immunoglobulin, or a or a functional antibody fragment capable of binding to an epitope of an antigen.
  • the therapeutic agent comprises a monoclonal antibody.
  • the therapeutic agent comprises a polyclonal antibody.
  • the therapeutic agent comprises an immunoglobulin.
  • the therapeutic agent comprises a functional antibody fragment capable of binding to an epitope of antigen.
  • Capsules described herein may contain a plurality of cells, for example, a plurality of engineered cells.
  • a cell may be derived from any mammalian organ or tissue, including the brain, nerves, ganglia, spine, eye, heart, liver, kidney, lung, spleen, bone, thymus, lymphatic system, skin, muscle, pancreas, stomach, intestine, blood, ovary, uterus, or testes.
  • a cell may be derived from a donor (e.g, an allogeneic cell), derived from a subject (e.g, an autologous cell), or from another species (e.g., a xenogeneic cell).
  • a cell can be grown in cell culture, or prepared from an established cell culture line, or derived from a donor (e.g., a living donor or a cadaver).
  • a cell is genetically engineered.
  • a cell is not genetically engineered.
  • a cell may include a stem cell, such as a reprogrammed stem cell, or an induced pluripotent cell.
  • Exemplary cells include mesenchymal stem cells (MSCs), fibroblasts (e.g., primary fibroblasts).
  • HEK cells e.g., HEK293T
  • Jurkat cells HeLa cells
  • retinal pigment epithelial (RPE) cells HUVEC cells
  • NIH3T3 cells CH0-K1 cells
  • COS-1 cells COS-7 cells
  • PC-3 cells HCT 116 cells
  • A549MCF-7 cells HuH-7 cells
  • U-2 OS cells HepG2 cells
  • Neuro-2a cells and SF9 cells.
  • a cell for use in an capsule is an RPE cell.
  • a cell included in a capsule may produce or secrete a therapeutic agent.
  • a cell included in an capsule may produce or secrete a single type of therapeutic agent or a plurality of therapeutic agents.
  • a capsule may comprise a cell that is transduced or transfected with a nucleic acid (e.g, a vector) comprising an expression sequence of a therapeutic agent.
  • a cell may be transduced or transfected with a lentivirus.
  • a nucleic acid introduced into a cell e.g. , by transduction or transfection
  • a nucleic acid introduced into a cell may include a region to enhance expression of the therapeutic agent and/or to direct targeting or secretion, for example, a promoter sequence, an activator sequence, or a cell-signaling peptide, or a cell export peptide.
  • exemplary promoters include EF-la, CMV, Ubc, hPGK, VMD2, and CAG.
  • exemplary activators include the TET1 catalytic domain, P300 core, VPR, rTETR, Cas9 (e.g.. from S. pyogenes or S. aureus), and Cpfl (e.g., from A. bacterium).
  • a capsule described herein may comprise a cell or a plurality of cells.
  • the concentration and total cell number may be varied depending on a number of factors, such as cell type, implantation location, and expected lifetime of the capsule.
  • the total number of cells included in a capsule is greater than about 2, 4, 6, 8, 10, 20, 30, 40, 50, 75, 100, 200, 250, 500, 750, 1000, 1500, 2000, 5000, 10000, or more.
  • the total number of cells included in an capsule is greater than about 1.0 x 10 2 , 1.0 x 10 3 , 1.0 x 10 4 , 1.0 x 10 5 , 1.0 x 10 6 , 1.0 x 10 7 , 1.0 x 10 8 , 1.0 x 10 9 , 1.0 x 10 10 , or more.
  • the total number of cells included in a capsule is less than about than about 10000, 5000, 2500, 2000, 1500, 1000, 750, 500, 250, 200, 100, 75, 50, 40, 30, 20, 10, 8, 6, 4, 2, or less.
  • the total number of cells included in a capsule is less than about 1.0 x 10 10 , 1.0 x 10 9 , 1.0 x 10 8 , 1.0 x 10 7 , 1.0 x 10 6 , 1.0 x 10 5 , 1.0 x 10 4 , 1.0 x 10 3 , 1.0 x 10 2 , or less.
  • a plurality of cells is present as an aggregate. In an embodiment, a plurality of cells is present as a cell dispersion.
  • cell viability, cell density, or cell expression level may be assessed.
  • cell viability, cell density, and cell expression level may be determined using standard techniques, such as cell microscopy, fluorescence microscopy, histology, or biochemical assay.
  • the capsule comprises a cell or a plurality of cells that are genetically engineered to produce or secrete a therapeutic agent.
  • the capsule comprises a cell producing or secreting a protein.
  • the protein may be of any size, e.g., greater than about 100 Da, 200 Da, 250 Da, 500 Da, 750 Da, 1 KDa, 1.5 kDa, 2 kDa, 2.5 kDa, 3 kDa, 4 kDa, 5 kDa, 6 kDa, 7 kDa, 8 kDa, 9 kDa, 10 kDa, 15 kDa, 20 kDa, 25 kDa, 30 kDa, 35 kDa, 40 kDa, 45 kDa, 50 kDa, 55 kDa, 60 kDa, 65 kDa, 70 kDa, 75 kDa, 80 kDa, 85 kDa, 90 kDa, 95 kD
  • the protein is composed of a single subunit or multiple subunits (e.g., a dimer, trimer, tetramer, etc.).
  • a protein produced or secreted by a cell may be modified, for example, by glycosylation, methylation, or other known natural or synthetic protein modification.
  • a protein may be produced or secreted as a pre-protein or in an inactive form and may require further modification to convert it into an active form.
  • Proteins produced or secreted by a cell may include antibodies or antibody fragments, for example, an Fc region or variable region of an antibody.
  • Exemplary antibodies include anti-PD- 1, anti-PD-Ll, anti-CTLA4, anti-TNFa, and anti-VEGF antibodies.
  • An antibody may be monoclonal or polyclonal.
  • Other exemplary proteins include a lipoprotein, an adhesion protein, blood clotting factor (e.g., Factor VII, Factor VIII, Factor IX, GCG, or VWF), hemoglobin, enzymes, proenkephalin, a growth factor (e.g., EGF, IGF-1, VEGF alpha, HGF, TGF beta, bFGF), or a cytokine.
  • a protein produced or secreted by a cell may include a hormone.
  • hormones include growth hormone, growth hormone releasing hormone, prolactin, lutenizing hormone (LH), anti-diuretic hormone (ADH), oxytocin, thyroid stimulating hormone (TSH), thyrotropin-release hormone (TRH), adrenocorticotropic hormone (ACTH), follicle-stimulating hormone (FSH), thyroxine, calcitonin, parathyroid hormone, aldosterone, cortisol, epinephrine, glucagon, insulin, estrogen, progesterone, and testosterone.
  • a protein produced or secreted by a cell may include a cytokine.
  • a cytokine may be a pro- inflammatory cytokine or an anti-inflammatory cytokine.
  • Example of cytokines include IL-1, IL- la, IL-1 , IL-IRA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-12a, IL-12b, IL-13, IL-14, IL-16, IL-17, G-CSF, GM-CSF, IL-20, IFN-a, IFN-0, IFN-y, CD154, LT-0, CD70, CD153, CD178, TRAIL, TNF-a, TNF-0, SCF, M-CSF, MSP, 4-1BBL, LIF, OSM, and others.
  • a cytokine may include any cytokine described in M.J. Cameron and D.J. Kelvin, Cytokines, Chemokines, and Their Receptors (2013), Austin Biosciences, which is incorporated herein by reference in its entirety.
  • a capsule may comprise a cell expressing a single type of therapeutic agent, e.g., a single protein or nucleic acid, or may express more than one type of therapeutic agent, e.g., a plurality of proteins or nucleic acids.
  • a capsule comprises a cell expressing two types of therapeutic agents (e.g., two types of proteins or nucleic acids).
  • a capsule comprises a cell expressing three types of therapeutic agents (e.g., three types of proteins or nucleic acids).
  • a capsule comprises a cell expressing four types of therapeutic agents (e.g., four types of proteins or nucleic acids).
  • a capsule comprises a cell expressing a single type of nucleic acid (e.g., DNA or RNA) or may express more than one type of nucleic acid, e.g., a plurality of nucleic acid (e.g., DNA or RNA).
  • a capsule comprises a cell expressing two types of nucleic acids (e.g., DNA or RNA).
  • a capsule comprises a cell expressing three types of nucleic acids (e.g., DNA or RNA).
  • a capsule comprises a cell expressing four types of nucleic acids (e.g., DNA or RNA).
  • a capsule comprises a cell expressing a single type of protein, or may express more than one type of protein, e.g., a plurality of proteins. In an embodiment, a capsule comprises a cell expressing two types of proteins. In an embodiment, a capsule comprises a cell expressing three types of proteins. In an embodiment, a capsule comprises a cell expressing four types of proteins.
  • a capsule comprises a cell expressing a single type of enzyme, or may express more than one type of enzyme, e.g., a plurality of enzymes. In an embodiment, a capsule comprises a cell expressing two types of enzymes. In an embodiment, a capsule comprises a cell expressing three types of enzymes. In an embodiment, a capsule comprises a cell expressing four types of enzymes.
  • a capsule comprises a cell expressing a single type of antibody or antibody fragment or may express more than one type of antibody or antibody fragment, e.g., a plurality of antibodies or antibody fragments.
  • a capsule comprises a cell expressing two types of antibodies or antibody fragments.
  • a capsule comprises a cell expressing three types of antibodies or antibody fragments.
  • a capsule comprises a cell expressing four types of antibodies or antibody fragments.
  • a capsule comprises a cell expressing a single type of hormone, or may express more than one type of hormone, e.g., a plurality of hormones. In an embodiment, a capsule comprises a cell expressing two types of hormones. In an embodiment, a capsule comprises a cell expressing three types of hormones. In an embodiment, a capsule comprises a cell expressing four types of hormones.
  • a capsule comprises a cell expressing a single type of enzyme, or may express more than one type of enzyme, e.g., a plurality of enzymes. In an embodiment, a capsule comprises a cell expressing two types of enzymes. In an embodiment, a capsule comprises a cell expressing three types of enzymes. In an embodiment, a capsule comprises a cell expressing four types of enzymes.
  • a capsule comprises a cell expressing a single type of cytokine or may express more than one type of cytokine, e.g., a plurality of cytokines. In an embodiment, a capsule comprises a cell expressing two types of cytokines. In an embodiment, a capsule comprises a cell expressing three types of cytokines. In an embodiment, a capsule comprises a cell expressing four types of cytokines.
  • the engineered cell expresses a therapeutic agent, e.g., a cytokine
  • a therapeutic agent e.g., a cytokine
  • the level of production of the therapeutic agent be auto regulated in order to prevent secretion of toxic levels of the cytokine.
  • One way to accomplish this is to introduce an operator site into the DNA region between the cytokine gene and its promoter in a first ORF.
  • a second ORF is used that encodes a transcriptional repressor that binds to the operator site under the control of a promoter that is activated as a result of signaling through the cytokine's receptor. In this way, the cells can sense the cytokine in their environment and reduce their production of the cytokine when there is sufficient cytokine already present.
  • Another possible strategy is to introduce a sequence that forms a higher-order structure into the 5' untranslated region (5' UTR) of the cytokine gene. Then a second ORF is used that encodes an RNA-binding protein that binds to the higher-order structure, and suppresses translation, under the control of a promoter that is activated as a result of signaling through the cytokine's receptor.
  • 5' UTR 5' untranslated region
  • Another possible strategy is to introduce several repeats of a synthetic microRNA (miRNA) target site into the 3' untranslated region (3' UTR) of the cytokine gene. Then a second ORF is used that encodes the miRNA under the control of a promoter that is activated as a result of signaling through the cytokine's receptor.
  • miRNA synthetic microRNA
  • Another possible strategy is to use a second ORF encoding a synthetic ubiquitin ligase that targets the cytokine, and leads to ubiquitin-mediated proteolysis, under the control of a promoter that is activated as a result of signaling through the cytokine's receptor.
  • a promoter that is activated as a result of signaling through the cytokine's receptor.
  • the promoter controlling the expression of the ubiquitin ligase could be a STAT transcription factor (FIG. 8).
  • the cytokine gene may be modified to include additional protein domains if doing so is necessary in order to make the cytokine recognizable by the synthetic ubiquitin ligase. Ideally, the addition of any additional protein domains will not alter the cytokine's immunological functions.
  • a further strategy is to incorporate a mechanism where the therapeutic agent is under control of a promoter, e.g., a synthetic promoter or a natural promoter), which binds to a native transcription factor whose activation is downstream of a receptor, e.g., a cytokine receptor, e.g., NF-KB or NFAT.
  • a promoter e.g., a synthetic promoter or a natural promoter
  • a native transcription factor whose activation is downstream of a receptor
  • a receptor e.g., a cytokine receptor, e.g., NF-KB or NFAT.
  • Post-transcriptional control of the cytokine expression is also possible using small molecule-dependent riboswitches - a short sequence could be added to the 5' or 3’ UTR of the cytokine gene that forms a small molecule-dependent functional higher-order structure, such as a frame-shifting aptamer or a mRNA-cleaving aptazyme, allowing for similar external control of the cytokine production, since there are examples of these systems that turn on frame-shifting or cleavage upon the addition of a small molecule and examples that turn off in the presence of the small molecule.
  • This type of control is also possible at the protein level by adding the sequence for a destabilization domain that can be stabilized by a small molecule to the beginning or end of the gene for the cytokine, which would lead to targeted degradation of the cytokine whenever the small molecule is not present.
  • the reverse is also possible by augmenting the gene for the cytokine with the sequence for a small molecule-assisted shutoff (SMASh) system, which includes a destabilization domain and a non-mammalian protease that cleaves the destabilization domain from the cytokine except in the presence of a small molecule protease inhibitor that would prevent cleavage and lead to degradation of the cytokine.
  • SMASh small molecule-assisted shutoff
  • All these modifications to the protein structure could also be done indirectly by instead modifying a synthetic transcription factor that activates the promoter controlling expression of the cytokine, which would ensure that all these protein modifications stay within the therapeutic cells instead of being secreted and potentially generating an immune response to these unnatural protein domains.
  • One possible synthetic transcription factor to use for this purpose is a fusion between the transcriptional activators VP64, p65, and Rta (VPR) and catalytically inactivated Cas9 (dCas9), which when coexpressed with a guide RNA (gRNA) will localize the VPR complex to the synthetic promoter with complementarity to the gRNA in order to activate transcription of the cytokine gene.
  • the vector systems contemplated in the engineered cells may further comprise a kill switch to arrest the therapy, similar to the kill switch designed for CAR T cells.
  • a kill switch to arrest the therapy, similar to the kill switch designed for CAR T cells.
  • two engineered proteins may be located inside the encapsulated cells, that dimerize when exposed to a small molecule drug called rimiducid. This drug activates a protein called caspase-9, which induces cell death.
  • rimiducid AP1903
  • FKBP12(F36V) FKBP12v36, FV36 or FV
  • Attachment of one or more FV domains onto one or more cell signaling molecules that normally rely on homodimerization can convert that protein to rimiducid control.
  • a molecular switch is provided that provides the option to activate a pro-apoptotic polypeptide, such as, for example, Caspase-9, with rimiducid, wherein the chimeric pro-apoptotic polypeptide comprises a rimiducid-induced switch.
  • a homodimerizer such as API 903 (rimiducid) activates a safety switch, causing apoptosis of the modified cell.
  • a chimeric pro-apoptotic polypeptide such as, for example, Caspase-9, comprising a FKBP12 multimerizing region is expressed in a cell.
  • the chimeric polypeptide dimerizes or multimerizes, and activates the cell.
  • the cell may, for example, be an engineered cell that expresses a protein, e.g., a cytokine.
  • a transmembrane sensor can be engineered into the engineered cells to create a feedback loop to regulate output of the therapeutic agent.
  • the transmembrane sensor responds to varying concentrations of the protein of interest and uses a negative feedback loop to suppress the transcription of the therapeutic agent of interest, e.g., cytokine or chemokine, with the help of an inducible promoter. This allows fine-tuning of the localized delivery of the protein of interest and ensures that there is no over-expression of the protein of interest.
  • the alginate biomaterial used allows for rapid diffusion across the inner and outer shell to give real-time feedback to this sense-and-respond genetic cellular circuit.
  • n capsule may be a sphere, spheroid, tube, cord, string, ellipsoid, disk, cylinder, sheet, torus, cube, stadiumoid, cone, pyramid, triangle, rectangle, square, or rod.
  • a capsule may comprise a curved or flat section.
  • the capsule may be prepared through the use of a mold, resulting in a custom shape.
  • the capsule may vary in size, depending, for example, on the use or site of implantation.
  • the capsule may have a mean diameter or size greater than 0.1 mm, e.g., greater than 0.25 mm, 0.5 mm, 0.75, 1 mm, 1.5 mm, 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 20 mm, 30 mm, 40 mm, 50 mm, or more.
  • the capsule may have a section or region with a mean diameter or size greater than 0.1 mm, e.g, greater than 0.25 mm, 0.5 mm, 0.75, 1 mm, 1.5 mm, 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 20 mm, 30 mm, 40 mm, 50 mm, or more.
  • the capsule may have a mean diameter or size less than 1 cm, e.g., less 50 mm, 40 mm, 30 mm, 20 mm, 10 mm, 7.5 mm, 5 mm, 2.5 mm, 1 mm, 0.5 mm, or smaller.
  • the capsule may have a section or region with a mean diameter or size less than 1 cm, e.g., less 50 mm, 40 mm, 30 mm, 20 mm, 10 mm, 7.5 mm, 5 mm, 2.5 mm, 1 mm, 0.5 mm, or smaller.
  • the capsule comprises a pore or opening to permit passage of an object, such as a small molecule (e.g., nutrients or waste), a protein, or a nucleic acid.
  • a pore in or on a capsule may be greater than 0.1 nm and less than 10 pm.
  • the capsule comprises a pore or opening with a size range of 0.1 pm to 10 pm, 0.1 pm to 9 pm, 0.1 pm to 8 pm, 0.1 pm to 7 pm, 0.1 pm to 6 pm, 0.1 pm to 5 pm, 0.1 pm to 4 pm, 0.1 pm to 3 pm, 0.1 pm to 2 pm.
  • the capsule described herein may comprise a chemical modification in or on any enclosed material.
  • exemplary chemical modifications include small molecules, peptides, proteins, nucleic acids, lipids, or oligosaccharides.
  • the capsule may comprise at least 0.5%, 1%, 2%, 3%, 4%, 5%, 7.5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or more of a material that is chemically modified, e.g., with a chemical modification described herein.
  • a capsule may be partially coated with a chemical modification, e.g., at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 99.9% coated with a chemical modification.
  • a chemical modification e.g., at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 99.9% coated with a chemical modification.
  • the capsule is chemically modified with a specific density of modifications.
  • the specific density of chemical modifications may be described as the average number of attached chemical modifications per given area.
  • the density of a chemical modification on or in an capsule may be 0.01, 0.1, 0.5, 1, 5, 10, 15, 20, 50, 75, 100, 200, 400, 500, 750, 1,000, 2,500, or 5,000 chemical modifications per square pm or square mm.
  • a capsule may be formulated or configured for implantation in any organ, tissue, cell, or part of a subject.
  • the capsule may be implanted or disposed into the intraperitoneal space of a subject.
  • An capsule may be implanted in or disposed on a tumor or other growth in a subject, or be implanted in or disposed about 0.1 mm, 0.5 mm, 1 mm, 0.25 mm, 0.5 mm, 0.75, 1 mm, 1.5 mm, 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 20 mm, 30 mm, 40 mm, 50 mm, 1 cm, 5, cm, 10 cm, or further from a tumor or other growth in a subject.
  • a capsule may be configured for implantation, or implanted, or disposed on or in the skin, a mucosal surface, a body cavity, the central nervous system (e.g., the brain or spinal cord), an organ (e.g, the heart, eye, liver, kidney, spleen, lung, ovary, breast, uterus), the lymphatic system, vasculature, oral cavity, nasal cavity, gastrointestinal tract, bone, muscle, adipose tissue, skin, or other area.
  • the central nervous system e.g., the brain or spinal cord
  • an organ e.g, the heart, eye, liver, kidney, spleen, lung, ovary, breast, uterus
  • the lymphatic system e.g, vasculature, oral cavity, nasal cavity, gastrointestinal tract, bone, muscle, adipose tissue, skin, or other area.
  • a capsule may be formulated for use for any period of time.
  • a capsule may be used for 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 1 day, 36 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 2 months, 3 months, 4 months,
  • a capsule can be configured for limited exposure (e.g, less than 2 days, e.g., less than 2 days, 1 day, 24 hours, 20 hours, 16 hours, 12 hours, 10 hours, 8 hours,
  • a capsule can be configured for prolonged exposure (e.g., at least 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, 1 year, 1.5 years, 2 years, 2.5 years, 3 years, 3.5 years, 4 years or more).
  • An capsule can be configured for permanent exposure (e.g., at least 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, 1 year, 1.5 years, 2 years, 2.5 years, 3 years, 3.5 years, 4 years or more).
  • permanent exposure e.g., at least 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, 1 year, 1.5 years, 2 years, 2.5 years, 3 years, 3.5 years, 4 years or more).
  • the capsules may be formulated to provide a therapeutic agent, e.g., a protein such as a cytokine to the lungs or other adjacent tissues of the respiratory system, directly or indirectly as a pharmaceutical composition or a pharmaceutical product.
  • a therapeutic agent e.g., a protein such as a cytokine
  • the capsules may be formulated to provide a therapeutic agent, e.g., a protein such as a cytokine, to the lungs or other adjacent tissues of the respiratory system, directly or indirectly as a pharmaceutical composition or a pharmaceutical product for the treatment of a disease, e.g., an immune disease or disorder, e.g., an autoimmune disease or disorder, or an inflammatory disorder, e.g., an autoinflammatory disease or disorder.
  • the capsule comprising a plurality of engineered cells is formulated as an inhalable composition.
  • the capsule is formulated for local delivery, e.g., via intratracheal instillation or intubation, e.g., with a bronchoscope or a catheter.
  • the composition may further comprise a pH modifier, a tonicity agent, a viscosity modifier, a carrier or diluent (e.g., a pharmaceutically acceptable carrier or diluent), a preservative, a surfactant, or a polymer.
  • the composition comprises a pH modifier.
  • a function of the pH modifier is to maintain the pH of the composition within a predetermined range, which is optimal for administration of the composition, efficacious for delivery of the therapeutic agent (e.g., a protein such as a cytokine) ensures the stability or prevents the degradation or hydrolysis of the therapeutic agent, and the like.
  • Suitable pH modifiers include pharmaceutically acceptable buffering agents, e.g., a combination of a weak Lewis acid and/or its conjugate base.
  • Exemplary pH modifiers featured in the composition include, without limitation, adipic acid, ammonium bicarbonate, sodium hydrogen carbonate, L-tartaric acid, and potassium citrate monohydrate.
  • the composition features a pH modifier such that the pH of the composition is maintained within a predetermined range.
  • the pH of the composition is between about 3 to about 10, about 4 to about 9, about 5 to about 8, or about 6 to about 7.
  • the pH of the composition is between about 3 to about 10.
  • the pH of the composition is between about 4 to about 9.
  • the pH of the composition is between about 5 to about 8.
  • the pH of the composition is between about 6 to about 7.
  • the composition comprises a tonicity agent.
  • exemplary tonicity agents include dextrose, glycerin, mannitol, potassium chloride, sodium chloride, and the like.
  • the composition may comprise between about 0.1% w/w to about 20% w/w of the tonicity agent. In some embodiments, the composition comprises between about 0.1% w/w to about 20% w/w, about 0.2% w/w to about 20% w/w, about 0.3% w/w to about 20% w/w, about 0.4% w/w to about 20% w/w, about 0.5% w/w to about 20% w/w, about 1% w/w to about 20% w/w, about 2% w/w to about 20% w/w, about 3% w/w to about 20% w/w, about 4% w/w to about 20% w/w, about 5% w/w to about 20% w/w, about 7.5% w/w to about 20% w/w, about 10% w/w to about 20% w/w, about 12.5% w/w to about 20% w/w, about 15% w/w to about 20% w/w, or about 17.5% w/
  • the composition comprises between about 0.2% w/w to about 20% w/w of the tonicity agent. In some embodiments, the composition comprises between about 0.3% w/w to about 20% w/w of the tonicity agent. In some embodiments, the composition comprises between about 0.4% w/w to about 20% w/w of the tonicity agent. In some embodiments, the composition comprises between about 0.5% w/w to about 20% w/w of the tonicity agent. In some embodiments, the composition comprises between about 1% w/w to about 20% w/w of the tonicity agent. In some embodiments, the composition comprises between about 2% w/w to about 20% w/w of the tonicity agent.
  • the composition comprises between about 3% w/w to about 20% w/w of the tonicity agent. In some embodiments, the composition comprises between about 4% w/w to about 20% w/w of the tonicity agent. In some embodiments, the composition comprises between about 5% w/w to about 20% w/w of the tonicity agent. In some embodiments, the composition comprises between about 7.5% w/w to about 20% w/w of the tonicity agent. In some embodiments, the capsule comprises between about 10% w/w to about 20% w/w of the tonicity agent. In some embodiments, the composition comprises between about 12.5% w/w to about 20% w/w of the tonicity agent. In some embodiments, the composition comprises between about 15% w/w to about 20% w/w of the tonicity agent. In some embodiments, the composition comprises between about 17.5% w/w to about 20% w/w of the tonicity agent.
  • the composition comprises a viscosity modifier.
  • Suitable pharmaceutically acceptable viscosity modifiers include guar gum, xanthan gum, gellan gum, dextran, pullulan, guar gum, acacia gum, carrageenan, pectin, starch or modified starch derivatives, cellulose, carboxymethylcellulose, chitosan, gelatin, hydroxypropyl methylcellulose, methyl hydroxypropyl cellulose, methyl hydroxyethyl cellulose, hydroxypropyl cellulose, nanocellulose, and the like.
  • the composition may comprise between about 0.1% w/w to about 20% w/w of the viscosity modifier.
  • the composition comprises between about 0.1% w/w to about 20% w/w, about 0.2% w/w to about 20% w/w, about 0.3% w/w to about 20% w/w, about 0.4% w/w to about 20% w/w, about 0.5% w/w to about 20% w/w, about 1% w/w to about 20% w/w, about 2% w/w to about 20% w/w, about 3% w/w to about 20% w/w, about 4% w/w to about 20% w/w, about 5% w/w to about 20% w/w, about 7.5% w/w to about 20% w/w, about 10% w/w to about 20% w/w, about 12.5% w/w to about 20% w/w, about 15% w/w to about 20% w/w, or about 17.5% w/w to about 20%
  • the composition comprises between about 0.2% w/w to about 20% w/w of the viscosity modifier. In some embodiments, the composition comprises between about 0.3% w/w to about 20% w/w of the viscosity modifier. In some embodiments, the composition comprises between about 0.4% w/w to about 20% w/w of the viscosity modifier. In some embodiments, the composition comprises between about 0.5% w/w to about 20% w/w of the viscosity modifier. In some embodiments, the composition comprises between about 1% w/w to about 20% w/w of the viscosity modifier. In some embodiments, the composition between about 2% w/w to about 20% w/w of the viscosity modifier.
  • the composition comprises between about 3% w/w to about 20% w/w of the viscosity modifier. In some embodiments, the composition comprises between about 4% w/w to about 20% w/w of the viscosity modifier. In some embodiments, the composition comprises between about 5% w/w to about 20% w/w of the viscosity modifier. In some embodiments, the composition comprises between about 7.5% w/w to about 20% w/w of the viscosity modifier. In some embodiments, the composition comprises between about 10% w/w to about 20% w/w of the viscosity modifier. In some embodiments, the composition comprises between about 12.5% w/w to about 20% w/w of the viscosity modifier. In some embodiments, the composition comprises between about 15% w/w to about 20% w/w of the viscosity modifier. In some embodiments, the composition comprises between about 17.5% w/w to about 20% w/w of the viscosity modifier.
  • the composition comprises a carrier or diluent, e.g., a pharmaceutically acceptable carrier or diluent.
  • a pharmaceutically acceptable carrier or diluent include lactose (e.g., lactose monohydrate), microcrystalline cellulose, native (uncooked starch), pregelatinized starch, calcium phosphate, calcium carbonate, sucrose, maltodextrin, D-mannitol, sorbitol, and sodium chloride.
  • the composition may comprise between about 0.1% w/w to about 20% w/w of the pharmaceutically acceptable carrier or diluent.
  • the composition comprises between about 0.1% w/w to about 20% w/w, about 0.2% w/w to about 20% w/w, about 0.3% w/w to about 20% w/w, about 0.4% w/w to about 20% w/w, about 0.5% w/w to about 20% w/w, about 1% w/w to about 20% w/w, about 2% w/w to about 20% w/w, about 3% w/w to about 20% w/w, about 4% w/w to about 20% w/w, about 5% w/w to about 20% w/w, about 7.5% w/w to about 20% w/w, about 10% w/w to about 20% w/w, about 12.5% w/w to about 20% w/w, about 15% w/w to about 20% w/w, or about 17.5% w
  • the composition comprises between about 0.2% w/w to about 20% w/w of the pharmaceutically acceptable carrier or diluent. In some embodiments, the composition comprises between about 0.3% w/w to about 20% w/w of the pharmaceutically acceptable carrier or diluent. In some embodiments, the composition comprises between about 0.4% w/w to about 20% w/w of the pharmaceutically acceptable carrier or diluent. In some embodiments, the composition comprises between about 0.5% w/w to about 20% w/w of the pharmaceutically acceptable carrier or diluent. In some embodiments, the composition comprises between about 1% w/w to about 20% w/w of the pharmaceutically acceptable carrier or diluent.
  • the composition comprises between about 2% w/w to about 20% w/w of the pharmaceutically acceptable carrier or diluent. In some embodiments, the composition comprises between about 3% w/w to about 20% w/w of the pharmaceutically acceptable carrier or diluent. In some embodiments, the composition comprises between about 4% w/w to about 20% w/w of the pharmaceutically acceptable carrier or diluent. In some embodiments, the composition comprises between about 5% w/w to about 20% w/w of the pharmaceutically acceptable carrier or diluent. In some embodiments, the composition comprises between about 7.5% w/w to about 20% w/w of the pharmaceutically acceptable carrier or diluent.
  • the composition comprises between about 10% w/w to about 20% w/w of the pharmaceutically acceptable carrier or diluent. In some embodiments, the composition comprises between about 12.5% w/w to about 20% w/w of the pharmaceutically acceptable carrier or diluent. In some embodiments, the composition comprises between about 15% w/w to about 20% w/w of the pharmaceutically acceptable carrier or diluent. In some embodiments, the composition comprises between about 17.5% w/w to about 20% w/w of the pharmaceutically acceptable carrier or diluent.
  • the composition comprises a preservative. In some embodiments, the composition comprises a preservative with bactericidal, bacteriostatic, anti-fungal, or antiprotozoal activity. In some embodiments, the preservative is a bactericide. In some embodiments, the preservative is an anti-fungal agent.
  • Exemplary preservatives include benzoic acid, benzyl alcohol, benzalkonium chloride, benzethonium chloride, bronidol, butylatehydroxytoluene (BHT), butyl paraben, chlorobutanol, chlorocresol, meta cresol, methyl paraben, phenyl ethyl alcohol, propyl paraben, phenol, propyl gallate, propylene glycol, sodium benzoate, sodium calcium edetate, sorbic acid, thiomersal, Vitamin C, and Vitamin E.
  • BHT butylatehydroxytoluene
  • BHT butyl paraben
  • chlorobutanol chlorocresol
  • meta cresol meta cresol
  • methyl paraben methyl paraben
  • phenyl ethyl alcohol propyl paraben
  • propyl paraben phenol
  • propyl gallate propylene glycol
  • sodium benzoate sodium calcium edetate
  • the composition may comprise between about 0.1% w/w to about 20% w/w of the preservative.
  • the capsule comprises between about 0.1% w/w to about 20% w/w, about 0.2% w/w to about 20% w/w, about 0.3% w/w to about 20% w/w, about 0.4% w/w to about 20% w/w, about 0.5% w/w to about 20% w/w, about 1% w/w to about 20% w/w, about 2% w/w to about 20% w/w, about 3% w/w to about 20% w/w, about 4% w/w to about 20% w/w, about 5% w/w to about 20% w/w, about 7.5% w/w to about 20% w/w, about 10% w/w to about 20% w/w, about 12.5% w/w to about 20% w/w, about 15% w/w to about 20% w/w, or about 17.5% w/w to about 20% w/w
  • the composition comprises between about 0.2% w/w to about 20% w/w of the preservative. In some embodiments, the composition comprises between about 0.3% w/w to about 20% w/w of the preservative. In some embodiments, the composition comprises between about 0.4% w/w to about 20% w/w of the preservative. In some embodiments, the composition comprises between about 0.5% w/w to about 20% w/w of the preservative. In some embodiments, the composition comprises between about 1% w/w to about 20% w/w of the preservative. In some embodiments, the composition comprises between about 2% w/w to about 20% w/w of the preservative.
  • the composition comprises between about 3% w/w to about 20% w/w of the preservative. In some embodiments, the composition comprises between about 4% w/w to about 20% w/w of the preservative. In some embodiments, the composition comprises between about 5% w/w to about 20% w/w of the preservative. In some embodiments, the composition comprises between about 7.5% w/w to about 20% w/w of the preservative. In some embodiments, the composition comprises between about 10% w/w to about 20% w/w of the preservative. In some embodiments, the composition comprises between about 12.5% w/w to about 20% w/w of the preservative. In some embodiments, the composition comprises between about 15% w/w to about 20% w/w of the preservative. In some embodiments, the composition comprises between about 17.5% w/w to about 20% w/w of the preservative.
  • the composition features a surfactant.
  • the composition comprises an anionic surfactant.
  • the anionic surfactant is a (C10-C20) carboxylate salt, e.g., a salt of capric acid, undecylic acid, lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid , margaric acid, stearic acid, nonadecylic acid, or arachidinic acid, wherein the counterion is selected from an alkali metal cation, e.g., sodium.
  • the anionic surfactant is an alkyl (poly)ether sulfate. Exemplary alkyl (poly)ether sulfates include ammonium lauryl sulfate, sodium dodecyl sulfate, sodium lauryl sulfate, and sodium pareth sulfate.
  • the composition comprises a cationic surfactant.
  • the cationic surfactant is an alkyl benzalkonium chloride.
  • the composition comprises a zwitterionic (i.e., an amphoteric) surfactant.
  • the zwitterionic (i.e., amphoteric) surfactant is a zwitterionic phospholipid, e.g., phosphatidylcholine, e.g., lecithin, e.g., soy lecithin or egg lecithin.
  • the composition comprising a polymer an plurality of engineered cells comprises a zwitterionic (i.e., an amphoteric) surfactant, wherein the zwitterionic (i.e., amphoteric) surfactant is cocamidopropyl betaine, or cocamidopropyl hydroxysultaine.
  • a zwitterionic i.e., an amphoteric
  • amphoteric i.e., amphoteric
  • the composition comprises a nonionic surfactant.
  • the nonionic surfactant is an alcohol ethoxylate, a poly ethoxylated glycol ether, a polysorbate, a sorbitan ester, or poly(ethylene oxide)-Z>-poly(propylene oxide)-£>-poly(ethylene oxide) (PEO-PPO-PEO).
  • the composition comprises a surfactant selected from any of the pharmaceutically relevant surfactants disclosed in Tadros, T.F. Applied surfactants: principles and applications. 2006: John Wiley & Sons.
  • the composition may comprise between about 0.1% w/w to about 20% w/w of the surfactant.
  • the composition comprises between about 0.1% w/w to about 20% w/w, about 0.2% w/w to about 20% w/w, about 0.3% w/w to about 20% w/w, about 0.4% w/w to about 20% w/w, about 0.5% w/w to about 20% w/w, about 1% w/w to about 20% w/w, about 2% w/w to about 20% w/w, about 3% w/w to about 20% w/w, about 4% w/w to about 20% w/w, about 5% w/w to about 20% w/w, about 7.5% w/w to about 20% w/w, about 10% w/w to about 20% w/w, about 12.5% w/w to about 20% w/w, about 15% w/w to about 20% w/w, or about 17.5% w/w to about 20% w/w
  • the composition comprises between about 0.2% w/w to about 20% w/w of the surfactant. In some embodiments, the composition comprises between about 0.3% w/w to about 20% w/w of the surfactant. In some embodiments, the composition comprises between about 0.4% w/w to about 20% w/w of the surfactant. In some embodiments, the composition comprises between about 0.5% w/w to about 20% w/w of the surfactant. In some embodiments, the composition comprises between about 1% w/w to about 20% w/w of the surfactant. In some embodiments, the composition comprises between about 2% w/w to about 20% w/w of the surfactant.
  • the composition comprises between about 3% w/w to about 20% w/w of the surfactant. In some embodiments, the composition comprises between about 4% w/w to about 20% w/w of the surfactant. In some embodiments, the composition comprises between about 5% w/w to about 20% w/w of the surfactant. In some embodiments, the composition comprises between about 7.5% w/w to about 20% w/w of the surfactant. In some embodiments, the composition comprises between about 10% w/w to about 20% w/w of the surfactant. In some embodiments, the composition comprises between about 12.5% w/w to about 20% w/w of the surfactant. In some embodiments, the composition comprises between about 15% w/w to about 20% w/w of the surfactant. In some embodiments, the composition comprises between about 17.5% w/w to about 20% w/w of the surfactant.
  • the composition features a polymer.
  • exemplary polymers include polyethylene glycol (PEG), polyvinylpyrrolidone (PVP) , polylactic acid (PLA), poly(s- caprolactone) (PCL), and any copolymer thereof.
  • the composition may comprise between about 0.1% w/w to about 20% w/w of the polymer.
  • the composition comprises between about 0.1% w/w to about 20% w/w, about 0.2% w/w to about 20% w/w, about 0.3% w/w to about 20% w/w, about 0.4% w/w to about 20% w/w, about 0.5% w/w to about 20% w/w, about 1% w/w to about 20% w/w, about 2% w/w to about 20% w/w, about 3% w/w to about 20% w/w, about 4% w/w to about 20% w/w, about 5% w/w to about 20% w/w, about 7.5% w/w to about 20% w/w, about 10% w/w to about 20% w/w, about 12.5% w/w to about 20% w/w, about 15% w/w to about 20% w/w, or about 17.5% w/w to about 20% w/w of the polymer.
  • the composition comprises between about 0.2% w/w to about 20% w/w of the polymer. In some embodiments, the composition comprises between about 0.3% w/w to about 20% w/w of the polymer. In some embodiments, the composition comprises between about 0.4% w/w to about 20% w/w of the polymer. In some embodiments, the composition comprises between about 0.5% w/w to about 20% w/w of the polymer. In some embodiments, the composition comprises between about 1% w/w to about 20% w/w of the polymer. In some embodiments, the composition comprises between about 2% w/w to about 20% w/w of the polymer.
  • the composition comprises between about 3% w/w to about 20% w/w of the polymer. In some embodiments, the composition comprises between about 4% w/w to about 20% w/w of the polymer. In some embodiments, the composition comprises between about 5% w/w to about 20% w/w of the polymer. In some embodiments, the composition comprises between about 7.5% w/w to about 20% w/w of the polymer. In some embodiments, the composition comprises between about 10% w/w to about 20% w/w of the polymer. In some embodiments, the composition comprises between about 12.5% w/w to about 20% w/w of the polymer. In some embodiments, the composition comprises between about 15% w/w to about 20% w/w of the polymer. In some embodiments, the composition comprises between about 17.5% w/w to about 20% w/w of the polymer.
  • the present disclosure provides modes for local delivery of a composition featuring capsules comprising a plurality of engineered cells.
  • the composition may be disposed in a cellular compartment, e g., an organ, or a particular region of an organ.
  • the composition is disposed in the respiratory system, e.g., the nose, the paranasal sinuses, the pharynx, the larynx, the trachea, the left bronchus, the right bronchus, the left lung, and/or the right lung.
  • the composition is disposed in the nose, e.g., the nasal cavity, the nasal conchae, or the nasal vestibule.
  • capsule is disposed in the paranasal sinuses, e.g., the frontal paranasal sinuses or the sphenoid nasal sinuses.
  • the composition is disposed in the pharynx or the oral cavity. In some embodiments, the composition is disposed in the larynx. In some embodiments, the composition is disposed in the trachea, e.g., adjacent to the carina of trachea. In some embodiments, the composition is disposed in the left bronchus. In some embodiments, the composition is disposed in the right bronchus.
  • the composition is disposed in the left lung, e.g., the inferior lobe, the middle lobe, or the superior lobe. In some embodiments, the composition is disposed in the left lung, e.g., the left bronchiole, the alveolar duct, the alveolar sac, or the alveolus. In some embodiments, the composition is disposed in the right lung, e.g., the inferior lobe, the middle lobe, or the superior lobe. In some embodiments, the composition is disposed in the right lung, e.g., the right bronchiole, the alveolar duct, the alveolar sac, or the alveolus.
  • the composition may be disposed in a cellular compartment, e.g., a cavity, e.g., the pleural cavity or the thoracic cavity. In some embodiments, the composition is disposed in the pleural cavity. In some embodiments, the capsule is disposed in the diaphragm.
  • the composition is provided as an implantable drug delivery system, e.g., the implantable drug delivery system is provided to a subject via surgical implantation.
  • the composition is characterized by an immediate release pharmacokinetic profile, e.g., a “burst” release profile, of the therapeutic agent.
  • the composition features a drug depot, wherein the pharmacokinetic profile is characterized by a sustained release pharmacokinetic profile.
  • the composition features a drug depot, wherein a therapeutic agent is released responsive to a stimulus, e.g., responsive to a disease or inflammatory marker, e.g., a cytokine, a chemokine, an antigen, an antibody, or a pathogen.
  • a disease or inflammatory marker e.g., a cytokine, a chemokine, an antigen, an antibody, or a pathogen.
  • the therapeutic agent is released responsive to a cytokine.
  • the therapeutic agent is released responsive to a chemokine.
  • the therapeutic agent is released responsive to an antigen.
  • the therapeutic agent is released responsive to an antibody.
  • the therapeutic agent is released responsive to a pathogen.
  • the therapeutic agent is released constitutively and/or responsive to a stimulus, e.g., responsive to a disease or inflammatory marker, e.g., a cytokine, a chemokine, an antigen, an antibody, or a pathogen.
  • a disease or inflammatory marker e.g., a cytokine, a chemokine, an antigen, an antibody, or a pathogen.
  • the constitutive release of the therapeutic agent is characterized by a sustained release pharmacokinetic profile.
  • the constitutive release of the therapeutic agent is characterized by an immediate “burst” release pharmacokinetic profile.
  • additional therapeutic agent is released responsive to the stimulus, characterized in that the additional release of the therapeutic agent is additive to the constitutive release of the therapeutic agent.
  • the stimulus is a cytokine and/or chemokine selected from one or more of: interleukin-1 (IL-1), interleukin-1 alpha (IL-la), interleukin- 1 beta (IL-ip), interleukin-1 receptor antagonist protein (IL-IRA), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin- 10 (IL-10), interleukin- 11 (IL-11) , interleukin- 12 (IL-12), interleukin- 12 alpha (IL-12a), interleukin- 12 beta (IL-12P), interleukin- 13 (IL-13), interleukin- 14 (IL-14), interleukin- 15 (IL-15), interleukin-16 (IL-16), interleukin- 17 (IL-17), interleukin-20 (IL-20), interleukin-1 receptor
  • the stimulus is an anti-inflammatory cytokine selected from IL- 1RA, IL-4, IL-10, IL-11, IL-13, and IL-35, and a combination thereof.
  • the stimulus comprises IL-lRa.
  • the stimulus is an anti-cytokine (auto)antibody or anti-chemokine (auto)antibody, e.g., anti-IL-1, anti-IL-la, anti-IL-ip, anti-IL-IRA, anti-IL-2, anti-IL-4, anti-IL- 5, anti-IL-6, anti-IL-7, anti-IL-8, anti-IL-9, anti-IL-10, anti-IL-11, anti-IL-12, anti-IL-12a, anti- IL-12P, anti-IL-13, anti-IL-14, anti-IL-15, anti-IL-16, anti-IL-17, anti-IL-20, anti-IL-22, anti- IFN-a, anti-IFN-P, anti-IFN-y, anti-TNF-a, anti-TNF-P, anti-TGF-P, anti-CCLl, anti-CCL2, anti-CCL3, anti-CCL4, anti-CCL5, anti-CCL6, anti-CCL7, anti-CCL8, anti-CCL9, anti-CCLIO,
  • the composition is provided as an implantable drug delivery system, wherein the drug delivery system is a drug depot.
  • a drug depot as contemplated herein is a local delivery system with a matrix comprised of polymers, hydrogels, or phospholipids and the like, allowing for local delivery of a therapeutic agent.
  • the drug depot features a polymer or copolymer selected from one or more of polycaprolactone (PCL), poly(ethylene glycol) (PEG), poly(hydroxybutyrate-co-hydroxyvalerate), poly(y-glutamic acid), polyglycolic acid (PGA), polylactic acid (PLA), poly(L-lactic acid) (PLLA), poly(lactic-co- glycolic acid) (PLGA), poly(ethylene glycol)-Z>-hyaluronic acid (PEG-HA), poly(ethylene glycol)-Z>-polycaprolactone (PEG-PCL), poly(ethylene glycol)-Z>-poly(glutamic acid) (PEG- PGA), polyethylene glycol)-/>-polylactic acid (PEG-PLA), poly(ethylene glycol)-/>- poly(glycolic-co-lactic acid) (PEG-PLGA), poly(ethylene glycol)-£>-poly(L-lactic acid) (PEG- PLLA), and poly(PCL), poly
  • the drug depot features a phospholipid selected from one or more of a phosphatidylcholine, a phosphatidylserine, a phosphatidylinositol, a phosphatidylglycerol, or a phosphatidic acid.
  • the drug depot features a phosphatidylcholine, e.g., lecithin (e.g., soy lecithin or egg lecithin), hydrogenated phosphatidylcholine (HPC), or 1,2-dipalmitoyl-sn- glycero-3 -phosphcholine (DPPC).
  • lecithin e.g., soy lecithin or egg lecithin
  • HPC hydrogenated phosphatidylcholine
  • DPPC 1,2-dipalmitoyl-sn- glycero-3 -phosphcholine
  • the drug depot features a polyethylene glycol-conjugated phospholipid, e.g., l,2-distearoyl- /7-glycero-3-phosphoethanolamine- poly(ethylene glycol) (DSPE-PEG).
  • DSPE-PEG polyethylene glycol-conjugated phospholipid
  • the drug depot features a hydrogelforming polymer selected from one or more of alginate, alginate-polyethylene glycol (alginate- PEG), alginate-polyacrylamide (alginate-PAAm), a-cyclodextrin, a-cyclodextrin-polyethylene glycol (a-cyclodextrin-PEG), chitosan, collagen, fibrin, heparin, hyaluronic acid (HA), polyethylene glycol (PEG), polyacrylic acid (PAA), polyacrylamide (PAAm), polyacrylamideferrocene (PAAm-Fc), poly(L-lysine)/polyacrylic acid (PLL/PAA), poly(N-isopropylacylamide) (PNIPAAM), poly((N-isopropylacrylamide)-co-(sodium acrylic acid)) (P(NIPAAM-co-AAcNa)), polyvinyl alcohol-polyacrylamide (PVA-PAAm),
  • the composition may be delivered with a device.
  • the device is bronchoscope.
  • the composition is delivered with a rigid bronchoscope.
  • the composition is delivered with a flexible bronchoscope.
  • the composition is delivered as part of an endoscopic procedure. In some embodiments, the composition is delivered through the mouth, e g., the oral cavity. In some embodiments, the composition is delivered through the nose. In some embodiments, the capsule is delivered through a tracheostomy. In some embodiments, the composition is delivered through the mouth and disposed in the bronchi, the bronchioles, or various parts of the lung. In some embodiments, the composition is delivered through the nose and disposed in the bronchi, the bronchioles, or various parts of the lung. Tn some embodiments, the composition is delivered through a tracheostomy and disposed in the bronchi, the bronchioles, or various parts of the lung. In some embodiments, the composition is delivered as part of a diagnostic procedure. In some embodiments, the capsule is delivered as part of a therapeutic procedure.
  • the composition is provided, e.g., administered, by injection, e.g., intramuscular injection or subcutaneous injection.
  • the composition is administered by intramuscular injection.
  • the composition is administered by subcutaneous injection.
  • the composition provided for injection may be formulated as a solid, e.g., a lyophilized powder that may be reconstituted before or at the time of administration.
  • the composition provided for injection may be formulated as a liquid.
  • the composition provided for injection may be formulated as a semi-solid preparation, e.g., a gel, a hydrogel, and the like.
  • the composition provided for injection may be formulated as a drug depot.
  • the composition provided for injection features a drug depot, wherein a therapeutic agent is released responsive to a stimulus, e.g., responsive to a disease or inflammatory marker, e.g., a cytokine, a chemokine, an antigen, an antibody, or a pathogen.
  • a disease or inflammatory marker e.g., a cytokine, a chemokine, an antigen, an antibody, or a pathogen.
  • the therapeutic agent is released responsive to a cytokine.
  • the therapeutic agent is released responsive to a chemokine.
  • the therapeutic agent is released responsive to an antigen.
  • the therapeutic agent is released responsive to an antibody.
  • the therapeutic agent is released responsive to a pathogen.
  • the composition provided for injection features a drug depot, wherein a therapeutic agent is released constitutively and/or responsive to a stimulus, e.g., responsive to a disease or inflammatory marker, e.g., a cytokine, a chemokine, an antigen, an antibody, or a pathogen.
  • a disease or inflammatory marker e.g., a cytokine, a chemokine, an antigen, an antibody, or a pathogen.
  • the constitutive release of the therapeutic agent is characterized by a sustained release pharmacokinetic profile.
  • the constitutive release of the therapeutic agent is characterized by an immediate “burst” release pharmacokinetic profile.
  • additional therapeutic agent is released responsive to the stimulus, characterized in that the additional release of the therapeutic agent is additive to the constitutive release of the therapeutic agent.
  • the stimulus is a cytokine and/or chemokine selected from one or more of interleukin-1 (IL-1), interleukin-1 alpha (IL-la), interleukin-1 beta (IL- 1 p), interleukin- 1 receptor antagonist protein (IL-IRA), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin- 10 (IL-10), interleukin- 11 (IL-11) , interleukin- 12 (IL-12), interleukin- 12 alpha (IL-12a), interleukin- 12 beta (IL-120), interleukin- 13 (IL-13), interleukin- 14 (IL-14), interleukin- 15 (IL-15), interleukin-16 (IL-16), interleukin- 17 (IL-17), interleukin-20 (IL-20), interleukin- 1
  • the stimulus is an anti-inflammatory cytokine selected from IL- 1RA, IL-4, IL-10, IL-11, IL-13, and IL-35, and a combination thereof.
  • the stimulus comprises IL-lRa.
  • the stimulus is an anti-cytokine (auto)antibody or anti-cytokine (auto)antibody, e.g., anti-IL-1, anti-IL-la, anti-IL-ip, anti-IL-IRA, anti-IL-2, anti-IL-4, anti-IL- 5, anti-IL-6, anti -IL-7, anti-IL-8, anti-IL-9, anti-IL-10, anti-IL-11, anti-IL-12, anti-IL-12a, anti- IL-12P, anti-IL-13, anti-IL-14, anti-IL-15, anti-IL-16, anti-IL-17, anti-IL-20, anti-IL-22, anti- IFN-a, anti-IFN-P, anti-IFN-y, anti-TNF-oi, anti-TNF-P, anti-TGF-P, anti-CCLl, anti-CCL2, anti-CCL3, anti-CCL4, anti-CCL5, anti-CCL6, anti-CCL7, anti-CCL8, anti-CCL9, anti-CCL
  • the composition provided for injection features a drug delivery system, wherein the drug delivery system is a drug depot.
  • a drug depot as contemplated herein is a local delivery system with a matrix comprised of polymers, hydrogels, or phospholipids and the like, allowing for local delivery of a therapeutic agent.
  • the drug depot features a polymer or copolymer selected from one or more of polycaprolactone (PCL), poly(ethylene glycol) (PEG), poly(hydroxybutyrate-co-hydroxyvalerate), poly(y-glutamic acid), polyglycolic acid (PGA), polylactic acid (PLA), poly(L-lactic acid) (PLLA), poly(lactic-co- glycolic acid) (PLGA), poly(ethylene glycol)-/?-hyaluronic acid (PEG-HA), poly(ethylene glycol)-Z>-polycaprolactone (PEG-PCL), poly(ethylene glycol)-Z>-poly(glutamic acid) (PEG- PGA), polyethylene glycol)-/>-polylactic acid (PEG-PLA), poly(ethylene glycol)-/>- poly(glycolic-co-lactic acid) (PEG-PLGA), poly(ethylene glycol)-£>-poly(L-lactic acid) (PEG- PLLA), and poly(
  • the drug depot features a phospholipid selected from one or more of a phosphatidylcholine, a phosphatidylserine, a phosphatidylinositol, a phosphatidylglycerol, or a phosphatidic acid.
  • the drug depot features a phosphatidylcholine, e.g., lecithin (e.g., soy lecithin or egg lecithin), hydrogenated phosphatidylcholine (HPC), or 1,2-dipalmitoyl-sn- glycero-3-phosphcholine (DPPC).
  • lecithin e.g., soy lecithin or egg lecithin
  • HPC hydrogenated phosphatidylcholine
  • DPPC 1,2-dipalmitoyl-sn- glycero-3-phosphcholine
  • the drug depot features a polyethylene glycol-conjugated phospholipid, e.g., phosph l,2-distcaroyl-.s//-glyccro-3-phosphocthanolaminc- poly(ethylene glycol) (DSPE-PEG).
  • a polyethylene glycol-conjugated phospholipid e.g., phosph l,2-distcaroyl-.s//-glyccro-3-phosphocthanolaminc- poly(ethylene glycol) (DSPE-PEG).
  • the drug depot features a hydrogelforming polymer selected from one or more of alginate, alginate-polyethylene glycol (alginate- PEG), alginate-polyacrylamide (alginate-PAAm), a-cyclodextrin, a-cyclodextrin-polyethylene glycol (a-cyclodextrin-PEG), chitosan, collagen, fibrin, heparin, hyaluronic acid (HA), polyethylene glycol (PEG), polyacrylic acid (PAA), polyacrylamide (PAAm), polyacrylamideferrocene (PAAm-Fc), poly(L-lysine)/polyacrylic acid (PLL/PAA), poly(N-isopropylacylamide) (PNIPAAM), poly((N-isopropylacrylamide)-co-(sodium acrylic acid)) (P(NIPAAM-co-AAcNa)), polyvinyl alcohol-polyacrylamide (PVA-PAAm),
  • the present disclosure provides modes for systemic delivery of a therapeutic agent, e.g., a protein such as a cytokine, by administering a composition featuring capsules comprising a plurality of engineered cells.
  • a therapeutic agent e.g., a protein such as a cytokine
  • the composition may be disposed in a cellular compartment, e.g., an organ, a cavity or a serous membrane.
  • the capsule is disposed in the abdomino-pelvic cavity, cranial cavity, dorsal cavity, ventral cavity, or thoracic cavity.
  • the composition is disposed in the intraperitoneal cavity or adjacent to the peritoneum.
  • the composition is provided as an implantable drug delivery system, e.g., the implantable drug delivery system is provided to a subject via surgical implantation.
  • the composition is implanted in a cellular compartment, e.g., a cavity or serous membrane.
  • the composition is implanted in the abdomino-pelvic cavity, cranial cavity, dorsal cavity, ventral cavity, or thoracic cavity.
  • the composition is implanted in the intraperitoneal cavity or adjacent to the peritoneum.
  • the composition is characterized by an immediate release pharmacokinetic profile, e.g., a “burst” release profile, of the therapeutic agent.
  • the pharmacokinetic profile is characterized by a sustained release pharmacokinetic profile.
  • the therapeutic agent is released responsive to a stimulus, e.g., responsive to a disease or inflammatory marker, e.g., a cytokine, a chemokine, an antigen, an antibody, or a pathogen.
  • a disease or inflammatory marker e.g., a cytokine, a chemokine, an antigen, an antibody, or a pathogen.
  • the therapeutic agent is released responsive to a cytokine.
  • the agent is released responsive to a chemokine.
  • the therapeutic agent is released responsive to an antigen.
  • the therapeutic agent is released responsive to an antibody.
  • the therapeutic agent is released responsive to a pathogen.
  • the therapeutic agent is released constitutively and/or responsive to a stimulus, e.g., responsive to a disease or inflammatory marker, e.g., a cytokine, a chemokine, an antigen, an antibody, or a pathogen.
  • a disease or inflammatory marker e.g., a cytokine, a chemokine, an antigen, an antibody, or a pathogen.
  • the constitutive release of the therapeutic agent is characterized by a sustained release pharmacokinetic profile.
  • the constitutive release of the therapeutic agent is characterized by an immediate “burst” release pharmacokinetic profile.
  • additional therapeutic agent is released responsive to the stimulus, characterized in that the additional release of the therapeutic agent is additive to the constitutive release of the therapeutic agent.
  • the stimulus is a cytokine and/or chemokine selected from one or more of: interleukin-1 (IL-1), interleukin-1 alpha (IL-la), interleukin-1 beta (IL-ip), interleukin-1 receptor antagonist protein (IL-IRA), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin- 10 (IL-10), interleukin- 11 (IL-11) , interleukin- 12 (IL-12), interleukin- 12 alpha (IL-12a), interleukin- 12 beta (IL-12P), interleukin- 13 (IL-13), interleukin- 14 (IL-14), interleukin- 15 (IL-15), interleukin- 16 (IL-16), interleukin- 17 (IL-17), interleukin-20 (IL-20), interfer
  • the composition featuring the capsules is characterized as a drug depot.
  • a drug depot as contemplated herein is a systemic delivery system with a matrix comprised of polymers, hydrogels, or phospholipids and the like, allowing for local or systemic delivery of a therapeutic agent.
  • the drug depot features a polymer or copolymer selected from one or more of polycaprolactone (PCL), poly(ethylene glycol) (PEG), poly(hydroxybutyrate-co-hydroxyvalerate), poly(y-glutamic acid), polyglycolic acid (PGA), polylactic acid (PLA), poly(L -lactic acid) (PLLA), poly(lactic-co-glycolic acid) (PLGA), polyethylene glycol)-Z>-hyaluronic acid (PEG-HA), poly(ethylene glycol)-Z>-polycaprolactone (PEG-PCL), poly(ethylene glycol)-£>-poly(glutamic acid) (PEG-PGA), poly(ethylene glycol)-Z>- polylactic acid (PEG-PLA), poly(ethylene glycol)-A-poly(glycolic-co-lactic acid) (PEG-PLGA), poly(ethylene glycol)-Z>-poly(L-lactic acid) (PEG-PLLA), and poly(
  • the drug depot features a phospholipid selected from one or more of a phosphatidylcholine, a phosphatidyl serine, a phosphatidylinositol, a phosphatidylglycerol, or a phosphatidic acid.
  • the drug depot features a phosphatidylcholine, e.g., lecithin (e.g., soy lecithin or egg lecithin), hydrogenated phosphatidylcholine (HPC), or l ⁇ -dipalmitoyl-sn-glycero-S -phosphcholine (DPPC).
  • lecithin e.g., soy lecithin or egg lecithin
  • HPC hydrogenated phosphatidylcholine
  • DPPC l ⁇ -dipalmitoyl-sn-glycero-S -phosphcholine
  • the drug depot features a polyethylene glycol-conjugated phospholipid, e.g., 1,2- distearoyl-s77-glycero-3-phosphoethanolamine-poly(ethylene glycol) (DSPE-PEG).
  • DSPE-PEG 1,2- distearoyl-s77-glycero-3-phosphoethanolamine-poly(ethylene glycol)
  • the drug depot features a hydrogel-forming polymer selected from one or more of alginate, alginate-polyethylene glycol (alginate-PEG), alginate-polyacrylamide (alginate-PAAm), a-cyclodextrin, a-cyclodextrin-polyethylene glycol (a-cyclodextrin-PEG), chitosan, collagen, fibrin, heparin, hyaluronic acid (HA), polyethylene glycol (PEG), polyacrylic acid (PAA), polyacrylamide (PAAm), polyacrylamide-ferrocene (PAAm-Fc), poly(L-lysine)/polyacrylic acid (PLL/PAA), poly(N-isopropylacylamide) (PNIPAAM), poly((N-isopropylacrylamide)-co- (sodium acrylic acid)) (P(NIPAAM-co-AAcNa)), polyvinyl alcohol-polyacrylamide (PVA- PA
  • composition featuring the capsules comprising a plurality of engineered cells may be delivered with a device.
  • the composition is provided, e.g., administered, by injection, e.g., intramuscular injection or subcutaneous injection.
  • the composition is administered by intramuscular injection.
  • the composition is administered by subcutaneous injection.
  • the composition may be formulated as a solid, e.g., a lyophilized powder that may be reconstituted before or at the time of administration.
  • the composition may be formulated as a liquid.
  • the composition may be formulated as a semi-solid preparation, e.g., a gel, a hydrogel, and the like.
  • the composition be formulated as a drug depot.
  • the composition provided for injection features a drug depot, wherein a therapeutic agent is released responsive to a stimulus, e.g., responsive to a disease or inflammatory marker, e.g., a cytokine, a chemokine, an antigen, an antibody, or a pathogen.
  • a disease or inflammatory marker e.g., a cytokine, a chemokine, an antigen, an antibody, or a pathogen.
  • the therapeutic agent is released responsive to a cytokine.
  • the therapeutic agent is released responsive to a chemokine.
  • the therapeutic agent is released responsive to an antigen.
  • the therapeutic agent is released responsive to an antibody.
  • the therapeutic agent is released responsive to a pathogen.
  • the therapeutic agent is released constitutively and/or responsive to a stimulus, e.g., responsive to a disease or inflammatory marker, e.g., a cytokine, a chemokine, an antigen, an antibody, or a pathogen.
  • a disease or inflammatory marker e.g., a cytokine, a chemokine, an antigen, an antibody, or a pathogen.
  • the constitutive release of the therapeutic agent is characterized by a sustained release pharmacokinetic profde.
  • the constitutive release of the therapeutic agent is characterized by an immediate “burst” release pharmacokinetic profile.
  • additional therapeutic agent is released responsive to the stimulus, characterized in that the additional release of the therapeutic agent is additive to the constitutive release of the therapeutic agent.
  • the stimulus is a cytokine and/or chemokine selected from one or more of: interleukin-1 (IL-1), interleukin-1 alpha (IL-la), interleukin- 1 beta (IL-i ), interleukin-1 receptor antagonist protein (IL-IRA), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin- 10 (IL-10), interleukin- 11 (IL-11) , interleukin- 12 (IL-12), interleukin- 12 alpha (IL-12a), interleukin- 12 beta (IL-123), interleukin- 13 (IL-13), interleukin- 14 (IL-14), interleukin- 15 (IL-15), interleukin-16 (IL-16), interleukin- 17 (IL-17), interleukin-20 (IL-20), interfer
  • the composition is provided for injection, wherein the drug delivery system is a drug depot.
  • a drug depot as contemplated herein is a local delivery system with a matrix comprised of polymers, hydrogels, or phospholipids and the like, allowing for local delivery of a therapeutic agent.
  • the drug depot features a polymer or copolymer selected from one or more of polycaprolactone (PCL), polyethylene glycol) (PEG), poly(hydroxybutyrate-co-hydroxyvalerate), poly(y-glutamic acid), polyglycolic acid (PGA), polylactic acid (PLA), poly(L -lactic acid) (PLLA), poly(lactic-co-glycolic acid) (PLGA), poly(ethylene glycol)-/>-hyaluronic acid (PEG-HA), poly(ethylene glycol)-6-poly caprolactone (PEG-PCL), poly(ethylene glycol)-Z>-poly(glutamic acid) (PEG-PGA), poly(ethylene glycol)-Z>- polylactic acid (PEG-PLA), poly(ethylene glycol)-/>-poly(glycolic-co-lactic acid) (PEG-PLGA), poly(ethylene glycol)-Z>-poly(L-lactic acid) (PEG-PLLA), and poly(ethylene(ethylene-cap
  • the drug depot features a phospholipid selected from one or more of a phosphatidylcholine, a phosphatidyl serine, a phosphatidylinositol, a phosphatidylglycerol, or a phosphatidic acid.
  • the drug depot features a phosphatidylcholine, e.g., lecithin (e.g., soy lecithin or egg lecithin), hydrogenated phosphatidylcholine (HPC), or l,2-dipalmitoyl-ST7-glycero-3 -phosphcholine (DPPC).
  • lecithin e.g., soy lecithin or egg lecithin
  • HPC hydrogenated phosphatidylcholine
  • DPPC l,2-dipalmitoyl-ST7-glycero-3 -phosphcholine
  • the drug depot features a polyethylene glycol -conjugated phospholipid, e.g., phosph l,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol) (DSPE-PEG).
  • DSPE-PEG polyethylene glycol -conjugated phospholipid
  • the drug depot features a hydrogel -forming polymer selected from one or more of alginate, alginate-polyethylene glycol (alginate-PEG), alginate-polyacrylamide (alginate-PAAm), a-cyclodextrin, a-cyclodextrin-polyethylene glycol (a-cyclodextrin-PEG), chitosan, collagen, fibrin, heparin, hyaluronic acid (HA), polyethylene glycol (PEG), polyacrylic acid (PAA), polyacrylamide (PAAm), polyacrylamide-ferrocene (PAAm-Fc), poly(L- lysine)/polyacrylic acid (PLL/PAA), poly(N-isopropylacylamide) (PNIPAAM), poly((N- isopropylacrylamide)-co-(sodium acrylic acid)) (P(NIPAAM-co-AAcNa)), polyvinyl alcoholpolyacrylamide (PVA-
  • the present disclosure provides modes for inhalable delivery of a composition featuring capsules comprising a plurality of engineered cells, e.g., with a device.
  • the device providing a mode for inhalable delivery of the composition features:
  • composition (ii) a second compartment, fixedly connected to the first compartment, wherein the composition is disposed in said second compartment, and wherein the composition comprises aerosolized capsules;
  • an actuator capable of providing means for aerosolizing/atomizing said composition
  • an ejector capable of providing means for dispersing said aerosolized composition
  • the device is a nebulizer, e.g., a jet nebulizer, a soft mist nebulizer, an ultrasonic nebulizer, or an ultrasonic vibrating mesh nebulizer, or an inhaler, e.g., a metered-dose inhaler, a dry powder inhaler, or a rotary inhaler.
  • a nebulizer e.g., a jet nebulizer, a soft mist nebulizer, an ultrasonic nebulizer, or an ultrasonic vibrating mesh nebulizer
  • an inhaler e.g., a metered-dose inhaler, a dry powder inhaler, or a rotary inhaler.
  • the device is a spray bottle. In some embodiments, the device is a spray can. In some embodiments, the device is an atomizer. In some embodiments, the device is a vaporizer.
  • the device forms an aerosol comprising a plurality of liquid droplets comprising capsules encapsulating a plurality of engineered cells for inhalable delivery.
  • the device is a nebulizer.
  • the device is an ultrasonic nebulizer, wherein the ultrasonic nebulizer forms an aerosol comprising a plurality of liquid droplets via piezoelectric actuation.
  • the device is an ultrasonic vibrating mesh nebulizer, wherein the ultrasonic vibrating mesh nebulizer forms an aerosol comprising a plurality of liquid droplets via the ultrasonic vibration of a membrane.
  • the device is a jet nebulizer or an atomizer, wherein the jet nebulizer forms an aerosol comprising a plurality of liquid droplets via an actuation facilitated or enabled by a compressed gas.
  • the nebulizer forms an aerosol comprising a plurality of liquid droplets via an actuation facilitated or enabled, i.e., at least in part, by the force of the subject’s respiration.
  • the device is a metered-dose inhaler.
  • the metered-dose inhaler forms an aerosol comprising liquid droplets via an actuation facilitated or enabled by a propellant or compressed gas.
  • the device is a metered-dose inhaler.
  • the metered-dose inhaler forms an aerosol comprising liquid droplets via an actuation facilitated or enabled, i.e., at least in part, by the force of the subject’s respiration.
  • the device forms an aerosol comprising a plurality of solid particles comprising polymeric capsules encapsulating a cell or plurality of engineered cells for inhalable delivery.
  • the device is an inhaler.
  • the device is a dry-powder inhaler or a rotary inhaler.
  • the dry-powder inhaler forms an aerosol comprising solid particles via an actuation facilitated or enabled, i.e., at least in part, by the force of the subject’s respiration.
  • the present disclosure provides methods for delivery of the composition featuring capsules and associated dosages, e.g., a predetermined, e.g., a prescribed dosage, or dosing schedule.
  • the capsule may be delivered via inhalation with a device, e.g., a nebulizer, e.g., a jet nebulizer, a soft mist nebulizer, an ultrasonic nebulizer, or an ultrasonic vibrating mesh nebulizer, or an inhaler, a metered-dose inhaler, a dry powder inhaler or rotary inhaler and the like at a predetermined dosage.
  • a nebulizer e.g., a jet nebulizer, a soft mist nebulizer, an ultrasonic nebulizer, or an ultrasonic vibrating mesh nebulizer
  • an inhaler e.g., a metered-dose inhaler, a dry powder inhaler or
  • the capsule for inhalable delivery may be delivered with a spray bottle, a spray can, an atomizer, or a vaporizer.
  • the capsule may be delivered locally, e.g., via surgical implantation, e.g., as a drug depot, or via intubation or instillation, e.g., intratracheal instillation, optionally with a device, e.g., a bronchoscope (e.g., a rigid bronchoscope or a flexible bronchoscope) or a catheter at a predetermined dosage.
  • a bronchoscope e.g., a rigid bronchoscope or a flexible bronchoscope
  • the composition may be provided at a predetermined dosage of the therapeutic agent of between about 10 ng to about 10 mg.
  • the composition is provided at a dosage of the therapeutic agent of between about 10 ng to about 10 mg, about 20 ng to about 10 mg, about 30 ng to about 10 mg, about 40 ng to about 10 mg, about 50 ng to about 10 mg about 100 ng to about 10 mg, about 200 ng to about 10 mg, 300 ng to about 10 mg, 400 ng to about 10 mg, 500 ng to about 10 mg, 1 pg to about 10 mg, 2 pg to about 10 mg, 3 pg to about 10 mg, 4 pg to about 10 mg, 5 pg to about 10 mg, 10 pg to about 10 mg, 20 pg to about 10 mg, 30 pg to about 10 mg, 40 pg to about 10 mg, 50 pg to about 10 mg, 100 pg to about 10 mg, 200 pg to about 10 mg, 300 pg to about 10 mg, 400 pg to about 10
  • the composition is provided at a dosage of the therapeutic agent of between about 20 ng to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 30 ng to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 40 ng to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 50 ng to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 100 ng to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 200 ng to about 10 mg.
  • the composition is provided at a dosage of the therapeutic agent of between about 300 ng to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 400 ng to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 500 ng to about 10 mg. In some embodiments, the composition featuring the capsules comprising a polymer and an plurality of engineered cells is provided at a dosage of the therapeutic agent of between about 1 pg to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 2 pg to about 10 mg. In some embodiments, the capsule is provided at a dosage of the therapeutic agent of between about 3 pg to about 10 mg.
  • the composition is provided at a dosage of the therapeutic agent of between about 4 pg to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 5 pg to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 10 pg to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 20 pg to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 30 pg to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 40 pg to about 10 mg.
  • the composition is provided at a dosage of the therapeutic agent of between about 50 pg to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 100 pg to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 200 pg to about 10 mg. Tn some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 300 pg to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 400 pg to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 500 pg to about 10 mg.
  • the composition is provided at a dosage of the therapeutic agent of between about 1 mg to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 2 mg to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 3 mg to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 4 mg to about 10 mg. In some embodiments, the composition is provided at a dosage of the therapeutic agent of between about 5 mg to about 10 mg.
  • the therapeutic agent comprises a protein such as a cytokine, a chemokine, and the like.
  • the cytokine and/or chemokine is selected from one or more of: interleukin-1 (IL-1), interleukin-1 alpha (IL-la), interleukin-1 beta (IL-10), interleukin-1 receptor antagonist protein (IL-IRA), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin- 10 (IL-10), interleukin- 11 (IL-11) , interleukin- 12 (IL-12), interleukin- 12 alpha (IL-12a), interleukin- 12 beta (IL-120), interleukin- 13 (IL-13), interleukin- 14 (IL-14), interleukin- 15 (IL- 15), interleukin-1
  • IL-1
  • the therapeutic agent is selected from IL- IRA, IL-4, IL- 10, IL- 11, IL- 13, and IL-35, and a combination thereof. In some embodiments, the therapeutic agent comprises IL-lRa.
  • the therapeutic agent is an anti-cytokine antibody or an anti- chemokine antibody, e.g., anti-IL-1, anti-IL-la, anti-IL-ip, anti-IL-IRA, anti-IL-2, anti-IL-4, anti-IL-5, anti-IL-6, anti-IL-7, anti-IL-8, anti-IL-9, anti-IL-10, anti-IL-11, anti-IL-12, anti-IL- 12a, anti-IL-12p, anti-IL-13, anti-IL-14, anti-IL-15, anti-IL-16, anti-IL-17, anti-IL-20, anti-IL- 22, anti-IFN-a, anti-IFN-P, anti-IFN-y, anti-TNF-a, anti-TNF-P, anti-TGF-P, anti-CCLl, anti- CCL2, anti-CCL3, anti-CCL4, anti-CCL5, anti-CCL6, anti-CCL7, anti-CCL8, anti-CCL9, anti- CCL10, anti-CCLll
  • the composition may be provided at a predetermined dosing schedule, e.g., to maintain a therapeutic concentration of the therapeutic agent.
  • the composition is provided between four times per day to once per month.
  • the composition is provided four times per day, three times per day, twice per day, once per day, once every other day, twice per week, once per week, once every two weeks, once every three weeks, once every four weeks, or once per month.
  • the composition is provided four times per day.
  • the composition is provided three times per day.
  • the composition is provided twice per day.
  • the composition is provided once per day.
  • the capsule is provided once every other day.
  • the composition is provided twice per week.
  • the composition is provided once per week. In some embodiments, the composition is provided once every two weeks. In some embodiments, the composition is provided once every three weeks. In some embodiments, the composition is provided once every four weeks. In some embodiments, the composition is provided once per month.
  • the composition may be provided at a predetermined time of the day.
  • the composition is provided in the morning, e.g., about 6:00 AM, about 7:00 AM, about 8:00 AM, about 9:00 AM, about 10:00 AM, or about 11 :00 AM.
  • the composition is provided in the afternoon, e.g., about 12:00 PM, about 1 :00 PM, about 2:00 PM, about 3:00 PM, about 4:00 PM, or about 5:00 PM.
  • the composition is provided in the evening, e.g., about 6:00 PM, about 7:00 PM, about 8:00 PM, or about 9:00 PM.
  • the composition is provided at night, e.g., about 10:00 PM, about 11:00 PM, about 12:00 AM, or later.
  • the present disclosure provides methods of treating a respiratory infection, comprising administering a composition featuring capsules comprising a plurality of engineered cells, wherein the engineered cells release, either constitutively and/or responsive to a stimulus, a therapeutic agent.
  • the therapeutic agent is for treating a respiratory infection, wherein the disease or disorder is caused by a pathogen, e.g., a virus, a bacterium, a fungus, a protozoan, a nematode, a flatworm, and the like.
  • the capsule releases a therapeutic agent for treating a respiratory disease or disorder caused by a virus.
  • the virus is selected from one or more of an adenovirus, a coronavirus, a coxsackievirus, a cytomegalovirus, a herpes virus, an influenza virus, a morbillivirus, an orthohantavirus, an orthopneumovirus, a parainfluenza virus, and a rhinovirus.
  • the disease or disorder is caused by an adenovirus.
  • adenovirus species include human adenovirus B, e.g., serotype 14, and human adenovirus C.
  • the disease or disorder is caused by a coxsackievirus.
  • coxsackievirus species include Coxsackie A virus.
  • the disease or disorder is caused by a cytomegalovirus.
  • cytomegalovirus species include human cytomegalovirus (i.e., human betaherpesvirus 5).
  • the disease or disorder is caused by a coronavirus.
  • exemplary coronaviruses include severe acute human coronavirus 229E, human coronavirus NL63 (HCoV- NL63), human coronavirus HKU1 (HCoV-HKUl), human coronavirus OC43, Middle East respiratory syndrome-related coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus- 1 (SARS-CoV-1), and severe acute respiratory syndrome coronavirus-2 (SARS- CoV-2).
  • the disease or disorder is caused by a herpes virus.
  • herpes virus species include herpes simplex virus 1.
  • influenza viruses include influenza A virus, influenza B virus, and influenza C virus.
  • influenza viruses include influenza A virus, influenza B virus, and influenza C virus.
  • exemplary serotypes of influenza A include H1N1 , H1N2, H2N2, H3N2, H5N1, and H7N9.
  • Exemplary serotypes of influenza B include the Victoria and Yamagata subtypes.
  • the disease or disorder is caused by a morbillivirus.
  • morbillivirus species include measles morbillivirus, the causative pathogen of measles.
  • the disease or disorder is caused by an orthohantavirus.
  • orthohantavirus species include black creek canal virus, Monongahela virus, new York orthohantavirus, and sin careful orthohantavirus.
  • the disease or disorder is caused by an orthopneumovirus.
  • orthopneumovirus species include human respiratory syncytial virus.
  • the disease or disorder is caused by a parainfluenza virus.
  • exemplary parainfluenza species include human parainfluenza virus type 3.
  • the disease or disorder is caused by a rhinovirus.
  • exemplary rhinoviruses include any of the infectious serotypes encompassed by human rhinovirus A, human rhinovirus B, and human rhinovirus C.
  • the disease or disorder is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus-2
  • the disease or disorder is caused by a virus, wherein the virus causes an opportunistic infection.
  • capsules release a therapeutic agent for treating a respiratory infection, wherein the disease or disorder is caused by a virus, wherein the subject is immuno-compromised.
  • the capsule releases a therapeutic agent wherein for treating a disease or disorder caused by a virus that is characterized as a hospital- acquired infection.
  • capsules release a therapeutic agent for treating a respiratory infection caused by a bacterium.
  • the disease or disorder is a bacteria selected from Chlamydia psiltaci. Chlamydia pneumoniae, Chlamydia trachomatis, Corynebacterium diptheriae, Corynebacterium haemolyticum, Coxiella burnetii, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Legionella pneumophila, Moraxella catarrhalis, Mycobacterium tuberculosis, Mycoplasma hominis, Mycoplasma pneumoniae, Neisseria gonorrhoaea, Neisseria meningiditis, Pseudomonas aeruginosa, Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus pyogenes, Yersinia pestis
  • the disease or disorder is caused by C. albicans. In some embodiments, the disease or disorder is caused by K. pneumoniae. In some embodiments, the disease or disorder is caused by L. pneumophila. In some embodiments, the disease or disorder is caused by P. aeruginosa. In some embodiments, the disease or disorder is caused by . aureus, e.g., methicillin-resistant S. aureus (MRSA). In some embodiments, the disease or disorder is caused by S. pyogenes.
  • MRSA methicillin-resistant S. aureus
  • capsules release a therapeutic agent for treating a respiratory infection caused by a bacterium, wherein the bacterium causes an opportunistic infection. In some embodiments, capsules release a therapeutic agent for treating a respiratory infection, wherein the disease or disorder is caused by a bacterium, wherein the subject is immunocompromised. In some embodiments, capsules release a therapeutic agent for treating a respiratory infection, wherein the caused by a bacterium that is characterized as a hospital- acquired infection.
  • capsules release a therapeutic agent for treating a respiratory infection caused by a fungal pathogen, e.g., a fungal pathogen selected from one or more of Aspergillus fumigatus, Candida albicans, Coccidioides immitis, Coccidioides posadasii, Cryptococcus gatti, Cryptococcus neoformans, Histoplasma capsulatum, Pneumocystis jiroveci, and Sporothrix schenckii.
  • a fungal pathogen selected from one or more of Aspergillus fumigatus, Candida albicans, Coccidioides immitis, Coccidioides posadasii, Cryptococcus gatti, Cryptococcus neoformans, Histoplasma capsulatum, Pneumocystis jiroveci, and Sporothrix schenckii.
  • capsules release a therapeutic agent for treating a respiratory infection caused by a fungus, wherein the fungus causes an opportunistic infection. In some embodiments, capsules release a therapeutic agent for treating a respiratory infection caused by a fungus, wherein the subject is immuno-compromised. In some embodiments, capsules release a therapeutic agent for treating a respiratory infection caused by a fungus, that is characterized as a hospital -acquired infection.
  • capsules release a therapeutic agent for treating a respiratory infection, wherein the disease or disorder is caused by a protozoan, e.g., wherein the protozoan is selected from one or more of Babesia divergens, Babesia microti, Entamoeba histolytica, Leishmania donovani, Plasmodium falciparum, and Toxoplasma gondii.
  • a protozoan e.g., wherein the protozoan is selected from one or more of Babesia divergens, Babesia microti, Entamoeba histolytica, Leishmania donovani, Plasmodium falciparum, and Toxoplasma gondii.
  • capsules release a therapeutic agent for treating a respiratory infection caused by a protozoan, wherein the protozoan causes an opportunistic infection. In some embodiments, capsules release a therapeutic agent for treating a respiratory infection caused by a protozoan, wherein the subject is immuno-compromised. In some embodiments, capsules release a therapeutic agent for treating a respiratory infection, wherein the disease or disorder is caused by a protozoan, that is characterized as a hospital -acquired infection.
  • capsules a therapeutic agent for treating a respiratory infection caused by a nematode, e.g., wherein the nematode is selected from Ascaris lumbricoides, Brugia malayi, Dirofilarasis immitis, Strongyloides stercoralis, Toxocara canis, Toxocara cati, Trichinella spiralis, and Wuchereria bancrofti.
  • the nematode is selected from Ascaris lumbricoides, Brugia malayi, Dirofilarasis immitis, Strongyloides stercoralis, Toxocara canis, Toxocara cati, Trichinella spiralis, and Wuchereria bancrofti.
  • capsules release a therapeutic agent for treating a respiratory infection caused by a nematode, wherein the nematode causes an opportunistic infection. In some embodiments, capsules release a therapeutic agent for treating a respiratory infection, wherein the disease or disorder is caused by a nematode, wherein the subject is immuno- compromised. In some embodiments, capsules release a therapeutic agent for treating a respiratory infection caused by a nematode, that is characterized as a hospital-acquired infection.
  • capsules release a therapeutic agent for treating a respiratory infection, wherein the disease or disorder is caused by a flatworm, e.g., wherein the flatworm is selected from one or more of Echinococcus granulosus, Echinococcus multilocularis, Paragnimiasis westermani, Schistosoma haemotobium, Schistosoma intercalatum, Schistosoma japonicum, Schistosoma mansoni, Schistosoma mekongi.
  • the flatworm is selected from one or more of Echinococcus granulosus, Echinococcus multilocularis, Paragnimiasis westermani, Schistosoma haemotobium, Schistosoma intercalatum, Schistosoma japonicum, Schistosoma mansoni, Schistosoma mekongi.
  • capsules release a therapeutic agent for treating a respiratory infection caused by Rhinosporidium seeberi.
  • capsules release a therapeutic agent for treating a respiratory infection caused by any of the parasitic organisms disclosed in Khemasuwan, D. et al. Diseases of the Central Airways, 2016, 231-253.
  • the present disclosure provides capsules comprising a plurality of engineered cells for administration of a therapeutic agent to a subject in need thereof.
  • the capsule is formulated for delivery via inhalation to a subject in need thereof.
  • the capsule is formulated for local delivery to a subject in need thereof, e.g., via surgical implantation, or intubation or instillation, e.g., intratracheal instillation, e.g., with a device, e.g., a bronchoscope (e.g., a rigid bronchoscope or flexible bronchoscope) or a catheter.
  • the subject may include a human.
  • the subject is a female.
  • the subject is a male.
  • the subject is aged 18 years or older. In some embodiments, the subject is less than 18 years of age.
  • the subject may be selected based on being at risk of developing one or more of an autoinflammatory condition or disorder or an autoimmune condition or disorder.
  • the subject is at risk of developing one or more of the following: anti -glomerular basement membrane disease, acute interstitial pneumonitis, asthma, bronchopulmonary dysplasia, bronchiectasis, chemical pneumonitis, chronic bronchitis, chronic obstructive pulmonary disease (COPD), conditions with a pleural effusion, cystic fibrosis, hypersensitivity pneumonitis (e.g., due to an environmental allergen, e.g., pollen, mold, dust, dander, and the like), (eosinophilic) granulomatosis with polyangiitis, Langerhans cell histiocytosis, lymphangioleiomyomatosis, infant respiratory distress syndrome (IRDS), pneumoconiosis (e.g., asbestosis), primary ciliary dyskinesia, pulmonary alveolar
  • the subject may be selected based on having one or more symptoms of one or more of an autoinflammatory condition or disorder or an autoimmune condition or disorder.
  • the subject has one or more symptoms of one or more of the following: anti- glomerular basement membrane disease, acute interstitial pneumonitis, asthma, bronchopulmonary dysplasia, bronchiectasis, chemical pneumonitis, chronic bronchitis, chronic obstructive pulmonary disease (COPD), conditions with a pleural effusion, cystic fibrosis, hypersensitivity pneumonitis (e.g., due to an environmental allergen, e g., pollen, mold, dust, dander, and the like), (eosinophilic) granulomatosis with polyangiitis, Langerhans cell histiocytosis, lymphangioleiomyomatosis, infant respiratory distress syndrome (IRDS), pneumoconiosis (e.g., asbestosis), primary ciliary dyskinesia, pulmonary al
  • the subject may be selected based on having had one or more of an autoinflammatory condition or disorder or an autoimmune condition or disorder.
  • the subject has had one or more of the following: anti -glomerular basement membrane disease, acute interstitial pneumonitis, asthma, bronchopulmonary dysplasia, bronchiectasis, chemical pneumonitis, chronic bronchitis, chronic obstructive pulmonary disease (COPD), conditions with a pleural effusion, cystic fibrosis, hypersensitivity pneumonitis (e.g., due to an environmental allergen, e.g., pollen, mold, dust, dander, and the like), (eosinophilic) granulomatosis with polyangiitis, Langerhans cell histiocytosis, lymphangioleiomyomatosis, infant respiratory distress syndrome (IRDS), pneumoconiosis (e.g., asbestosis), primary ciliary dyskinesia, pulmonary alveolar proteinosis (e
  • the subject may be selected based on having one or more of a respiratory condition or disorder.
  • the subject has one or more of the following: acute bronchitis, acute chest syndrome, acute respiratory distress syndrome (ARDS) aspergillosis, bronchiectasis, bronchiolitis, bronchiolitis obliterans, chronic bronchitis, chronic coughing, coccidioidomycosis, common cold, COVID-19, cryptogenic organizing pneumonia, emphysema, hantavirus pulmonary syndrome, histoplasmosis, human metapneumovirus, influenza, interstitial lung disease (ILD), legionnaire’s disease, mycobacterium avium complex disease, middle eastern respiratory syndrome (MERS), nontuberculous mycobacteria lung disease, pertussis, pneumonia, pneumothorax, respiratory syncytial virus (RSV), severe acute respiratory syndrome (SARS), and tuberculosis.
  • ARDS acute respiratory distress syndrome
  • the subject may be selected based on being at risk of developing one or more of a respiratory condition or disorder.
  • the subject is at risk of developing one or more of the following: acute bronchitis, acute chest syndrome, acute respiratory distress syndrome (ARDS) aspergillosis, bronchiectasis, bronchiolitis, bronchiolitis obliterans, chronic bronchitis, chronic coughing, coccidioidomycosis, common cold, COVID-19, cryptogenic organizing pneumonia, emphysema, hantavirus pulmonary syndrome, histoplasmosis, human metapneumovirus, influenza, interstitial lung disease (ILD), legionnaire’s disease, mycobacterium avium complex disease, middle eastern respiratory syndrome (MERS), nontuberculous mycobacteria lung disease, pertussis, pneumonia, pneumothorax, respiratory syncytial virus (RSV), severe acute respiratory syndrome (SARS), and tuberculosis.
  • ARDS acute
  • the subject may be selected based on having one or more symptoms of one or more of a respiratory condition or disorder.
  • the subject has one or more symptoms of one or more of the following: acute bronchitis, acute chest syndrome, acute respiratory distress syndrome (ARDS) aspergillosis, bronchiectasis, bronchiolitis, bronchiolitis obliterans, chronic bronchitis, chronic coughing, coccidioidomycosis, common cold, COVID-19, cryptogenic organizing pneumonia, emphysema, hantavirus pulmonary syndrome, histoplasmosis, human metapneumovirus, influenza, interstitial lung disease (ILD), legionnaire’s disease, mycobacterium avium complex disease, middle eastern respiratory syndrome (MERS), nontuberculous mycobacteria lung disease, pertussis, pneumonia, pneumothorax, respiratory syncytial virus (RSV), severe acute respiratory syndrome (SARS), and tuberculosis.
  • the subject may be selected based on having had one or more of a pulmonary condition or disorder.
  • the subject has had one or more of the following: acute bronchitis, acute chest syndrome, acute respiratory distress syndrome (ARDS) aspergillosis, bronchiectasis, bronchiolitis, bronchiolitis obliterans, chronic bronchitis, chronic coughing, coccidioidomycosis, common cold, COVID-19, cryptogenic organizing pneumonia, emphysema, hantavirus pulmonary syndrome, histoplasmosis, human metapneumovirus, influenza, interstitial lung disease (ILD), legionnaire’s disease, mycobacterium avium complex disease, middle eastern respiratory syndrome (MERS), nontuberculous mycobacteria lung disease, pertussis, pneumonia, pneumothorax, respiratory syncytial virus (RSV), severe acute respiratory syndrome (SARS), and tuberculosis.
  • ARDS acute respiratory distress syndrome
  • the subject may be selected based on having one or more of an inflammatory condition, disease, or disorder.
  • the subject has one or more of the following: endometriosis, arthritis, psoriasis, alopecia, areata, eczema, familial Mediterranean fever, adenomyosis and uterine fibroids, Addison’s disease, autoimmune hepatitis, celiac disease, Crohn’s disease, type I diabetes, Grave’s disease, Hashimoto’s thyroiditis, pernicious anemia, multiple sclerosis, primary biliary cholangitis (biliary cirrhosis), sclerosing cholangitis, ulcerative colitis, myasthenia gravis, or Gillian Barre syndrome.
  • the subject may be selected based on being at risk of developing one or more of an inflammatory condition, disease, or disorder.
  • the subject is at risk of developing one or more of the following: endometriosis, arthritis, psoriasis, alopecia, areata, eczema, familial Mediterranean fever, adenomyosis and uterine fibroids, Addison’s disease, autoimmune hepatitis, celiac disease, Crohn’s disease, type I diabetes, Grave’s disease, Hashimoto’s thyroiditis, pernicious anemia, multiple sclerosis, primary biliary cholangitis (biliary cirrhosis), sclerosing cholangitis, ulcerative colitis, myasthenia gravis, or Gillian Barre syndrome.
  • the subject may be selected based on having one or more symptoms of one or more of an inflammatory condition, disease or disorder.
  • the subject has one or more symptoms of one or more of the following: endometriosis, arthritis, psoriasis, alopecia, areata, eczema, familial Mediterranean fever, adenomyosis and uterine fibroids, Addison’s disease, autoimmune hepatitis, celiac disease, Crohn’s disease, type I diabetes, Grave’s disease, Hashimoto’s thyroiditis, pernicious anemia, multiple sclerosis, primary biliary cholangitis (biliary cirrhosis), sclerosing cholangitis, ulcerative colitis, myasthenia gravis, or Gillian Barre syndrome.
  • the subject may be selected based on having had one or more of an inflammatory condition, disease or disorder.
  • the subject has had one or more of the following: endometriosis, arthritis, psoriasis, alopecia, areata, eczema, familial Mediterranean fever, adenomyosis and uterine fibroids, Addison’s disease, autoimmune hepatitis, celiac disease, Crohn’s disease, type I diabetes, Grave’s disease, Hashimoto’s thyroiditis, pernicious anemia, multiple sclerosis, primary biliary cholangitis (biliary cirrhosis), sclerosing cholangitis, ulcerative colitis, myasthenia gravis, or Gillian Barre syndrome.
  • compositions featuring capsules comprising a plurality of engineered cells which may be concomitantly administered with an additional therapeutic regimen. It is contemplated that encompassed within certain modes of the invention as described herein, the composition is administered, e.g., co-administered, with an additional therapy. In some embodiments, the composition is administered for the treatment of an immune disease or condition or an autoimmune disease or condition.
  • the subject is administered an additional therapy, wherein the additional therapy is useful in the treatment of an autoinflammatory disease or condition or autoimmune disease or condition associated with the lungs, respiratory system, and/or the pleura or pleural cavity.
  • the autoinflammatory disease or condition or autoimmune disease or condition associated with the lungs, respiratory system, and/or the pleura or pleural cavity is selected from one or more of: anti-glomerular basement membrane disease, acute interstitial pneumonitis, asthma, bronchopulmonary dysplasia, bronchiectasis, chemical pneumonitis, chronic bronchitis, chronic obstructive pulmonary disease (COPD), conditions with a pleural effusion, cystic fibrosis, hypersensitivity pneumonitis (e.g., due to an environmental allergen, e.g., pollen, mold, dust, dander, and the like), (eosinophilic) granulomatosis with polyangiitis, Langerhans cell histiocytos
  • the subject is administered an additional therapy, wherein the additional therapy is useful in the treatment of an autoinflammatory disease or condition or an autoimmune disease or condition.
  • the additional therapy is an antibiotic, e.g., amoxicillin, azithromycin, doxycycline, and levofloxacin.
  • the additional therapy is an antiviral, e.g., ensitrelvir, molnupiravir, oseltamivir, remdesivir, and zanamivir.
  • the additional therapy is an analgesic, e.g., aspirin, buprenorphine, celecoxib, codeine, dihydromorphine, etoricoxib, hydrocodone, ibuprofen, morphine, naproxen, oxycodone, paracetamol, pethidine, rofecoxib, tapentadol, and tramadol.
  • analgesic e.g., aspirin, buprenorphine, celecoxib, codeine, dihydromorphine, etoricoxib, hydrocodone, ibuprofen, morphine, naproxen, oxycodone, paracetamol, pethidine, rofecoxib, tapentadol, and tramadol.
  • the additional therapy is an antipyretic, e.g., aspirin, celecoxib, clonidine, diclofenac, etoricoxib, flurbiprofen, ibuprofen, ketoprofen, magnesium salicylate, naproxen, nimesulide, paracetamol rofecoxib, and sodium salicylate.
  • the additional therapy is a cough suppressant.
  • the additional therapy is a decongestant, e.g., beclomethasone dipropionate, budesonide, ciclesonide, dexamethasone, ephedrine, flunisolide, fluticasone, fluticasone furoate, fluticasone propionate, levomethamphetamine, mometasone furoate naphazoline, oxymetazoline, phenylephrine, phenylpropanolamine, prednisolone, propylhexedrine, pseudoephedrine, synephrine, tetryzoline, tixocortol, tramazoline, triamcinolone, triamcinolone acetonide, and xylometazoline.
  • a decongestant e.g., beclomethasone dipropionate, budesonide, ciclesonide, dexamethasone, ephedrine, flunisolide
  • the additional therapy is an antihistamine, e.g., brompheniramine, cetirizine, chlorpheniramine, diphendramine, fexofenadine, levocetirizine, and loratadine.
  • the additional therapy is an expectorant or a mucolytic, e.g., acetylcysteine, ambroxol, ammonium chloride, bromhexine, carbocisteine, dornase alfa, erdosteine, guaifenesin, mecysteine, potassium citrate, potassium iodide, and sodium citrate.
  • the subject is administered an additional therapy, wherein the additional therapy is useful in the treatment of a respiratory disease or condition.
  • the respiratory disease or condition is selected from one or more of: acute bronchitis, acute chest syndrome, acute respiratory distress syndrome (ARDS) aspergillosis, bronchiectasis, bronchiolitis, bronchiolitis obliterans, chronic bronchitis, chronic coughing, coccidioidomycosis, COVID- 19, cryptogenic organizing pneumonia, emphysema, hantavirus pulmonary syndrome, histoplasmosis, human metapneumovirus, influenza, interstitial lung disease (ILD), legionnaire’s disease, mycobacterium avium complex disease, middle eastern respiratory syndrome (MERS), nontuberculous mycobacteria lung disease, pertussis, pneumonia, pneumothorax, respiratory syncytial virus (RSV), severe acute respiratory syndrome (SARS), and tuberculosis.
  • ARDS acute respiratory distress
  • the subject is administered an additional therapy useful in the treatment of a pulmonary disease or condition.
  • the additional therapy is an antibiotic, e.g., amoxicillin, azithromycin, doxycycline, and levofloxacin.
  • the additional therapy is an antiviral, e g., ensitrelvir, molnupiravir, oseltamivir, remdesivir, and zanamivir.
  • the additional therapy is an analgesic, e.g., aspirin, buprenorphine, celecoxib, codeine, dihydromorphine, etoricoxib, hydrocodone, ibuprofen, morphine, naproxen, oxycodone, paracetamol, pethidine, rofecoxib, tapentadol, and tramadol.
  • analgesic e.g., aspirin, buprenorphine, celecoxib, codeine, dihydromorphine, etoricoxib, hydrocodone, ibuprofen, morphine, naproxen, oxycodone, paracetamol, pethidine, rofecoxib, tapentadol, and tramadol.
  • the additional therapy is an antipyretic, e.g., aspirin, celecoxib, clonidine, diclofenac, etoricoxib, flurbiprofen, ibuprofen, ketoprofen, magnesium salicylate, naproxen, nimesulide, paracetamol rofecoxib, and sodium salicylate.
  • the additional therapy is a cough suppressant.
  • the additional therapy is a decongestant, e.g., beclomethasone dipropionate, budesonide, ciclesonide, dexamethasone, ephedrine, flunisolide, fluticasone, fluticasone furoate, fluticasone propionate, levomethamphetamine, mometasone furoate naphazoline, oxymetazoline, phenylephrine, phenylpropanolamine, prednisolone, propylhexedrine, pseudoephedrine, synephrine, tetryzoline, tixocortol, tramazoline, triamcinolone, triamcinolone acetonide, and xylometazoline.
  • a decongestant e.g., beclomethasone dipropionate, budesonide, ciclesonide, dexamethasone, ephedrine, flunisolide
  • the additional therapy is an antihistamine, e.g., brompheniramine, cetirizine, chlorpheniramine, diphendramine, fexofenadine, levocetirizine, and loratadine.
  • the additional therapy is an expectorant or a mucolytic, e.g., acetylcysteine, ambroxol, ammonium chloride, bromhexine, carboci steine, dornase alfa, erdosteine, guaifenesin, mecysteine, potassium citrate, potassium iodide, and sodium citrate.
  • the subject is administered an additional therapy that is useful in the treatment of an inflammatory disease, disorder or condition.
  • the disease, disorder, or condition affects the uterus, adrenal glands, liver, gastrointestinal tract, pancreas, thyroid, nervous system, stomach, or muscles.
  • the disease, disorder, or condition is selected from one or more of endometriosis, arthritis, psoriasis, alopecia areata, eczema, familial Mediterranean fever, adenomyosis and uterine fibroids, Addison’s disease, autoimmune hepatitis, celiac disease, Crohn’s disease, type I diabetes, Grave’s disease, Hashimoto’s thyroiditis, pernicious anemia, multiple sclerosis, primary biliary cholangitis (biliary cirrhosis), sclerosing cholangitis, ulcerative colitis, myasthenia gravis, or Gillian Barre syndrome.
  • the additional therapy is useful in the treatment of an inflammatory condition, disease, or disorder.
  • the additional therapy is an antibiotic, e.g., amoxicillin, azithromycin, doxycycline, and levofloxacin.
  • the additional therapy is an antiviral, e g., ensitrelvir, molnupiravir, oseltamivir, remdesivir, and zanamivir.
  • the additional therapy is an analgesic, e.g., aspirin, buprenorphine, celecoxib, codeine, dihydromorphine, etoricoxib, hydrocodone, ibuprofen, morphine, naproxen, oxycodone, paracetamol, pethidine, rofecoxib, tapentadol, and tramadol.
  • analgesic e.g., aspirin, buprenorphine, celecoxib, codeine, dihydromorphine, etoricoxib, hydrocodone, ibuprofen, morphine, naproxen, oxycodone, paracetamol, pethidine, rofecoxib, tapentadol, and tramadol.
  • the additional therapy is an antipyretic, e g., aspirin, celecoxib, clonidine, diclofenac, etoricoxib, flurbiprofen, ibuprofen, ketoprofen, magnesium salicylate, naproxen, nimesulide, paracetamol rofecoxib, and sodium salicylate.
  • the additional therapy is an antihistamine, e.g., brompheniramine, cetirizine, chlorpheniramine, diphendramine, fexofenadine, levocetirizine, and loratadine.
  • the subject is administered an additional therapy, wherein the additional therapy is an anti-inflammatory agent.
  • the anti-inflammatory agent is a corticosteroid, e.g., beclomethasone dipropionate, budesonide, ciclesonide, cortisone, dexamethasone, flunisolide, fluticasone furoate, fluticasone propionate, hydrocortisone, methylprednisolone, mometasone furoate, prednisone and triamcinolone acetonide.
  • the subject is administered an additional therapy, wherein the additional therapy is an immunomodulatory or immunosuppressive agent, e.g., azathioprine, cyclophosamide, methotrexate, mycophenolate mofetil, obinutuzumab, ocrelizumab, ofatumumab, and rituximab.
  • an immunomodulatory or immunosuppressive agent e.g., azathioprine, cyclophosamide, methotrexate, mycophenolate mofetil, obinutuzumab, ocrelizumab, ofatumumab, and rituximab.
  • the present disclosure provides methods for making capsules comprising a plurality of engineered cells, for delivery of a therapeutic agent, e.g., a protein, e.g., a cytokine.
  • a therapeutic agent e.g., a protein, e.g., a cytokine.
  • the present disclosure further provides devices to fabricate said capsules.
  • the method features a device, e.g., an electrostatic spraying device.
  • the method of making features a device that is a custom-built, coaxial electrostatic spraying device.
  • the custom-built device comprises a voltage-generator that is fixedly connected to a tip of a coaxial needle and grounded to a bath comprising reagents for crosslinking or forming a hydrogel from a hydrogel -forming polymer.
  • the co-axial needles contain the polymer capable of forming a hydrogel responsive to contacting with a crosslinker, e.g., a barium or calcium salt, e.g., BaCh.
  • the method of making the capsules features the following steps: (i) fixedly connecting a voltage generator to a tip of a 30 g needle of an, electrostatic spraying device, wherein the tip of the needle is grounded to a 1 :4 BaCh: mannitol cross-linking bath ; (ii) combining a mixture comprising 1.4% w/v SLG20 sodium alginate diluted in 0.9%w/v saline with a cell suspension of engineered cells, e.g., ARPE-19 cells, capable of constitutively or inducibly expressing a therapeutic agent, e.g., a protein, e g., a cytokine, thereby forming an alginate-cell mixture; (iii) loading the alginate-cell mixture of step (ii) into the 30 g needle (iv) contacting the alginate-cell mixture with the BaChmiannitol bath, e.g., via applying pressure, e.g., manually or mechanically
  • the method of making the capsules features the following steps: (i) fixedly connecting a voltage generator to a tip of a coaxial needle of a co-axial, electrostatic spraying device, wherein the tip of the coaxial needle is grounded to a 1 :4 BaC12:mannitol crosslinking bath ; (ii) combining a mixture comprising 1.4% w/v SLG20 sodium alginate diluted in 0.9%w/v saline with a cell suspension of engineered cells, e.g., ARPE-19 cells, capable of constitutively or inducibly expressing a therapeutic agent, e.g., a protein such as, thereby forming an alginate-cell mixture; (iii) loading the alginate-cell mixture of step (ii) into the interior a plurality of the coaxial needles (e.g., 2 coaxial needles); (iv) contacting the alginate- cell mixture with the BaC12:mannitol bath, e.g., via
  • the method of making comprises the use of a BUCHI Encapsulator (e.g., models B-390TM, B-395TM and the like, commercially available form BUCHI).
  • a BUCHI Encapsulator e.g., models B-390TM, B-395TM and the like, commercially available form BUCHI.
  • the capsules are fabricated according to the manufacturer’s instructions for the formation of microcapsules.
  • the method of making capsules allows for the capsules to comprise between about 250 to about 1.86e6 cells, e.g., engineered cells, e.g., ARPE-19 cells. In an embodiment, the method of making capsules allows for a capsule diameter of between about 50 pm to about 3 mm.
  • the method of making capsules allows for the target size of capsules to be approximately equivalent to the actually measured capsule diameter when the capsule diameter is 150, 300, 600, 800, 1200, or 1700 pm and when the number of capsules is at least between one and five.
  • the viability of encapsulated engineered cells, e.g., ARPE-19 cells, in alginate capsules is greater than 80%, wherein the capsule diameter is 150, 300, 800, or 1200 pm. In an embodiment, the viability of encapsulated engineered cells, e.g., ARPE-19 cells, in alginate capsules is greater than 90%, wherein the capsule diameter is 300 pm. In an embodiment, the cell count of encapsulated engineered cells, e.g., ARPE-19 cells, in alginate capsules is between about 2*10 6 and 3*10 6 cells, wherein the capsule diameter is 150, 300, 800, or 1200 pm.
  • rat IL-IRa production is about 2*10 6 pg/mL/day for capsules having a capsule diameter of 150, 300, 800, and 1200 pm. In an embodiment, rat IL-IRa production is about 2*10 6 pg/mL/day and is not a function of capsule diameter between about 150 and about 1200 pm.
  • the production of IL- 13 attains a maximum concentration of 10 3 ng/mL between about 12 and 24 h after instillation as measured by a protein-specific ELISA.
  • the production of FGF21 attains a maximum concentration of 10 3 ng/mL between about 12 and 24 h after instillation as measured by a protein-specific ELISA.
  • the production of IL-IRa attains a maximum concentration of 10 3 ng/mL between about 12 and 24 h after instillation as measured by a protein-specific ELISA.
  • capsules comprising a plurality of engineered cells e.g., ARPE-19 cells
  • capsules comprising a plurality of engineered cells localize adjacent to or in the vicinity of alveolar tissue, e.g., rodent alveolar tissue, when the capsule dose is 100, 200 or 300 pl.
  • capsules comprising a plurality of engineered cells, e.g., ARPE-19 cells localize adjacent to or in the vicinity of alveolar tissue, e.g., rodent alveolar tissue, irrespective of the particular capsule dose when the capsule dose is between about 100 and about 300 pl.
  • the administration of capsules via intubation is sufficient for a 10,000- fold increase in the local IL-IRa concentration in the bronchoalveolar lavage (BAL) fluid obtained from the lungs relative to the systemic, i.e., blood plasma and pleural, IL-IRa concentrations.
  • the administration of capsules via intubation is sufficient for a reduction of IL- 17 concentration of about 20 pg/mL as measured in bronchoalveolar lavage fluid (BALF) in a LPS injury rodent model.
  • BALF bronchoalveolar lavage fluid
  • the administration of capsules via intubation is sufficient for the IL- 17 concentration in BALF to decrease from about 30 pg/mL to about 10 pg/mL in an LPS injury rodent model.
  • the administration of capsules via intubation is sufficient for a measurable reduction in neutrophil recruitment to the injured lung tissue in an LPS injury rodent model, characterized in that the LPS samples treated with instilled capsules comprising IL-lRa- producing cells, e.g., ARPE-19 cells, regains or partially regains the healthy histological phenotype after 24 h.
  • LPS samples treated with instilled capsules comprising IL-lRa- producing cells e.g., ARPE-19 cells
  • the distribution of capsules comprising a plurality of engineered cells fluorescently labeled with FITC dextran are homogenously distributed in rodent lung tissue after administration, e.g., instillation.
  • the production of FGF21 attains a maximum concentration of between about 10 2 and about 10 3 ng/mL between about 12 and 24 h after instillation as measured by a protein-specific ELISA.
  • the administration of capsules via intubation is sufficient for a measurable reduction in neutrophil recruitment to the injured lung tissue in an LPS injury rodent model, characterized in that the LPS samples treated with instilled capsules comprising IL-lRa- producing cells, e.g., ARPE-19 cells, regains or partially regains the healthy histological phenotype after 1 day, 7 days, or 14 days.
  • LPS samples treated with instilled capsules comprising IL-lRa- producing cells e.g., ARPE-19 cells
  • luciferase production of engineered cells e.g., ARPE-19 cells, stably transfected with a plasmid encoding for a luciferase enzyme (Luc) with aNF-KB-responsive promoter (NFkB TRE) and a polyadenylation (PA) signal treated with no cytokines for 24 h is less than 10,000 RLU.
  • luciferase production of engineered cells e.g., ARPE- 19 cells, stably transfected with a plasmid encoding for a luciferase enzyme (Luc) with a NF-KB- responsive promoter (NFkB TRE) and a polyadenylation (PA) signal treated with IFNy for 24 h is less than 10,000 RLU.
  • engineered cells e.g., ARPE- 19 cells
  • luciferase production of engineered cells e.g., ARPE-19 cells, stably transfected with a plasmid encoding for a luciferase enzyme (Luc) with a NF-KB-responsive promoter (NFkB TRE) and a poly adenylation (PA) signal treated with IL- 1 for 24 h is less between about 20,000 to about 30000 RLU.
  • luciferase production of engineered cells e.g., ARPE-19 cells, stably transfected with a plasmid encoding for a luciferase enzyme (Luc) with a NF-KB-responsive promoter (NFkB TRE) and a polyadenylation (PA) signal treated with TNF-a for 24 h is less between about 20,000 to about 30000 RLU.
  • cells e.g., ARPE-19 cells loaded with FITC dextran and encapsulated in alginate capsules, are homogenously distributed as evaluated by a fluorescence imaging technique.
  • capsules comprising GFP-expressing cells are uniformly distributed in rat alveolae after instillation as evaluated by In Vivo Imaging System (IVIS).
  • IVIS In Vivo Imaging System
  • the average radiance of firefly luciferase producing capsules reaches a maximum of about 10 4 p/s/cm 2 about one day after encapsulation relative to a maximum radiance of about 10 3 p/s/cm 2 for capsules comprising free cells.
  • radiance measured in rats instilled with the firefly luciferase expressing capsules was greater than the radiance measured in rats instilled with the free cell containing capsules through seven days postinstillation.
  • capsules are retained in the lungs, e.g., the lungs of rats, for 12, 24, 36, 48, 72 h or more as measured by in vivo total flux analysis. In an embodiment, capsules are retained in the lungs, e.g., the lungs of rats, for 12 h or more as measured by in vivo total flux analysis. In an embodiment, capsules are retained in the lungs, e.g., the lungs of rats, for 24 h or more as measured by in vivo total flux analysis. In an embodiment, capsules are retained in the lungs, e.g., the lungs of rats, for 36 h or more as measured by in vivo total flux analysis.
  • capsules are retained in the lungs, e.g., the lungs of rats for 48 h or more as measured by in vivo total flux analysis. In an embodiment, capsules are retained in the lungs, e.g., the lungs of rats for 72 h, or more as measured by in vivo total flux analysis.
  • capsules are uniformly distributed in the lungs, e.g., the lungs of rats, subsequent to instillation as characterized by ex vivo fluorescent imaging.
  • IL-10 production is localized to BAL and is between about 10 to about 100 ng/mL compared to about 0.1 to 1 ng/mL in plasma.
  • IL-IRa production is localized to BAL and is between about 10 to about 100 ng/mL compared to about 0.01 to 0.1 ng/mL in plasma.
  • FGF21 production is localized to BAL and is between about 10 to about 100 ng/mL compared to about 1 to 10 ng/mL in plasma.
  • IL-13 production is localized to BAL and is about 100 ng/mL compared to about 0.01 to 0.1 ng/mL in plasma.
  • IL-4 production is localized to BAL and is between about 1 to about 10 ng/mL compared to about 0.01 to 0.1 ng/mL in plasma.
  • the IL- 10 concentration increases from about 0.1 ng/mL in BAL to about 100 ng/mL as the capsule dose increases from 0 to 150 pl, whereas the IL-10 concentration in plasma remains relatively constant at about 0.1 ng/mL regardless of capsule dose volume administered.
  • IL-10 in BAL increases from about 0.01 ng/mL to between about 10 to about 100 ng/mL as the cell concentration per mL of alginate increases from 0 to about l*10 7 cells/mL
  • IL-10 in plasma remains relatively constant between about 0.01 to 0.1 ng/mL as the cell concentration per mL of alginate increases from 0 to about l*10 7 cells/mL.
  • repeat administration of rat IL-10 producing capsules on Day 30 yields an equivalent local concentration of rat IL- 10 in bronchoalveolar lavage (BAL) of about 1- 100 ng/mL and an equivalent plasma concentration of about 10' 4 to about 10’ 2 ng/mL compared to a single administration.
  • BAL bronchoalveolar lavage
  • the rat IL-10 concentration in BAL is about 10 ng/mL upon repeat administration of 100 pl ofRPE IL-10 capsules.
  • the rat IL-10 concentration in plasma is about 10’ 3 ng/mL upon repeat administration of 100 pl ofRPE IL- 10 capsules.
  • the in vitro concentration of a therapeutic is about 1, about 10, 10 2 , 103, 104 ng/mL or greater 24 h after administration of a capsule capable of producing a therapeutic agent.
  • the therapeutic agent is IL-IRa, FGF21, IL-13, or IL-4.
  • the diameter of the capsule is about 150, 300, 800, 1200, or 1700 pm.
  • 10, 50, 100, 200, 300, 500 pl or more of the capsules are administered.
  • the IL-IRa concentration is about 10 3 ng/mL 24 h after administration of a IL-IRa producing capsule.
  • the FGF21 concentration is between about 10 3 to about 10 4 ng/mL 24 h after administration of a FGF21 producing capsule.
  • the IL-13 concentration is between about 10 3 to about 10 4 ng/mL 24 h after administration of a IL-13 producing capsule.
  • the IL-4 concentration is about 10 2 ng/mL 24 h after administration of a IL-4 producing capsule.
  • IL-10 concentration is uniformly distributed across various lobes of the lung, e.g., the post caval, middle, superior, inferior, and left lobes, 24 hours after instillation of IL- 10 capsules in rats.
  • the IL-10 concentration is about 5, 10, 15, 20, 25 or 30 pg/mg across various lobes of the lung, e.g., the post-caval, middle, superior, inferior, and left lobes, 24 hours after instillation of IL-10 capsules in rats.
  • the IL-10 concentration is about 12 pg/mg in the post caval lobe 24 hours after instillation of IL-10 capsules in rats.
  • the IL-10 concentration is about 8 pg/mg in the middle lobe 24 hours after instillation of IL-10 capsules in rats. In an embodiment, the IL-10 concentration is about 12 pg/mg in the middle lobe 24 hours after instillation of IL-10 capsules in rats. In an embodiment, the IL-10 concentration is about 17 pg/mg in the middle lobe 24 hours after instillation of IL-10 capsules in rats. In an embodiment, the IL-10 concentration is about 14 pg/mg in the middle lobe 24 hours after instillation of IL-10 capsules in rats.
  • IL- 10 concentrations in bronchoalveolar lavage fluid (BALF) and plasma return to baseline levels 50, 60, 70, 80, 90, 100, 200, 300 days or longer following a single intratracheal instillation of IL-10 producing capsules.
  • IL-10 concentrations in bronchoalveolar lavage fluid (BALF) and plasma return to baseline levels 100 days following a single intratracheal instillation of 100 pl of 300 pm diameter IL-10 producing capsules.
  • rat IL-10 in rats administered 300 pm-diameter IL-10-producing capsules, rat IL-10 is elevated in BAL relative to plasma over a 14-day period, attaining a maximum value of between about 10 to about 100 ng/mL in BAL one day post-instillation.
  • rat IL-10 in rats administered 300 pm-diameter IL- 10-producing capsules, rat IL-10 is elevated in BAL relative to plasma over a 14-day period and there is a concomitant progressive diminution in markers of inflammation as indicated by histological sectioning of rat lung tissue.
  • hIL-IRa levels in BAL are about 30 ng/mL two days post-installation while remaining undetectable in plasma.
  • hIL-10 levels in BAL are about 13 ng/mL two days post-installation while remaining undetectable in plasma.
  • triglycerides decrease from about 27 mg/dl to about 25 mg/dl from prior to instillation to two days after instillation of capsules.
  • total cholesterol increases from about 80 mg/dl to about 70 mg/dl from prior to instillation to two days after instillation of capsules.
  • glucose slightly increases from about 80 mg/dl to about 90 mg/dl from prior to instillation to two days after instillation of capsules.
  • albumin levels do not materially change from about 3.4 g/dl from prior to instillation to two days after instillation of capsules, indicating no deterioration in liver function.
  • triglycerides decrease from about 27 mg/dl to about 25 mg/dl from prior to instillation to two days after instillation of capsules.
  • total cholesterol increases from about 80 mg/dl to about 70 mg/dl from prior to instillation to two days after instillation of capsules.
  • glucose slightly increases from about 80 mg/dl to about 90 mg/dl from prior to instillation to two days after instillation of capsules.
  • albumin levels do not materially change from about 3.4 g/dl from prior to instillation to two days after instillation of capsules, indicating no deterioration in liver function.
  • local concentrations of cytokines are elevated in bronchoalveolar lavage (BAL) fluid relative to plasma for about 7, 14, 21, 28, days or longer following instillation of cytokine-producing capsules in healthy pigs via bronchoscope.
  • human IL-IRa concentration in BAL fluid is between about 30 to about 40 ng/mL on Day 2 following instillation of cytokine-producing capsules in healthy pigs via bronchoscope before returning to baseline on Day 28.
  • human IL- 10 concentration in BAL fluid is between about 15 to about 20 ng/mL on Day 2 following instillation of cytokine-producing capsules in healthy pigs via bronchoscope before returning to baseline on Day 28.
  • markers of general health in pigs e g., plasma triglycerides, total cholesterol, and glucose
  • plasma triglycerides is between about 10 to about 30 mg/dl prior to instillation, 2 days after, and 28 days after instillation.
  • total cholesterol is between about 70 to about 110 mg/dl prior to instillation, 2 days after, and 28 days after instillation.
  • glucose is between about 60 to about 120 mg/dl prior to instillation, 2 days after, and 28 days after instillation.
  • markers of liver function in pigs e.g., albumin
  • markers of liver function in pigs do not significantly change over the course of 28 days following instillation of cytokine-producing capsules in healthy pigs via bronchoscope.
  • albumin is between about 3 to about 5 g/dl prior to instillation, 2 days after, and 28 days after instillation.
  • spCh and EtCCh do not significantly change over the course of 28 days following instillation of cytokine-producing capsules in healthy pigs via bronchoscope.
  • spCh is between about 100 mmHg prior to instillation, 2 days after, and 28 days after instillation.
  • EtCh is between about 40 to about 60 mmHg prior to instillation, 2 days after, and 28 days after instillation.
  • the local concentration of a therapeutic agent in the pleural fluid is elevated for 7, 14, 21, 28 days or longer following administration of lipopolysaccharide (LPS) intratracheally and concomitant implantation into the pleural cavity of rats of capsules capable of producing a therapeutic agent.
  • the therapeutic agent is IL-IRa and/or IL-10.
  • rat IL-IRa concentration in pleural fluid is about 104 pg/mL over a period of 28 days following administration of lipopolysaccharide (LPS) intratracheally and concomitant implantation into the pleural cavity of IL-IRa and IL- 10 producing capsules.
  • IL-IRa and IL-10 producing capsules produce IL-IRa at a rate of about 15 pg/day. . In an embodiment, IL-IRa and IL-10 producing capsules produce IL-10 at a rate of about 3 pg/day.
  • explanted capsules demonstrate no substantial fibrotic overgrowth for a period of 7, 14, 21, 28 days or longer following administration of lipopolysaccharide (LPS) intratracheally and concomitant implantation into the pleural cavity of rats of capsules capable of producing a therapeutic agent.
  • the therapeutic agent is IL-IRa and/or IL-10.
  • explanted capsules demonstrate no substantial fibrotic overgrowth for a period of 28 days following administration of lipopolysaccharide (LPS) intratracheally and concomitant implantation into the pleural cavity of rats of IL-IRa and IL- 10 producing capsules.
  • IL-IRa and IL-10 producing capsules produce IL-IRa at a rate of about 15 pg/day. . In an embodiment, IL-IRa and IL-10 producing capsules produce IL-10 at a rate of about 3 pg/day.
  • the lung histology score in rats administered LPS and capsules capable of producing a therapeutic agent is less than rats administered LPS only after 7, 14, 21, 28 days or longer following administration.
  • the therapeutic agent is IL-IRa and/or IL-10.
  • the lung histology score in rats of IL-IRa is about 0, 0.2, 0.4, 0.6, 0.8, or 1 on Day 1, 7, 14, 21, or 28 following administration of lipopolysaccharide (LPS) intratracheally and concomitant implantation into the pleural cavity of rats of IL-IRa and IL- 10 producing capsules.
  • LPS lipopolysaccharide
  • IL-IRa and IL-10 producing capsules produce IL-IRa at a rate of about 15 pg/day. .
  • IL-IRa and IL-10 producing capsules produce IL- 10 at a rate of about 3 pg/day.
  • capsules remain localized to the lungs for about 1, 3, 5, 7, 9, 11 days or longer as measured by fluorescent IVIS imaging.
  • 50 pl of 300 pm diameter RPE -Flue capsules instilled into the lungs of mice remain localized to the lungs for about 7 days.
  • the fluorescent signal of fluorescent capsules instilled into the lungs is measurable for about 1, 3, 5, 7, 9, 11 days or longer.
  • the luminescent signal of 50 pl of 300 pm diameter RPE -Flue capsules instilled into the lungs of mice is measurable for about 11 days.
  • fluorescent capsules are uniformly distributed in the lungs of rats following instillation, euthanasia, and harvesting.
  • lOOpl of 300 pm green fluorescent protein (GFP) producing capsules instilled into the lungs of mice are uniformly distributed as characterized by fluorescence microscopy and fluorescent IVIS imaging.
  • histological sections of lungs of subjects administered LPS + IL-10 producing capsules intratracheally are characterized by reduced inflammation compared to subject administered LPS only.
  • histological sections of lungs of rats administered 5 mg/kg LPS and 300 pm IL-10 producing capsules are characterized by reduced inflammation compared to rats administered 5 mg/kg LPS only 24 h after administration.
  • the BAL total cells collected from subjects administered LPS + IL- 10 producing capsules is reduced compared to Blank or LPS only.
  • the BAL total cells collected from rats administered 5 mg/kg LPS and 300 pm IL-10 producing capsules is about 5 X 10 8 cells compared to about 1.5 X 107 cells for both the LPS only and Blank groups 24 h after administration.
  • local concentrations of inflammatory proteins are reduced in BAL of subjects administered LPS + IL-10 capsules compared to Blank or LPS only.
  • the IL la concentration in BAL is about 0.1 ng/mL compared to about 0.7 ng/mL for LPS only and 0.4 ng/mL for Blank 24 h after administration of 300 pm IL-10 capsules.
  • the ILlb concentration in BAL is about 3 ng/mL compared to about 6 ng/mL for LPS only and 6 ng/mL for Blank 24 h after administration of 300 pm IL-10 capsules.
  • the TNFa concentration in BAL is about 0.1 ng/mL compared to about 0.3 ng/mL for LPS only and 0.25 ng/mL for Blank 24 h after administration of 300 pm IL-10 capsules.
  • the MCP1 concentration in BAL is about 10 ng/mL compared to about 60 ng/mL for LPS only and 80 ng/mL for Blank 24 h after administration of 300 pm IL-10 capsules.
  • the BAL total cells collected from subjects administered LPS and IL- 10 +IL-lRa producing capsules is less than about 3 X 10 7 , 2 X 10 7 , 1 X 10 7 cells or less 12 or 24 h after administration.
  • the BAL total cells collected from the lungs of rats administered 5 mg/kg LPS and 300 gm IL-10 and ILIRa producing capsules is about 3 X 10 8 cells after about 12 h.
  • the BAL total cells collected from the lungs of rats administered 5 mg/kg LPS and 300 pm IL-10 and ILIRa producing capsules is about 6 X 10 8 cells after about 12 h.
  • local concentrations of inflammatory proteins are reduced in BAL of subjects administered LPS and IL-10 + IL-IRa capsules compared to LPS only.
  • the IL-la concentration in BAL is about 0.05 ng/mL 12 h after administration of 5 mg/kg LPS and 300 pm IL-10 and ILIRa producing capsules.
  • the IL-la concentration in BAL is about 0.1 ng/mL 24 h after administration of 5 mg/kg LPS and 300 pm IL-10 and ILIRa producing capsules.
  • the TNFa concentration in BAL is about 0.1 ng/mL 12 h after administration of 5 mg/kg LPS and 300 pm IL-10 and ILIRa producing capsules. In an embodiment, the TNFa concentration in BAL is about 0.1 ng/mL 24 h after administration of 5 mg/kg LPS and 300 pm IL-10 and ILIRa producing capsules. In an embodiment, the MCP1 concentration in BAL is about 2 ng/mL 12 h after administration of 5 mg/kg LPS and 300 pm IL-10 and ILIRa producing capsules. In an embodiment, the MCP1 concentration in BAL is about 25 ng/mL 24 h after administration of 5 mg/kg LPS and 300 pm IL-10 and ILIRa producing capsules.
  • the IL-lb concentration in BAL is about 2 ng/mL 12 h after administration of 5 mg/kg LPS and 300 pm IL-10 and ILIRa producing capsules. In an embodiment, the IL-lb concentration in BAL is about 3 ng/mL 24 h after administration of 5 mg/kg LPS and 300 pm IL-10 and ILIRa producing capsules.
  • the BAL total cells collected from subjects administered LPS and IL- 10 producing capsules is reduced compared to LPS+Blank or LPS only.
  • the BAL total cells is collected from rats administered LPS and IL- 10 producing capsules us about 5 X 10 8 cells 24 h after instillation, compared to between about 1 X 10 7 to about 2 X 10 7 cells for LPS only and LPS only+ Blank capsules.
  • local concentrations of inflammatory proteins e.g., IL-la, TNFa, IL-lb, and MCP1, inter alia, are reduced in BAL of subjects administered LPS+Blank or LPS only.
  • the IL-la concentration BAL collected from rats is about 0.1 ng/mL compared to 0.7 ng/mL for LPS only and 0.4 ng/mL for LPS+Blank 24 h after administration of IL-10 producing capsules !
  • the TNFa concentration BAL collected from rats is about 0.1 ng/mL compared to 0.3 ng/mL for LPS only and 0.25 ng/mL for LPS+Blank 24 h after administration of IL- 10 producing capsules.
  • the IL- lb concentration in BAL collected from rats is about 3 ng/mL compared to 6 ng/mL for LPS only and 6 ng/mL for LPS+Blank 24 h after administration of IL- 10 producing capsules.
  • the MCP1 concentration in BAL collected from rats is about 10 ng/mL compared to 60 ng/mL for LPS only and 80 ng/mL for LPS+Blank 24 h after administration of IL- 10 producing capsules.
  • the histological score of inflammation as a factor of neutrophil density, distribution, and presence of immune consolidations for rats administered LPS and IL- 10 producing capsules is less than about 1.5, 1.4, 1.3, 1.2, 1.1, 1.0 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1 or 0 on Day 1, 7, 14, or 21 post administration.
  • the inflammation score as a factor of neutrophil density, distribution, and presence of immune consolidations for rats administered LPS and IL-10 producing capsules is about 0 on Day 7, 14, or 21 post administration.
  • the inflammation score as a factor of neutrophil density, distribution, and presence of immune consolidations for rats administered LPS and IL-10 producing capsules is about 0 on Day 7 post administration. In an embodiment, the inflammation score as a factor of neutrophil density, distribution, and presence of immune consolidations for rats administered LPS and IL-10 producing capsules is about 0 on Day 14 post administration. In an embodiment, the inflammation score as a factor of neutrophil density, distribution, and presence of immune consolidations for rats administered LPS and IL- 10 producing capsules is about 0 on Day 21 post administration.
  • the histological score of regulatory response as a factor of macrophage, fibroblast, and chronic inflammatory cells for rats administered LPS and IL-10 producing capsules is greater than 0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2.0 on Day 1, 7, 1, or 21 post administration.
  • the histological score of regulatory response as a factor of macrophage, fibroblast, and chronic inflammatory cells for rats administered LPS and IL-10 producing capsules is between about 1.5 to about 2.0 on Day post administration.
  • perivascular lymphoid cuffing of rats administered LPS and IL-10 producing capsules on Day 1, Day 7, Day 14, and Day 21 post administration is reduced compared to rats administered LPS only
  • perivascular lymphoid cuffing of rats administered LPS and IL-10 producing capsules on Day 7, Day 14, and Day 21 post administration is between about 2 to about 5 compared to about 18 to about 25 for the LPS only group.
  • a histological scan of the lungs of rats administered LPS and IL- 10 producing capsules on Day 1, Day 7, Day 14, and Day 21 post administration manifests an improved immune phenotype compared to the LPS+Blank and LPS only groups.
  • BAL levels of TNF-a on Day 2 post administration of 20 mg/kg LPS are between about 100 and 1000 pg/mL compared to about 1 to about 10 pg/mL for the saline group.
  • BAL levels of IL-la on Day 2 post-administration of 20 mg/kg LPS are about 1000 pg/mL compared to about 10 pg/mL for the saline group.
  • BAL levels of MCP1 on Day 2 post-administration of 20 mg/kg LPS are about 10 5 pg/mL compared to about 10 pg/mL for the saline group.
  • BAL levels of MIP2 on Day 2 post-administration of 20 mg/kg LPS is between about 10 3 and about 10 4 pg/mL compared to between about 10 to about 100 pg/mL for the saline group.
  • BAL levels of total cell count derived lung homogenate are about 4* 10 7 cells compared to about 1 * 10 7 to about 2* 10 7 cells for the saline group.
  • the custom-built device consists of a voltage generator that is connected to the tip of a co-axial needle and grounded to a 1:4 BaC12:mannitol cross-linking bath.
  • the co-axial needle is fed by two separate syringes containing 1.4% alginate solutions diluted in 0.9% saline.
  • Engineered cells e.g., ARPE-19 cells, programmed to constitutively express cytokines are combined with the 1.4% alginate solutions to form cross-linked hydrogel capsules containing the engineered cells.
  • the cytokine dosage may be modulated according to necessary constraints on a per patient basis by altering the number of cells in an individual capsule, or alternatively altering the number of capsules per dose, or a combination thereof.
  • the fabrication technique at least allows for individual capsules to contain between 250 to 1.86e6 cells and for capsule diameters between 50 pm - 3 mm.
  • Example 2. Direct Instillation of Capsules to the Lungs
  • the capsules comprising a polymer and an plurality of engineered cells may be delivered via instillation with a device (FIG. 2), e.g., a catheter, or a bronchoscope, e.g., a therapeutic bronchoscope or a diagnostic bronchoscope.
  • the device may extend down to the trachea, e.g., for intratracheal instillation, or deeper into lungs, e.g., the bronchi.
  • the capsules are prepared as a liquid composition which is imparted gradually. At the distal end of the device, the liquid composition is aerosolized, allowing for the subject to inhale the capsules to enable local distribution deep into the lungs and allowing for superior localization of the therapeutic agent in alveolar tissue relative to other delivery modes.
  • the example set forth below describes methods to reproducibly generate capsules comprising a cell or a plurality of engineered cells of various diameters, e.g., capsules having diameters of 150, 300, 600, 800, 1200, and 1700 pm.
  • the capsules are synthesized as in Example 1 employing a custom-built, two-fluid co-axial electrostatic spraying device.
  • the custom-built device consists of a voltage generator that is connected to the tip of a co-axial needle and grounded to a 1 :4 BaCkmannitol cross-linking bath.
  • the co-axial needle is fed by two separate syringes containing 1.4% SLG20 sodium alginate solutions diluted in 0.9% saline.
  • Engineered cells e.g., ARPE-19 cells, programmed to constitutively express cytokines are combined with the 1.4% alginate solutions to form cross-linked hydrogel capsules containing the engineered cells.
  • Multiple syntheses demonstrate that the target size of the capsules closely aligns with the actual measured diameter as shown in the bar graph in FIG. 4A.
  • the synthesized capsules may then be administered directly, e.g., intratracheally instilled directly to the lungs with a device, e.g., a bronchoscopic device or a catheter.
  • LIVE/DEADTM cell viability assay (commercially available from ThermoFisher Scientific) was used to assess viability of the engineered ARPE-19 cells and was determined to be greater than 80% for all of the capsule diameters tested, as shown in FIG. 5A. Cells were counted on an automatic cell counter. The cell count between capsule samples having a diameter of 150, 300, 800 and 1200 pm was between approximately 2*10 6 and 3*10 6 cells, and the difference was determined not to be statistically significant among capsule diameters as shown in FIG. 5C.
  • Rat IL-IRa production between capsules having a diameter of 150, 300, 800 and 1200 pm was approximately 2*10 6 pg/mL/day, and statistically determined to be insignificant among the various capsule diameters as illustrated in the bar graph in FIG. 5D.
  • barium alginate hydrogel capsules comprising ARPE-19 cells were synthesized according to the scheme as described in Examples 1 and 8.
  • the capsules were suspended in 300 pl liquid buffer and introduced directly into rat lungs via intratracheal instillation with a bronchoscopic device, e.g., a bronchoscope, e.g., a therapeutic bronchoscope or a diagnostic bronchoscope.
  • the bronchoscope was introduced via the mouth or nasal passages of the rodent and directed to a region adjacent to the lungs, e.g., the trachea, for local delivery of the capsules to the lungs.
  • Bronchoalveolar lavage (BAL) was then performed to recover instilled capsules. Rodents were sacrificed and lung tissue was prepared for histological sectioning and staining with hematoxylin and eosin employing methods commonly understood in the art to interrogate capsule localization in the lungs.
  • FIG. 7B demonstrate that, independent of the dose of capsules (e.g., 100, 200 or 300pl), capsules were localized adjacent to rodent alveolar tissue.
  • capsules comprising engineered ARPE-19 cells results in local delivery of therapeutic cytokines.
  • barium alginate hydrogel capsules comprising ARPE-19 cells capable of expressing IL-IRa were synthesized according to the fabrication methods described in Examples 1 and 8.
  • the capsules were then formulated as a liquid pharmaceutical composition for administration to a rodent lung injury model via intubation.
  • Lipopolysaccharide (LPS) lung injury in rodents was used to induce respiratory inflammation and distress.
  • the rodents were anesthetized via intraperitoneal injection. Rodents received LPS in buffered saline, and the remaining rodents received a vehicle control.
  • LPS-treated rodents were further divided into groups with LPS only and LPS with capsule treatment. Capsules were instilled intratracheally and localized to alveolar tissue in the lungs as confirmed by histological sectioning. Bronchoalveolar lavage (BAL) was subsequently performed and the bronchoalveolar lavage fluid (BALF) was collected for analysis. Samples were also collected from the pleural cavity and blood plasma for the detection of cytokines. As shown in FIG.
  • Example 7 Histological Sections Show a Reduction in Neutrophil Infiltration at 24-h PostTreatment
  • the example set forth below indicates a reduction in neutrophil infiltration 24 h after administration of capsules comprising ARPE-19 cells capable of expressing IL-IRa in a rodent model of lung injury.
  • barium alginate hydrogel capsules comprising ARPE-19 cells capable of expressing IL-IRa were synthesized according to the fabrication methods described in Example 1.
  • the capsules were then formulated as a liquid pharmaceutical composition for administration to a rodent lung injury model via intubation.
  • Lipopolysaccharide (LPS) lung injury in rodents was used to induce respiratory inflammation and distress.
  • the rodents were anesthetized via intraperitoneal injection. Rodents received LPS in buffered saline, and the remaining rodents received a vehicle control.
  • LPS-treated rodents were further divided into groups with LPS only and LPS with capsule treatment.
  • the capsules were instilled intratracheally for direct localization of the capsules to alveolar tissue.
  • 24 hours after instillation rodents were sacrificed and lung tissue was prepared for histological sectioning and staining with hematoxylin and eosin employing methods commonly understood in the art.
  • FIGS. 9A-C demonstrate a significant reduction in neutrophil recruitment to the injured lung tissue in LPS samples treated with instilled capsules after 24 h relative to the histology of the LPS-only lung tissue. Capsule instillation significantly abrogates the immunological and inflammatory response to LPS injury relative to health lung tissue.
  • the example set forth below illustrates the distribution of fluorescent capsules in instilled rat lungs.
  • fluorescent capsules were fabricated wherein the capsules were loaded with the fluorescent dye FITC dextran.
  • the rats were euthanized, and the lungs were surgically removed for fluorescence microscopy imaging.
  • imaging with a Leica microscope in the GFP channel shows the prevalence of the capsules in rat lung tissue, as indicated by the bright spots.
  • a vector comprising therapeutic sequences for IL-10, IL-IRa, IL-13, IL-4, FGF-21 with a PiggyBac inverted terminal repeat sequences (ITRs) is transfected into an exemplary cell line, as shown in FIG. 9.
  • Transposases identify ITRs on the PiggyBac vector, enabling the transposition of therapeutic genes into genomic DNA, thereby creating a genetically engineered therapeutic cell line capable of expressing IL-10, IL-IRa, IL-13, IL-4, FGF-21.
  • FIG. 12 illustrates FGF-21 protein expression in the hours following transposition employing the PiggyBac method
  • Example 10 Rat IL-10 Production in an LPS-Induced Lung Injury Model
  • the example set forth below characterizes rat IL-10 production in a rodent model of lung injury. Briefly, barium alginate hydrogel capsules comprising ARPE-19 cells capable of expressing IL-10 were synthesized according to the fabrication methods described in Example 1. The capsules were then formulated as a liquid pharmaceutical composition for administration to a rodent lung injury model via intubation. Lipopolysaccharide (LPS) lung injury in rodents was used to induce respiratory inflammation and distress. Briefly, the rodents were anesthetized via intraperitoneal injection. Rodents received LPS in buffered saline, and the remaining rodents received a vehicle control.
  • LPS Lipopolysaccharide
  • FIG. 16A shows rat IL- 10 concentration (ng/mL) in plasma and bronchoalveolar lavage fluid at various doses (0, 50, 100, and 150 pl) of the capsules 24 h after instillation.
  • FIG. 12 shows rat IL- 10 concentration (ng/mL) in plasma and bronchoalveolar lavage fluid at various doses (0, 50, 100, and 150 pl) of the capsules 24 h after instillation.
  • Example 11 Histological Sections Show a Reduction in Neutrophil Recruitment 1 Day, 7 Days, and 14 Days After Administration
  • the example set forth below indicates a reduction in neutrophil infdtration 1 day, 7 days, and 14 days after administration of capsules comprising ARPE-19 cells capable of expressing IL- IRa in a rodent model of lung injury.
  • barium alginate hydrogel capsules comprising ARPE-19 cells capable of expressing IL-IRa were synthesized according to the fabrication methods described in Examplel.
  • the capsules were then formulated as a liquid pharmaceutical composition for administration to a rodent lung injury model via intubation.
  • Lipopolysaccharide (LPS) lung injury in rodents was used to induce respiratory inflammation and distress.
  • the rodents were anesthetized via intraperitoneal injection.
  • FIGS. 17A-C demonstrate a significant reduction in neutrophil recruitment to the injured lung tissue in LPS samples treated with instilled capsules after 1, 7 and 14 days relative to the histology of the LPS-only lung tissue. Capsule instillation significantly abrogates the immunological and inflammatory response to LPS injury relative to health lung tissue.
  • FIG. 20 is a representative image of lungs with each representative capsule diameter, demonstrating the distribution by capsule diameter in rat lungs.
  • Example 1 demonstrates the viability of engineered ARPE-19 cells in capsules of various diameters. Briefly, capsules were fabricated according to the methods outlined in Example 1 encapsulating ARPE-19 cells. A LIVE-DEAD cell assay (commercially available from Thermo Fisher Scientific) was employed to the assess the cell viability after encapsulation following the manufacturer’s instructions.
  • FIG. 21 shows cell viability of capsules comprising a plurality of engineered cells employing a LIVE/DEAD assay, where the live channel has signal and dead channel has no signal.
  • ARPE-19 cells expressing a transgene to pro-inflammatory cytokines.
  • cultured ARPE-19 cells were stably transfected with a plasmid encoding for a luciferase enzyme (Luc) with a NF-KB- responsive promoter (NFkB TRE) and a polyadenylation (PA) signal, as shown in FIG. 22A, using LipofectamineTM 3000 Transfection Reagent (ThermoFisher Scientific) following manufacturer’s instructions.
  • Luc luciferase enzyme
  • NFkB TRE NF-KB- responsive promoter
  • PA polyadenylation
  • Luciferase production was characterized by measuring the relative luminescence of engineered ARPE-19 cells in media containing no cytokines (Control), 10 ng/mL IFN-y, 15 ng/mL IL-ip, and 15 ng/mL TNF-a, as shown in FIG. 22B. As demonstrated in the bar graph, luciferase production was upregulated in response to IFN-y, IL-ip, and TNF-a.
  • the example set forth below delineates strategies to autoregulate the genetic system underlying inducible expression of a therapeutic agent, e.g., a protein, e.g., a cytokine in a capsule comprising a plurality of engineered cells. It may be advantageous within certain modes that the level of cytokine production be auto regulated in order to prevent secretion of toxic levels of the cytokine.
  • the first route to accomplish this feedback mechanism is to introduce an operator site into the DNA region between the cytokine gene, e.g., IL-2, IL- 10, etc. and its promoter in a first ORF.
  • a second ORF will be used that encodes a transcriptional repressor that binds to the operator site under the control of a promoter that is activated as a result of signaling through the cytokine's receptor.
  • a promoter that is activated as a result of signaling through the cytokine's receptor.
  • the promoter controlling the expression of the transcriptional repressor could be a STAT transcription factor. In this way, the cells can sense the cytokine in their environment and reduce their production of the cytokine when there is sufficient cytokine already present.
  • a second route entails introduction of a sequence that forms a higher-order structure into the 5' untranslated region (5 1 UTR) of the cytokine gene. Then a second ORF is utilized that encodes an RNA-binding protein, which binds to the higher-order structure, and suppresses translation, under the control of a promoter that is activated as a result of signaling through the cytokine's receptor.
  • a promoter that is activated as a result of signaling through the cytokine's receptor.
  • the promoter controlling the expression of the RNA-binding protein could be a STAT transcription factor.
  • a further strategy to accomplish gene autoregulation and a feedback mechanism for secretion of the therapeutic agent is to introduce several repeats of a synthetic microRNA (miRNA) target site into the 3' untranslated region (3' UTR) of the cytokine gene. Then a second ORF is used that encodes the miRNA under the control of a promoter that is activated as a result of signaling through the cytokine's receptor. For example, if the cytokine is IL-2, then the promoter controlling the expression of the miRNA could be a STAT transcription factor.
  • miRNA synthetic microRNA
  • an alternative strategy is to employ a second ORF encoding a synthetic ubiquitin ligase that targets the cytokine, and leads to ubiquitin-mediated proteolysis, under the control of a promoter that is activated as a result of signaling through the cytokine's receptor.
  • a promoter that is activated as a result of signaling through the cytokine's receptor.
  • the promoter controlling the expression of the ubiquitin ligase could be a STAT transcription factor.
  • the cytokine gene may be modified to include additional protein domains if doing so is necessary in order to make the cytokine recognizable by the synthetic ubiquitin ligase. Ideally, the addition of any additional protein domains will not alter the cytokine's immunological functions.
  • Example 16 Capsule Distribution in Lungs Results in a Gradient in Cytokine Concentration between Local and Systemic Compartments
  • FIG. 13A shows a representative micrograph of the 300 pm-diameter cell-laden capsules loaded with FITC dextran. Note that the capsules are uniformly green, indicating that ARPE-19 capsules are homogenously distributed.
  • FIG. 13A shows a representative micrograph of the 300 pm-diameter cell-laden capsules loaded with FITC dextran. Note that the capsules are uniformly green, indicating that ARPE-19 capsules are homogenously distributed.
  • FIG. 13B is a representative IVIS (In Vivo Imaging System) image of rat lungs after instillation of 300 pm capsules comprising GFP-expressing cells which show their uniformity in rat alveolae.
  • FIGS. 13C-D are representative ex vivo fluorescent images of lungs of instillation with dextran capsules which demonstrate their homogeneous distribution in rat alveolar tissue.
  • FIG. 13E is a micrograph of 300 pm-diameter capsules comprising cells capable of expressing the firefly luciferase protein, indicating that the cell-laden capsules are all apportioned a similar amount of cells, e g., about 10,000 cells.
  • FIG. 25 shows additional fluorescence microscopy and fluorescent IVIS imaging of rat lungs instilled with 100 pl of 300pm green fluorescent protein (GFP) capsules.
  • FIG. 14A is a graph depicting the average radiance of rats instilled with either 300 pm capsules comprising a plurality of firefly-luciferase cells or free cells over a 1 week period. As shown in the graph, the average radiance of the firefly luciferase producing capsules reaches a maximum of about 10 4 p/s/cm 2 about one day after encapsulation relative to a maximum radiance of about 10 3 p/s/cm 2 for capsules comprising free cells.
  • FIG. 14B shows a series of representative images of rats that were instilled 300 pm-diameter capsules comprising a plurality of firefly-luciferase expressing cells. Corroborating the average radiance data as shown in FIG. 14A, the radiance measured in rats instilled with the firefly luciferase expressing capsules was greater than the radiance measured in rats instilled with the free cell containing capsules through the seven day period post-instillation. The radiance appears to reach its maximum value approximately one day post-instillation for both groups.
  • FIG. 14A shows a series of representative images of rats that were instilled 300 pm-diameter capsules comprising a plurality of firefly-luciferase expressing cells. Corroborating the average radiance data as shown in FIG. 14A, the radiance measured in rats instilled with the firefly luciferase expressing capsules was greater than the radiance measured in rats instilled with the free cell
  • FIG. 14C shows in vivo bioluminescent total flux analysis demonstrating capsule retention for up to three days versus one day in unencapsulated cells.
  • Ex vivo fluorescent images of lungs after instillation with fluorescent dextran-loaded capsules and in vivo bioluminescent imaging of ex vivo lung one day after capsule instillation further show retention of capsules in the lungs of rats.
  • FIG. 15A illustrating the production and distribution of IL-10 in bronchoalveolar lavage (BAL) and plasma 24 h subsequent to instillation of capsules comprising IL-10-producing cells.
  • BAL bronchoalveolar lavage
  • plasma 24 h subsequent to instillation of capsules comprising IL-10-producing cells.
  • IL- 10 production is localized to BAL and is between about 10 to about 100 ng/mL compared to about 0.1 to 1 ng/mL in plasma.
  • FIG. 15B illustrating the production and distribution of IL-IRa in bronchoalveolar lavage (BAL) and plasma 24 h subsequent to instillation of capsules comprising IL-lRa-producing cells.
  • IL-IRa production is localized to BAL and is between about 10 to about 100 ng/mL compared to about 0.01 to 0.1 ng/mL in plasma.
  • FIG. 15C illustrating the production and distribution of FGF21 in bronchoalveolar lavage (BAL) and plasma 24 h subsequent to instillation of capsules comprising FGF21- producing cells.
  • FIG. 15D illustrating the production and distribution of IL-13 in bronchoalveolar lavage (BAL) and plasma 24 h subsequent to instillation of capsules comprising IL- 13 -producing cells.
  • IL-13 production is localized to BAL and is about 100 ng/mL compared to about 0.01 to 0.1 ng/mL in plasma.
  • FIG. 15E illustrating the production and distribution of IL-4 in bronchoalveolar lavage (BAL) and plasma 24 h subsequent to instillation of capsules comprising IL-4-producing cells.
  • IL-4 production is localized to BAL and is between about 1 to about 10 ng/mL compared to about 0.01 to 0.1 ng/mL in plasma.
  • the example set forth below illustrates a dose titration and pharmacokinetics study of 300-pm capsules delivered via intratracheal instillation to rat lungs. Briefly, escalating doses (0, 50, 100, and 150 pl) of capsules capable of secreting rat IL- 10 were instilled to rat lungs. Rat IL- 10 concentrations in BAL and plasma were assessed over time to determine cytokine localization and pharmacokinetic parameters. Changes in alveolar histology were also assessed to complement the pharmacokinetic analysis. FIG.
  • 16A is a bar graph showing IL- 10 protein levels in bronchoalveolar lavage (BAL) and plasma from rats instilled 300 pm-diameter capsules at increasing volumes, i.e., 0, 50, 100, and 150 pl.
  • BAL bronchoalveolar lavage
  • IL-10 is localized to BAL relative to plasma and demonstrates a direct dose-response relationship.
  • IL- 10 concentration increases from about 0.1 ng/mL in BAL to about 100 ng/mL as the capsule dose increases from 0 to 150 pl.
  • the IL-10 concentration in plasma remains relatively constant at about 0.1 ng/mL regardless of capsule dose volume administered.
  • 16B is a bar graph illustrating the relationship between increasing cell density per capsule (cell concentration per mL alginate) and rat IL- 10 production as measured in bronchoalveolar lavage (BAL) and plasma.
  • IL- 10 in BAL increases from about 0.01 ng/mL to between about 10 to about 100 ng/mL as the cell concentration per mL of alginate increases from 0 to about l*10 7 cells/mL.
  • IL-10 in plasma remains relatively constant between about 0.01 to 0.1 ng/mL as the cell concentration per mL of alginate increases from 0 to about l*10 7 cells/mL.
  • FIG. 16C shows BAL and plasma concentrations of IL- 10 24 hours post-instillation with 100 pL of RPE-IL-10 capsules and upon repeat dose at 30 days, demonstrating that there is no significant difference in local concentrations between day 1 and day 31, indicating no anti-drug antibody development.
  • FIG. 16D is a graph quantifying rat IL- 10 levels in bronchoalveolar lavage (BAL) and plasma over the duration of 14 days post-instillation with rat IL-10-producing capsules. As indicated in the graph, rat IL- 10 levels are particularly elevated in BAL relative to plasma, peaking between about 10 to about 100 ng/mL about one day after instillation.
  • BAL bronchoalveolar lavage
  • Rat IL-10 levels in plasma remain relatively constant over the course of 14 days at about 0.1 ng/mL.
  • FIG. 16E shows in vitro concentrations of IL-IRa, FGF-21, IL-13, and IL-4 24 hours after administration of 100 pl of 300 pm capsules.
  • FIG. 16F demonstrates that IL-10 levels in the post caval, middle, superior, inferior, and left lobes of lungs of rats 24 hours after instillation with IL- 10 producing capsules.
  • FIG. 16G shows that Rat IL-10 concentration in bronchoalveolar lavage (BAL) and plasma at Day 100, demonstrating a return to baseline levels.
  • 16H is a series of histological sections of rat lung (alveolar) tissue corresponding to the kinetic timepoints (Day 1, Day 2, Day 3, Day 4, Day 7, and Day 14) as shown in FIG. 16D.
  • Scale bar 200 pm.
  • a progressive diminution in inflammation and improvement in healthy lung tissue is observed, corresponding to the production of rat IL- 10 from instilled rat IL-10-producing capsules.
  • Example 18 Capsule Administration in Porcine Lung via Bronchoscopy
  • FIG. 18A shows IL-10 and IL-IRa concentrations in BAL and plasma on Day 0, Day 2 and Day 28.
  • FIG. 18B is a representative image of blue-dyed capsules instilled into porcine lungs via this technique.
  • FIG. 18C is a bar graph of human IL-IRa (hIL-IRa) levels in bronchoalveolar lavage (BAL) and plasma prior to and two days after instillation of hIL-lRa-secreting capsules.
  • Human IL-IRa production is localized to the lungs; hIL-IRA in BAL and plasma is nearly undetectable prior to administration, whereas two days post-instillation hIL-IRa levels in BAL are about 30 ng/mL while remaining undetectable in plasma.
  • FIG. 18D is a bar graph of human IL-10 (hlL- 10) levels in bronchoalveolar lavage (BAL) and plasma prior to and two days after instillation of hIL-10-secreting capsules.
  • FIG. 18E presents the general health of pigs prior to, two days after, and twenty-eight days after instillation of IL- 10 and IL-IRa producing capsules as characterized by triglycerides, total cholesterol and glucose.
  • FIG. 18F shows any changes in liver function of pigs prior to, two days after, and twenty-eight days after instillation of hIL-IRa- and hIL-10 producing capsules as characterized by albumin concentration.
  • FIG. 18E presents the general health of pigs prior to, two days after, and twenty-eight days after instillation of IL- 10 and IL-IRa producing capsules as characterized by triglycerides, total cholesterol and glucose.
  • FIG. 18F shows any changes in liver function of pigs prior to, two days after, and twenty-eight days after instillation of hIL-IRa- and hIL-10 producing capsules as characterized by albumin concentration.
  • 18G are graphs showing spCh and EtC Ch levels in pigs throughout the duration of the procedure. These data demonstrate that hIL-IRa- and hIL-10-secreting capsules can be successfully delivered to porcine lungs to deliver anti-inflammatory cytokines and improve biomarkers associated with decreased inflammation and improved overall health, e.g., triglycerides, cholesterol, glucose, and liver functioning.
  • LPS lipopolysaccharide
  • ARDS acute respiratory distress syndrome
  • BAL levels of TNF-a on Day 2 post administration of 20 mg/kg LPS are between about 100 and 1000 pg/mL compared to about 1 to about 10 pg/mL for the saline group (FIG. 19B).
  • BAL levels of IL- la on Day 2 post-administration of 20 mg/kg LPS are about 1000 pg/mL compared to about 10 pg/mL for the saline group (FIG. 19C).
  • BAL levels of MCP1 on Day 2 post-administration of 20 mg/kg LPS are about 10 5 pg/mL compared to about 10 pg/mL for the saline group (FIG. 19D).
  • BAL levels of MIP2 on Day 2 post-administration of 20 mg/kg LPS is between about 10 3 and about 10 4 pg/mL compared to between about 10 to about 100 pg/mL for the saline group (FIG. 19E).
  • BAL levels of total cell count derived lung homogenate are about 4*10 7 cells compared to about l*10 7 to about 2*10 7 cells for the saline group (FIG. 19F).
  • FIG. 19G shows representative images from a homogenized post caval left lung lobe.
  • Example 20 IL-10 and IL-IRa Combination Therapy in an LPS Model of ARDS
  • IL-10 and IL-IRa combination therapy in an LPS model of ARDS in rats. Briefly, rats were administered lipopolysaccharide (LPS) via intratracheal instillation and 300 pm capsules producing ⁇ 3 pg/day IL-10 and ⁇ 15 pg/day IL-IRa were implanted into the pleural cavity. Local concentrations of IL-10 and I:-lRa remained elevated for the duration of the experiment. Systemic concentrations were elevated 24 hours after transplantation; however, the systemic concentrations were an order of magnitude less than local concentrations. Capsules explanted on Day 28 also presented minimal fibrotic overgrowth, demonstrating that immune response to the capsules was attenuated. FIG.
  • LPS lipopolysaccharide
  • FIG. 23A are graphs showing concentrations of rat IL-IRa and Rat IL-10 in pleural fluid and plasma over 28 days, demonstrating localization of both IL- 10 and IL-IRa in the pleural fluid.
  • FIG. 23B are microscopy images of explanted capsules on Day 1, 3, 7, and 28 demonstrating minimal fibrotic overgrowth.
  • FIG. 23C is a graph showing lung histology score for the LPS only and LPS + IL- 10 + IL-Ra capsules, demonstrating .
  • FIG. 26A are images of histological sections of rat lungs treated with LPS only and LPS + IL-10 producing capsules after 24 hours, highlighting the reduced inflammation.
  • FIG. 26A are images of histological sections of rat lungs treated with LPS only and LPS + IL-10 producing capsules after 24 hours, highlighting the reduced inflammation.
  • FIG. 26B shows total cell counts collected 12 and 24 hours after LPS instillation, as well as IL-la and TNFa BAL concentrations 12 and 24 days after LPS treatment and administration of IL-10/IL-la producing capsules.
  • FIG. 26C show IL lb and MCP-1 BAL concentrations 24 hours after LPS and capsule treatment.
  • Example 22 Constitutive Production of Anti-IL-8, IL-10, and IL-IRA from ARPE-19 Cells
  • ARPE-19 cells engineered to constitutively express anti-IL-8, IL-10, and IL-IRa in the absence of stimulus.
  • ARPE-19 cells were stably transfected with a plasmid encoding for one of anti -IL-8, IL- 10, or IL-IRa expressed under the CAG promoter using LipofectamineTM 3000 Transfection Reagent (ThermoFisher Scientific) following manufacturer’s instructions and integrated into the cells using a piggybac transposase system. After selection, the engineered cells were plated, allowed to adhere, and incubated with fresh media for 24 h.
  • ARPE-19 cells engineered to constitutively express anti-IL-6 in the absence of stimulus.
  • ARPE-19 cells were stably transfected with a plasmid encoding for anti-IL-6 under the control of a CAG promoter using LipofectamineTM 3000 Transfection Reagent (ThermoFisher Scientific) following manufacturer’s instructions, and integrated into the cells using a piggybac transposase system. After selection, the engineered cells were plated, allowed to adhere, and incubated with fresh media for 24 h. After selection, media was harvested and constitutive anti-IL-6 expression was determined to be -500 ng/mL, as shown in the FIG. 30.
  • the example set forth below characterizes therapeutic cell lines engineered to express anti-IL-8, IL- 10, or IL-IRa in response to pro-inflammatory cytokines such as IL-ip and TNF-a under the control of NF-KB promoter expression systems.
  • ARPE-19 cells were stably transfected with a plasmid encoding for a NF-KB-responsive promoter and one of anti-IL-8, IL- 10 or IL-IRa using LipofectamineTM 3000 Transfection Reagent (ThermoFisher Scientific) following manufacturer’s instructions and integrated into the cells using a piggybac transposase system.
  • the engineered cells were then plated, allowed to adhere and incubated with fresh media treated with the inflammatory cytokines IL- 1 P or TNF-a.
  • Production of each of anti-IL-8, IL-10 and IL-IRa was measured by a protein-specific ELISA. Although there is some background constitutive expression of anti-IL-8, IL-10 and IL-IRa in the absence of any inflammatory cytokines, anti -IL-8, IL- 10, and IL-IRa production all increase significantly in the presence of IL-ip or TNFa as demonstrated in FIGS. 31A-C. As shown in FIG.
  • luciferase production in a NF-KB-luciferase therapeutic cell line which expresses luciferase in response to pro-inflammatory stimuli.
  • ARPE-19 cells were stably transfected with a plasmid encoding for a NF -KB -responsive promoter and luciferase using LipofectamineTM 3000 Transfection Reagent (ThermoFisher Scientific) following manufacturer’s instructions. Luciferase production was measured in engineered cells incubated in media containing no treatment, 10 ng/mL IFNy, 15 ng/mL IL-ip, and 15 ng/mL TNFa, as shown in FIG. 32.
  • Relative fluorescence was negligible in the control and 10 ng/mL IFNy-treated samples; however, the 15 ng/mL IL-ip-treated sample had -30,000 RLU and the 15 ng/mL TNF-a-treated sample had -40,000 RLU.
  • Example 26 Production of Anti-inflammatory Cytokines from Engineered Cells is Dose Responsive.
  • IL-IRa and IL-10 are dose-responsive.
  • ARPE-19 cells were stably transfected with a plasmid encoding for a NF-KB-responsive promoter and one of IL-IRa or IL- 10 using LipofectamineTM 3000 Transfection Reagent (ThermoFisher Scientific) following manufacturer’s instructions. After selection, cells were plated and adhered and incubated for 16 h (IL-IRa) or 24 h (IL-10).
  • IL-IRa production follows a sigmoidal dose-response relationship relative to both IL- 1 p and TNFa.
  • IL-IRa production plateaus at -8000 pg/mL for TNF-a between 0.1 and 100 ng/mL and plateaus between 1000 and 2000 pg/mL for IL-ip for concentrations greater than -1 ng/mL.
  • IL-10 production increases relative to both IL-ip and TNF-a does, reaching a plateau near -5000-12000 pg/mL for 15 pg/mL and 15 ng/mL IL-ip, respectively.
  • Mouse IL- 10 production was measured in engineered cells incubated in media containing no treatment, 15 ng/mL IL-ip, and 15 pg/mL IL- 1 P (as shown in FIG. 34B).
  • mIL-10 production follows IL-ip concentration, with higher levels of pro-inflammatory cytokine resulting in higher mIL-10 expression.
  • Example 27 ARPE-19 Maintain Viability and Productivity Upon Encapsulation
  • the example set forth below demonstrates that engineered ARPE-19 cells remain highly viable when encapsulated in alginate capsules. Specifically, cells engineered to express IL-10 in response to inflammation maintain function while encapsulated and produce IL- 10 in response to IL-ip and TNF-a. Briefly, ARPE-19 cells were engineered to produce IL-10 under the control of an NF-KB-responsive promoter and encapsulated in alginate capsules as previously described. The encapsulated cells were then live/dead stained using Calcein AM and Ethidium Homodimer and imaged (FIGS. 36A-C). FIG.
  • FIG. 36A is a micrograph of capsules containing a number of capsules containing engineered ARPE-19 cells.
  • FIG. 36B demonstrates that capsules may be loaded with a number of capsules containing engineered ARPE-19 cells that remain viable.
  • FIG. 36C shows that there is a negligible number of dead cells as evidenced by a lack of any significant staining.
  • IL- 10 production was evaluated by assaying capsules treated with media containing IL-ip or TNF-a for 16 h. IL- 10 production was then determined by protein-specific ELISA as previously described as shown in FIG. 36D.
  • IL- 10 production in the absence of inflammatory marker was -1000 pg/mL, whereas in the presence of IL-ip and TNF-a it is -8000 pg/mL.
  • ARPE-19 cells engineered to constitutively express anti -IL-8 or IL-IRa were encapsulated into alginate hydrogel capsules and subsequently implanted in the peritoneal cavity of healthy mice. After 24 h blood and intraperitoneal fluid (IP fluid) were collected and anti-IL-8 and IL-IRa concentrations were measured by protein-specific ELISAs as previously described. As shown in FIGS. 37A-B, both anti-IL-8 and IL-IRA are detected in collected, engineered ARPE-19 samples; however, the protein are localized to the IP fluid a the implantation site.
  • Anti-IL-8 is more than 2000 ng/mL in IP fluid (FIG. 37A), whereas it is less than 500 ng/mL in plasma.
  • IL-IRa is nearly 20,000 pg/mL in IP fluid (FIG. 37B), whereas it is nearly undetectable in plasma.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)

Abstract

La présente divulgation concerne des méthodes de traitement d'une maladie ou d'un trouble dans le poumon ou à caractère pulmonaire chez un sujet, à l'aide d'une capsule contenant une pluralité de cellules modifiées.
PCT/US2025/010263 2024-01-04 2025-01-03 Cellules encapsulées pour le traitement de maladies et de troubles respiratoires Pending WO2025147631A1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202463617707P 2024-01-04 2024-01-04
US202463617724P 2024-01-04 2024-01-04
US202463617718P 2024-01-04 2024-01-04
US63/617,724 2024-01-04
US63/617,718 2024-01-04
US63/617,707 2024-01-04
US202463552882P 2024-02-13 2024-02-13
US63/552,882 2024-02-13

Publications (1)

Publication Number Publication Date
WO2025147631A1 true WO2025147631A1 (fr) 2025-07-10

Family

ID=96300735

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/010263 Pending WO2025147631A1 (fr) 2024-01-04 2025-01-03 Cellules encapsulées pour le traitement de maladies et de troubles respiratoires

Country Status (1)

Country Link
WO (1) WO2025147631A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100063005A1 (en) * 2006-12-11 2010-03-11 Kaare Fiala Methods for Treating Cystic Fibrosis or Pneumonia with Bacterial Infection via Pulmonary Administration of Fosfomycin
US8377442B2 (en) * 2005-06-21 2013-02-19 Xoma Technology Ltd. Method of treating inflammatory eye disease with IL-1β binding antibodies
WO2023070000A1 (fr) * 2021-10-20 2023-04-27 William Marsh Rice University Procédés d'utilisation et d'administration de cellules encapsulées

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377442B2 (en) * 2005-06-21 2013-02-19 Xoma Technology Ltd. Method of treating inflammatory eye disease with IL-1β binding antibodies
US20100063005A1 (en) * 2006-12-11 2010-03-11 Kaare Fiala Methods for Treating Cystic Fibrosis or Pneumonia with Bacterial Infection via Pulmonary Administration of Fosfomycin
WO2023070000A1 (fr) * 2021-10-20 2023-04-27 William Marsh Rice University Procédés d'utilisation et d'administration de cellules encapsulées

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AGHLARA FOTOVAT SAMIRA, MENDEZ SOSA MIGUEL A, ASSOCIATE POSTDOCTORAL, MALIK SAAD, CABLER JACOB, GHANTA RAVI, , , , , , : "Poster W19 - Alginate Encapsulated Cells for Local Delivery oflmmunomodulatory Cytokines in Acute Respiratory Distress Syndrome", 2024 BMES ANNUAL MEETING, 24 October 2024 (2024-10-24), XP093336327, Retrieved from the Internet <URL:https://2024bmesannual.eventscribe.net/fsPopup.asp?PresentationID=1501367&mode=presInfo> *
GHANTA: "Cell Based Immunomodulation to Suppress Lung Inflammation and Promote Repair", 16 August 2024 (2024-08-16), XP093336330, Retrieved from the Internet <URL:https://reporter.nih.gov/project-details/10940864> *

Similar Documents

Publication Publication Date Title
US20250090451A1 (en) Formulations and doses of pegylated uricase
US12194078B2 (en) Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US8580735B2 (en) Local complement inhibition for treatment of complement-mediated disorders
JP6120452B2 (ja) 抗体製剤
US11576862B2 (en) Methods and compositions for preparing a silk microsphere
ES2689674T3 (es) Microcápsulas de liberación sostenida basadas en poli(lactida-co-glicólido) que comprenden un polipéptido y un azúcar
EP2913047B1 (fr) Agent thérapeutique spécifique de maladie pulmonaire
US7993666B2 (en) Methods and compositions for treating pain comprising a statin
CN105829349A (zh) 肽嵌合抗原受体t细胞开关和其用途
JP2015211676A (ja) タンパク質発現用未修飾および修飾ヌクレオチドの組み合わせを有するｒｎａ
JP2013515741A (ja) 持続放出性送達デバイス
JP2011518180A (ja) クロニジンを含んでなる、術後疼痛を治療するための方法及び組成物
CN101056613A (zh) 抗炎组合物的控制和定向局部递送
JP7404231B2 (ja) 改良された超粒子
US12553041B2 (en) Formulations and doses of pegylated uricase
US20260041786A1 (en) Mineral coated microparticles for sustained delivery of biologically active molecules
CN107530425A (zh) 治疗疾病的方法
US20190358344A1 (en) Mineral coated microparticles for sustained delivery of steroids
WO2025147631A1 (fr) Cellules encapsulées pour le traitement de maladies et de troubles respiratoires
CN102316855A (zh) 基于需求并可逆的通过外部信号进行的药物释放
CA3235778A1 (fr) Procedes d&#39;utilisation et d&#39;administration de cellules encapsulees
US20060228420A1 (en) Pharmaceutical compositions comprising microparticles for delivery into neurons
US20240307455A1 (en) Compositions, devices and methods for treating immune-mediated inflammatory diseases
KR20160046570A (ko) 염증성 또는 통증성 질환 치료를 위한 복합 약물 전달 제형 및 이것의 제조방법
TW202122109A (zh) 經黏膜投予藥劑

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25736538

Country of ref document: EP

Kind code of ref document: A1